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SUMMARY (FRENCH) 
  
La myéline est une gaine formée par l’enroulement de la membrane plasmique de la cellule de 
Schwann autour de l’axone dans le nerf périphérique. Lorsque cette gaine est détruite, on parle de 
démyélinisation, cela provoque de nombreuses maladies, dont les maladies de Charcot Marie 
Tooth (CMT) de type 1. Les maladies CMT sont héréditaires et atteignent le système nerveux 
périphérique. Les symptômes communs incluent : une faiblesse musculaire, une démarche 
maladroite, des troubles de l’équilibre et des pieds très cambrés ou très plats. Le type le plus 
fréquent est la forme autosomique dominante CMT1A.Une duplication du bras court du 
chromosome 17 contenant le gène PMP22 (Peripheral Myelin Protein 22) induit la CMT1A. La 
PMP22, une petite protéine exprimée par les cellules de Schwann, est donc en excès et entraine 
une démyélinisation. Il existe un modèle de rats transgéniques PMP22 (ou rats CMT1A) mimant 
cette pathologie humaine. Les rats CMT1A surexpriment la pmp22 de souris de façon 
hétérozygote. Jusqu’à présent, aucun remède n’existe pour les maladies CMT. Un des traitements 
envisageables est la thérapie génique. Le but de mon projet de thèse était d’étudier la validité et 
l'efficacité de la thérapie génique chez les rats CMT1A. La stratégie consiste à réduire la 
surexpression de la protéine PMP22 chez le rat CMT1A à l’aide d’ARNsh anti-PMP22. Pour ne 
pas être détruits par l’organisme et maintenir une expression longue, ces ARN sh-PMP22 sont 
transférés chez le rat grâce à des vecteurs viraux dérivés de virus adéno-associés, ou AAV (pour 
adeno-associated virus). Nous avons donc injecté un des différents sérotypes d'AAV, l'AAV9 
exprimant les ARN sh-PMP22 de souris ainsi que la GFP comme marqueur des cellules infectées 
dans les nerfs sciatiques de rats CMT1A à l’âge de 6 jours ou 7 jours. Nous avons d’abord confirmé 
que les virus thérapeutiques infectaient une très large proportion de cellules de Schwann dans le 
nerf sciatique de rat CMT1A et ensuite que l’infection de ces cellules par les virus exprimant les 
ARN sh-PMP22 induisait une diminution significative de l’expression de la protéine PMP22. 
L'analyse du phénotype moteur des rats CMT1A traités avec les AAV9 exprimant les ARN sh-
PMP22 montre que les rats CMT1A traités ne développent pas la maladie observée dans les 
contrôles. Egalement, les rats CMT1A présentent une hypoalgésie, un phénotype qui n’apparait 
pas dans les CMT1A traités avec les vecteurs thérapeutiques. Le traitement par thérapie génique 
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empêche la réduction de la vitesse de conduction nerveuse observé dans les rats malades. 
Concernant la biodistribution des virus, 2,5 mois après le traitement, en dehors des nerfs sciatiques 
ou les virus ont été injectés, le virus était présent dans les muscles qui entourent le nerf et aussi 
dans quelques ganglion dorsaux. Pour la réponse immunitaire, les rats injectés, à seulement 2 
exceptions près, n’ont pas développé de facteurs neutralisants anti-AAV9. Cette thérapie génique 
pourrait être utilisée dans les essais cliniques. Avant de passer aux études cliniques pour le 
traitement de la maladie CMT1A à l’aide d’AAV9 exprimant des ARN sh-PMP22 humain, la dose 
d’expression de ce ARN sh-PMP22 doit être très soigneusement déterminée car si la PMP22 est 
trop réduite, une autre maladie peut se développer, la neuropathie héréditaire avec hypersensibilité 
à la pression. Il est aussi important d’avoir un outil bien adapté qui permet d’évaluer l’efficacité 
du traitement. Aucun existant n’est assez fiable pour mesurer la myéline du nerf périphérique. Pour 
remédier à ce manque, nous avons testé la technique d'imagerie Coherent Anti-stokes Raman 
Scattering (CARS) en caractérisant avec succès les défauts de la myéline. Par conséquent, le CARS 
est une technique prometteuse permettant d’évaluer l’avancement des maladies de la myéline et 
l’efficacité de nouvelles thérapies pour les neuropathies périphériques démyélinisantes. 
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SUMMARY (ENGLISH) 
Myelin which is synthesized by Schwann cells, covers and protects nerves. If damaged, it causes 
many demyelinating diseases such as the inherited peripheral nervous system disorder Charcot 
Marie Tooth or CMT type 1. CMT neuropathies display a large variability from one patient to 
another. Nevertheless, the most common symptoms include muscle weakness, an awkward way 
of walking (gait), equilibrium problem and highly arched or very flat feet. The most common 
subtype of CMT is an autosomal dominant disorder known as CMT1A. CMT1A is caused by the 
duplication of the peripheral myelin protein 22 (PMP22) gene on the short arm of chromosome 
17 (17p11.2) resulting in an excess of PMP22. This leads to demyelination. PMP22 is a small 
protein expressed by Schwann cells. There is still no cure for CMT diseases. One approach for a 
treatment is gene therapy. The aim of my thesis project was to deliver proof of principle for a gene 
therapy approach on a CMT1A rat model characterized by extra copies of mouse pmp22 gene 
(CMT1A rat).  The treatment strategy consisted in reducing PMP22 overexpression in CMT1A 
rats with shRNA against PMP22. Viral vectors like adeno-associated virus (AAV having serotypes 
from1-10) are used to deliver shRNA in vivo so that they won’t be destroyed by the organism and 
for them to be long-lasting. Thus, we injected sciatic nerves of 6-7-day-old CMT1A rats with 
AAV9 expressing shRNA PMP22 with a GFP marker. We first confirmed that the virus highly 
transduced Schwann cells and that AAV9 shRNA PMP22 decreased PMP22 protein expression in 
CMT1A rats’ sciatic nerves. CMT1A rats treated with AAV9 shRNA PMP22 showed that they 
didn’t develop the motor phenotype seen in controls. Moreover, hypoalgesia observed in CMT1A 
rats was alleviated by treatment. In addition, gene therapy increased the reduced nerve conduction 
velocity found in CMT1A rats. Concerning safety, no viral off-targets were detected except in 
muscles close to the injection site (sciatic nerve) and in the dorsal root ganglions. Except for 2 rats, 
there was no immune response against AAV; no anti-AAV9 neutralizing factors. Consequently, 
this gene therapy could be used in clinical trials. Before moving to clinical studies, the minimal 
effective dosage should be very carefully defined because if PMP22 is completely deleted, another 
disease is caused: Hereditary Neuropathy with Pressure Palsies. It is also crucial to have a strong 
readout to evaluate the outcome of a treatment. However, no tool consistent enough exists for 
examining the peripheral nerve. Thus, we tested the label-free imaging technique Coherent Anti-
stokes Raman Scattering (CARS) and successfully characterized myelination defects. 
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Consequently, CARS could be used as a consistent outcome measure for developing new therapies 
for demyelinating peripheral neuropathies.    
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Prolog 
 
Myelin, a tissue mainly made of lipids and proteins, covers and protects nerves. It increases 
nerve conduction velocity. If damaged, it causes many neuropathies such as the inherited 
peripheral nervous system disorder Charcot Marie Tooth or CMT. These diseases have been 
named after the three physicians Jean-Martin Charcot, Pierre Marie and Howard Henry Tooth who 
first identified it in 1886. CMT diseases affect 1 in 2 500 people worldwide. They usually start in 
the first two decades of life. 
CMT diseases display a large variability from one patient to another even from one twin 
brother to another. Nevertheless, the most common symptoms include muscle weakness in the 
feet, ankles, legs and hands, an awkward way of walking (gait), highly arched or very flat feet and 
numbness in the feet, arms and hands. In severe cases, patients use a wheelchair. CMT diseases 
are caused by more than 90 gene mutations. However, the most common subtype of CMT is an 
autosomal dominant disorder known as CMT1A. This neuropathy is caused by the duplication of 
the peripheral myelin protein 22 (PMP22) gene on the short arm of chromosome 17 (17p11.2) 
resulting in an excess of PMP22. PMP22 is a membrane protein of myelin in the peripheral nervous 
system. Its overexpression leads to demyelination. The exact mechanisms are not yet fully known.  
There is still no cure for CMT diseases. One approach for a treatment is gene therapy. The 
aim of my thesis project was to deliver proof of principle for a gene therapy approach on a CMT1A 
rat model characterized by extra copies of mouse pmp22 gene.  The treatment strategy, designed 
by Dr. Benoit Gautier (my thesis supervisor) and Dr. Nicolas Tricaud (my thesis director), 
consisted in injecting Adeno-Associated Virus serotype 9 (AAV9) viral vectors expressing short 
hairpin ribonucleic acid (shRNA) against mouse PMP22 in the sciatic nerves of transgenic rats in 
order to reduce PMP22 overexpression and hence prevents the disease.   
In this thesis manuscript I will first introduce the myelinated fiber of the peripheral nervous 
system, then the CMT diseases and in particular CMT1A and the problems generated by PMP22 
protein overexpression. I will introduce the different animal models for CMT1A and the therapy 
approaches that have been tested in preclinical and clinical assays. Then I will introduce the gene 
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therapy approach, the shRNA tools we proposed to use and the different gene therapies that are 
clinically developed at the moment. 
In the material and methods chapter, I will first develop the techniques used for the gene 
therapy approach. Then I will describe all the tests and measurements used to assess the 
effectiveness of the gene therapy.  After that, in the results section, I will present our data showing 
a high transduction rate of the viral vector, downregulation of PMP22 and an almost full recovery 
of treated rats. Finally, I will discuss the results obtained in terms of possible translation to clinical 
trials. 
Before moving to clinical trials, as there is not any reliable enough tool for examining the 
peripheral nerve, it is important to find a strong readout to evaluate the outcome of a treatment.  
Non-linear, label free microscopy seems very promising. This is why at the end of this thesis 
manuscript I will present another project I have done in collaboration with Hassan Boukhaddaoui, 
the responsible of the Resource Imaging Platform (RIO) of Montpellier (MRI platform) at the 
Institute for Neurosciences of Montpellier (INM). In this project, we used label-free non-invasive 
imaging techniques to study the myelin sheath in the sciatic nerve of rodents. 
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Introduction 
 
I.   The myelinated peripheral nerve 
A. Introduction 
 Charcot- Marie-Tooth type 1A (CMT1A) affects the peripheral nervous system (PNS), in 
particular myelin. The key roles of myelin are to promote rapid conduction of nerve impulses and 
to nurture axons through metabolic and neurotrophic support. Myelin wraps around many axons 
(Figure 1) but not all (Lemke, 1988; Ozcelik et al., 2010; Taveggia, Feltri, & Wrabetz, 2010). 
Indeed, axons can be either myelinated or unmyelinated. In the peripheral nervous system, the 
fibers are divided into three groups: A, B and C. Group A includes the myelinated motor fibers 
which are the largest fibers with the fastest conduction. Group B encloses the myelinated pre-
ganglionic fibers of the autonomic nervous system (part of the nervous system regulating 
involuntary processes like breathing and heart rate 
https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0025455). Group C contains the 
unmyelinated and the post-ganglionic autonomic fibers which are the smallest-diameter, slowest-
conducting fibers (Chapman & Hall, 1976). In the PNS, Schwann cells (SCs) produce myelin 
(Chapman & Hall, 1976; Lemke, 1988; Taveggia et al., 2010). 
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Figure 1: Peripheral nerve: A: Diagram of nerve’s composition. Adapted from 
nerve.wustl.edu/nd_compression.php. B: Semi-thin section of a 2.5 month-old-rat sciatic nerve 
stained with Toluidine Blue. Thickly and thinly myelinated fibers are clearly seen with pale 
areas in the background representing the unmyelinated fibers. Scale bar=20µm. C: High 
power view of a myelinated axon: Myelin wraps around nerve fiber. Electron microscopy 
ultra-thin section of a 6-month-old rat sciatic nerve. Scale bar= 50nm.  
 
B. Structure of Myelin 
 Sheaths enveloping nerve fibers were first seen by Virchow as early as 1854 and were 
named myelin (Raine, 1977; Snipes & Suter, 1995). Myelin is constituted of several discrete units 
each separated by a small gap free of myelin. This gap is called Node of Ranvier and the units are 
named internodal segments (Figure 2). Thus, the myelin sheath is not continuous along the axon. 
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Those internodal segments are each synthesized by a single SC in the PNS (Peters & PALAY SL, 
1991; Snipes & Suter, 1995; THOMAS PK, BERTHOLD C-H, 1993).  
 
 
Figure 2 : Structure of a myelinated axon: In the peripheral nervous system (PNS), Schwann cells wrap their 
membrane many times around the axon creating the myelin sheath. Internodes are spaces in the axon covered by 
myelin whereas nodes of Ranvier (Nodes in figure) are small gaps free of myelin. Adapted by permission from Springer 
Nature: Nature Reviews Neuroscience, The local differentiation of myelinated axons at nodes of Ranvier, Poliak and 
Peles, 2003. 
 
 The myelin sheath is formed by successive turns of the Schwann cell plasma membrane 
that spiral around the axon. The wrappings are then compacted by the exclusion of the cytoplasm 
and the tight interaction of the membranes in order to make the ‘compact’ myelin  (Ghabriel & 
Allt, 1981; Snipes & Suter, 1995; Tricaud, 2005) (Figure 3). 
 
Figure 3 : Myelin sheath formation: A Schwann cell wraps around the axon forming myelin sheath. Adapted from 
biology dictionary. 
Compact myelin is responsible for the electrical insulation of the axon. An ‘uncompacted’ 
myelin is also generated during myelination. This uncompacted myelin is critical to form and 
maintain the compact myelin and to nurture axons. It is distributed semiregularly along the myelin 
sheath generating distinct domains inside the myelinating Schwann cell. Those domains are called 
Schmidt-Lanterman incisures and paranodal loops (Ghabriel & Allt, 1981; Snipes & Suter, 1995; 
Tricaud, 2005). Schmidt-Lanterman incisures are crucial in maintaining the myelin sheath 
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metabolically and in longitudinally extending the sheath (Arroyo & Scherer, 2000; Ghabriel & 
Allt, 1981; Tricaud, 2005). Those incisures comprise adherens junctions that are mostly composed 
of E-cadherin (Fannon et al., 1995; Ghabriel & Allt, 1981; Tricaud, 2005). The paranodal loops 
are located next to the nodes of Ranvier. They constitute the extremities of each turn of compact 
myelin (Meyer-Franke & Barres, 1994; Snipes & Suter, 1995; Trapp, 1990)(Figure 4).  
 
Figure 4: Compact and uncompacted myelin: Schematic of a longitudinal view of a myelinated axon depicting the 
several compartments around the node of Ranvier. Schmidt-Lanterman incisures (incisures in figure) enclose adherens 
junctions. Adapted from Tricaud et al., 2005. 
 On the axon the node and paranodes are both actively involved in propagating action 
potentials along nerve (Sun et al., 2016) (Figure 5).  
 
          
Figure 5: Propagation of Action Potentials: In a myelinated fiber, action potentials (yellow arrows) jump from one 
Node of Ranvier to the next one. This is known as “Saltatory conduction”.  
The structure of a myelinated Schwann cell is complex and well organized. Many 
junctional complexes such as desmosome-like structures and tight junctions are found inside the 
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same myelinating Schwann cell (autotypic junctions) between the terminal myelin loops in the 
paranodal region, at the lateral margins of the Schmidt-Lanterman incisures or in compact myelin 
(Ghabriel & Allt, 1981; Shinowara, Beutel, & Revel, 1980; Snipes & Suter, 1995). Additionally, 
intercellular junctions are present between the axon and the paranodal loops, termed axo-glial 
junctions (Figure 6) (Snipes & Suter, 1995; Wiley & Ellisman, 1980). 
 
Figure 6 : Myelin junctions: Schematic view of an unrolled Schwann cell showing adherens junctions (2 continuous 
line) surrounding compact myelin with gap junctions (orange ovals) between their rows. In addition, adherens 
junctions are found in incisures. Nodes (blue), paranodes (red) and juxtaparanodes (green) are axonal membrane 
regions. Adapted from Arroyo et al., 1999. 
 
C. Molecular composition of myelin 
 Myelin is essentially composed of lipids (70-80% of dry weight), water and proteins 
(Quarles, Macklin, & Morell, 2006; Snipes & Suter, 1995; Suter & Snipes, 1995). Lipids are 
mainly cholesterol, cerebrosides, sulphatides, phosphatidylethanolamines, phosphatidylcholines, 
phosphatidylserines, spingomyelins, and phosphatidylinositols (Inouye & Kirschner, 1988; Snipes 
& Suter, 1995). Contrarily to lipids, some PNS myelin proteins such as protein zero (P0 or MPZ), 
P2 (protein 2), peripheral myelin protein 22 (PMP22), myelin basic protein (MBP), myelin-
associated glycoprotein (MAG) and connexin 32 (Cx32) are myelin-specific (Snipes & Suter, 
1995). Mutations in genes of those myelin proteins have been associated with many inherited 
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peripheral neuropathies. For example, PMP22 gene duplication causes CMT1A (Lupski et al., 
1991; Snipes & Suter, 1995; Suter et al., 1992). P0, PMP22, P2 and MBP are distributed in 
compact myelin while MAG and Cx32 are present in uncompacted myelin (Snipes & Suter, 1995).  
 
D. Regulation of myelin formation 
 The development and the maintenance of the myelin sheath is possible through several 
types of molecules that promote or inhibit myelination (Taveggia et al., 2010). These molecules 
include  transcription factors and co-factors, myelin proteins, factors of signaling pathways, 
adhesion proteins and polarity proteins (Arnaud et al., 2009; Fernando et al., 2016; Fields & 
Stevens, 2000; Hu et al., 2008a; Jacob et al., 2011; Ozcelik et al., 2010; J. A. Pereira et al., 2009; 
Perrin-Tricaud, Rutishauser, & Tricaud, 2007; Svaren & Meijer, 2008; Taveggia et al., 2010; 
Tricaud, 2005; Vijay, Chiu, Dacks, & Roberts, 2016; von Boxberg et al., 2014; Willem et al., 
2006). I have chosen only a few, mostly the ones that have been studied in our laboratory. 
1. Transcription factors  
 Transcription factors of SCs capable of enhancing myelination include POU3F1 (POU 
domain class 3 transcription factor 1; Oct6), EGR2 (early growth response protein 2; Krox20) and 
SOX-10 (Svaren & Meijer, 2008). Dedifferentiation factors such as SOX2 and Notch inhibit EGR2 
facilitating myelin regeneration after nerve injury (Mager et al., 2008; Parkinson et al., 2008; 
Taveggia et al., 2010; Woodhoo et al., 2009).  
 Other transcription factors comprise Histone deacetylases (HDACs), HDAC1 and 
HDAC2. Both are chromatin-remodeling proteins and major epigenetic regulators. They promote 
SC myelination as well as survival in the PNS. While HDAC1 and HDAC2 compensate for each 
other, they have distinctive functions. HDAC1 decreases active beta catenin (ABC) thus 
controlling SC survival whereas HDAC2 interacts with Sox10 in order to induce the transcriptional 
program of myelination (Jacob et al., 2011). 
 YAP (Yes-Associated protein) is a transcription co-factor involved in myelination, myelin 
elongation and myelin regeneration (Deng et al., 2017; Fernando et al., 2016; Grove et al., 2017; 
Poitelon et al., 2016). Extending the myelin sheath is crucial for the conduction of nerve impulses. 
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Charcot Marie Tooth 4F is an example of a peripheral neurological disorder in which myelin 
internodal length is decreased (Fernando et al., 2016; Sherman & Brophy, 2018). YAP promotes 
myelin sheath internodal extension during nerve elongation due to postnatal body growth. YAP 
regulates myelin sheath elongation by stimulating some myelin gene promoters such as Egr2 and 
inhibiting others like P0. The process of myelin sheath extension is carefully controlled in SC as 
the cell polarity factor Crb3 prevents myelin sheath over elongation through the HIPPO pathway 
that inhibits YAP activity (Fernando et al., 2016). 
2. Myelin proteins 
 P0 and MBP mediate myelin wrapping and compaction whereas MAG mediates the axon 
interaction with SC (Garbay, Heape, Sargueil, & Cassagne, 2000; Lemke, 1988; Snipes & Suter, 
1995). P0 interacts with other similar P0 molecules of the SC plasma membrane to form and 
maintain the compact myelin sheath (Lemke, 1988; Snipes & Suter, 1995). MBP is a strongly basic 
protein that plays a role in the synthesis of compact myelin by electrostatic interactions with the 
membrane’s acidic lipids (Garbay et al., 2000). So, they both stably keep the close apposition of 
lipid bilayers for maintaining a very tight compaction of myelin (Garbay et al., 2000; Han, 
Myllykoski, Ruskamo, Wang, & Kursula, 2013).  
 MAG connects with specific gangliosides on the axonal membrane. Those gangliosides are 
involved in the adhesion of myelinating SC to the axon. Hence, MAG initiates and maintains the 
structural integrity of the myelin sheath  (Garbay et al., 2000). 
3. Factors of signaling pathways 
a) Neuregulins (NRGs) 
 Neuregulins (NRGs) are a family of growth and differentiation factors encoded by 4 genes. 
They display in their receptor-interacting sequence a homology with the epidermal growth factor 
(EGF) receptor. Many distinct NRG isoforms have been identiﬁed (Birchmeier & Nave, 2008; 
Gambarotta, Fregnan, Gnavi, & Perroteau, 2013; Gambarotta, Ronchi, Geuna, & Perroteau, 2014). 
The best-studied member and the prototype of the family is NRG1, which represents one of the 
largest mammalian genes. NRG1 elicits the activation of signal cascades downstream of the ErbB 
receptors, such as the activation of ras/ Mitogen-activated protein kinase (MAP) kinase, 
phosphatidylinositol 4,5-bisphosphate 3 (PI3) kinase/Akt, or focal adhesion kinase (FAK). Those 
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diverse signal transduction pathways are responsible for the transcription of genes involved in 
myelination as well as survival, migration, differentiation and proliferation of Schwann cells 
(Birchmeier & Nave, 2008; Fricker & Bennett, 2011; Gambarotta et al., 2013; Ma et al., 2011). 
NRG1 isoforms are categorized on the base of their N-terminus and C-terminus domains into many 
sub-types (Falls, 2003; Mei & Xiong Wen-Cheng, 2008) (Figure 7.A).  
NRG1 types I, II and III can be cut by the β-secretase β-site amyloid precursor protein 
cleaving enzyme 1 (BACE1) or by α secretases tumor necrosis factor- α-converting enzyme 
(TACE) (Gambarotta et al., 2013) (Figure 7.B). This proteolysis process is critical to activate 
NRG1 as BACE1 promotes myelination and remyelination (Hu et al., 2008b; Taveggia et al., 2010; 
Willem et al., 2006). On the other hand, TACE cleavage impacts negatively on myelination (Marca 
et al., 2011) (Figure 7.C). NRG1 Type I and II are expressed by Schwann cells while type III is 
expressed by axons (Gambarotta et al., 2014). After cleavage, NRG1 types I and II are released in 
the extracellular domain and function in a paracrine manner (soluble NRG1) whereas type III stays 
linked to membrane and undergoes juxtacrine signaling from axons to Schwann cells (Falls, 2003; 
Gambarotta et al., 2013; Syed & Kim, 2010). NRG1 type I expressed by Schwann cells is 
dispensable for myelination or myelin maintenance but is critical for nerve regeneration after 
injury (Stassart et al., 2013). NRG1 type III plays an important role in promoting myelination by 
SCs (Cotter et al., 2010; Taveggia et al., 2010), in particular in determining how thick the myelin 
sheath becomes (Birchmeier & Nave, 2008; Gambarotta et al., 2013; Taveggia et al., 2010). 
Reduced NRG1 type III expression causes hypomyelination (Taveggia et al., 2005; Michailov et 
al., 2004) while its overexpression increased myelin thickness thus causing hypermyelination 
(Birchmeier & Nave, 2008; Gambarotta et al., 2013; Michailov et al., 2004).  
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Figure 7 : Neuregulin 1 (NRG1) isoforms: A: 6 isoforms (types I-VI) different in their N-terminal. 
Ig=Immunoglobulin; CRD=cystein-rich domain; TMn= transmembrane domain; EGF= epidermal growth factor; 
TMc=transmembrane domain. NRG1 cleavage (B) and effect on myelination (C): BACE has positive effect while 
TACE has a negative effect. Adapted from Gambarotta et al., 2013 
 
b) Akt  
 The serine-threonine kinase Akt, or protein kinase B, a downstream effector of the PI3K 
pathway, is activated by axonal NRG1 type III in myelinating Schwann cells. Akt is involved in 
increasing myelin protein expression, in promoting myelin sheath formation during regeneration 
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and in regulating myelin sheath thickness (Cotter et al., 2010; Nave & Salzer, 2006). PI3K-Akt 
pathway also induces differentiation of SCs most probably from the immature to the 
promyelinating stage (He et al., 2011; W. Wu, Liu, Liu, Yu, & Wang, 2016; Yamazaki et al., 
2009)(Wu et al., 2016, He et al., 2011; Yamazaki et al., 2009). 
c) ILK 
 Integrin-linked kinase (ILK), a 52 kDa protein located in focal adhesion points, stimulates 
the growth of Schwann cell processes which completely encircle axon and start the segregation of 
single axons by Schwann cells. Additionally, it plays a crucial role in axonal remyelination most 
probably through activating Akt that is essential for SC myelination (J. A. Pereira et al., 2009). 
4.  Adhesion proteins 
a) AHNAK 
 Prerequisites for the myelination process in the PNS include intricate contact of SCs with 
laminin-containing basement membrane (Cornbrooks, Carey, Mcdonaldt, Timpl, & Bunge, 1983; 
McKee et al., 2012). AHNAK, a SC giant scaffold protein (700kDa), impacts the length of myelin 
segments in vivo (reduced internodal length) through interactions with the transmembrane form of 
the laminin receptor dystroglycan on Schwann cells (von Boxberg et al., 2014). 
b) E-cadherin 
E-cadherin constituting the core of SC adherens junction in the uncompacted myelin sheath 
(Fannon et al., 1995; Tricaud, 2005) is crucial for maintaining Schmidt–Lanterman incisures 
through recruiting p120 catenin to its juxtamembrane domain (Perrin-Tricaud et al., 2007; Tricaud, 
2005). Low levels of p120 catenin inhibit the formation of Schmidt–Lanterman incisures and lead 
to an important decrease in myelin sheath thickness (Perrin-Tricaud et al., 2007). 
5. Polarity proteins 
a)  Pals1 
 Protein Associated with Lin Seven 1 (pals1), a cell polarity protein involved in the 
epithelial cell polarization and in particular in the formation of the apical domain. In myelinating 
Schwann cells Pals1 is necessary for the distribution of myelin proteins PMP22 and MAG along 
the plasma membrane. It also plays an important role in the radial and longitudinal growth of the 
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myelin sheath as Pals-1 silenced cells display a thinner myelin sheath with fewer turns around the 
axon   (Ozcelik et al., 2010).  
b)  Inhibitors of myelination 
 PTEN (phosphatase and tensin homolog deleted on chromosome 10) is an inhibitor of Akt 
pathway, which is critical for myelination. In Schwann cells, PTEN interacts with mammalian 
disks large homolog 1 (Dlg1), a cell polarity factor involved in the formation of the baso-lateral 
domain of epithelial cells. Silencing Dlg1 in Schwann cells of mice showed decreased levels of 
PTEN and Akt hyperactivation. This lead to radial hypermyelination of myelinating Schwann 
cells. Consequently, Dlg1 role is to negatively regulate myelination and to limit myelin sheath 
thickness. Interestingly, Dlg1 appears to affect the thickness but not the length of myelin sheath 
(Cotter et al., 2010).   
 On the opposite, Crb3, a cell polarity protein involved in the formation of the apical domain 
of epithelial cells, inhibits myelin sheath elongation without significantly affecting myelin 
thickness. Crb3 stimulates the HIPPO pathway to phosphorylate and thus inactivate YAP and stop 
myelination (Fernando et al., 2016). 
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II. Peripheral neuropathies 
 Peripheral neuropathies are diseases of the peripheral nervous system. They can affect 
either the myelin sheath or the peripheral axons. They are subdivided into two main categories, 
acquired and inherited diseases, depending of the origin of the disease. Since acquired neuropathies 
have a large number of causes, I will briefly present the most important ones in term of patients: 
immune-mediated, infectious, toxic and metabolic. I will then focus on inherited diseases, which 
are mostly known as CMT diseases and in particular on CMT1A, the most common of these CMT 
diseases (Dimachkie & Barohn, 2015; Lunn & Sheikh, 2014; Saporta & Shy, 2015).   
A. Acquired neuropathies 
1. Immune-mediated peripheral neuropathies  
 Abnormal humoral and cellular immunological responses against self-antigens in the PNS 
can be linked to peripheral neuropathies. Those immune-mediated diseases are highly 
heterogeneous and they are sometimes poorly characterized. The large majority are chronic forms 
from unknown etiologies, which are generally termed as Chronic Inflammatory Demyelinating 
Polyneuropathy (CIDP). The acute forms of these diseases are known as Guillain-Barré syndrome 
(Lunn & Sheikh, 2014; M. A. Saporta & Shy, 2015). 
 Guillain-Barré syndrome regroup acute, acquired, inflammatory diseases of the peripheral 
nervous system. High cerebrospinal fluid (CSF) protein levels with low CSF cell counts and a 
monophasic progression with at least partial recovery are the typical features of this neuropathy. 
Typical Guillain–Barré syndrome is macrophage-mediated attack on the Schwann cell or the 
axolemma. Important characteristics of this disease are demyelination and lymphocytic 
inflammatory lesions in proximal PNS regions (spinal rootlets) (Hughes & Cornblath, 2005; M. 
A. Saporta & Shy, 2015). 
2. Infectious peripheral neuropathies 
 Infectious peripheral neuropathies are caused by the direct effect of microbes or their 
neurotoxins on peripheral nerves or by the consequences of a crossed immune reaction against 
peripheral nerve antigens by pathogens such as Mycobacterium leprae (Leprosy disease), Human 
Immunodeficiency Virus, Varicella-Zoster virus, Borrelia burgdorferi (Lyme disease) and 
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Corynebacterium diphtheria (Diphteria disease) (Brizzi & Lyons, 2014; M. A. Saporta & Shy, 
2015).  
3. Toxic peripheral neuropathies 
 Toxic neuropathies are caused by environmental exposure to heavy metals such as lead, to 
chemical compounds such as acrylamide or as a result of medications’ side effects mostly cardiac 
medications, antimicrobial agents and cancer drugs (B. Morrison & Chaudhry, 2012; M. A. 
Saporta & Shy, 2015).  
4. Metabolic peripheral neuropathies 
 Diabetes, a metabolic disease, is the most frequent cause of peripheral neuropathy in the 
Western world. Symmetrical, predominantly sensory or autonomic neuropathies (or both) and 
asymmetrical mononeuropathies or plexopathies are the two main groups of diabetic peripheral 
neuropathies. Chronic forms include demyelinating peripheral neuropathies (B. Morrison & 
Chaudhry, 2012; M. A. Saporta & Shy, 2015). 
B. Inherited peripheral neuropathies 
 Inherited peripheral neuropathies, a clinically and genetically heterogeneous group of 
diseases, can be categorized into two groups: the first one affects essentially the peripheral nervous 
system (CMT diseases) and the second one affects many systems of the human body among which 
the peripheral nervous system (Pisciotta & Shy, 2018; Rossor et al., 2017). The former group will 
be discussed in the following chapter.  
 The latter group is also called complex inherited neuropathy syndromes. It is further 
divided into many subgroups such as: 1) Hepatic, gastrointestinal and neuropathy syndromes 
(Rossor et al., 2017; Schmidt et al., 2015) as well as 2) Skin and connective tissue and neuropathy 
syndromes. Familial visceral amyloidosis constitutes one of the diseases from the first subgroup. 
It is an autosomal dominant autonomic and sensory axonal neuropathy with adult-onset chronic 
diarrhea (Rossor et al., 2017; Valleix et al., 2012). Xeroderma pigmentosum is an example from 
the second subgroup. It is an autosomal recessive sensory-motor axonal peripheral neuropathy 
with photosensitivity and increased risk of cutaneous malignancy, global developmental delay and 
deafness (Rossor et al., 2017; Tachi et al., 1988).  
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III. Charcot Marie Tooth (CMT)  
 Two French physicians Jean-Martin Charcot and Pierre Marie as well as one English 
physician Howard Henry Tooth first identified an inherited peripheral neuropathy in 1886 
(Brennan, Bai, & Shy, 2015), hence the name Charcot Marie Tooth or CMT given to these group 
of diseases in 1968 (Magy et al., 2018). CMT diseases are a group of clinically and genetically 
heterogeneous diseases of the peripheral nervous system (Table 1). More than 90 gene mutations 
can cause CMT diseases (Pisciotta & Shy, 2018). Symptoms are different from one patient to 
another even from one twin brother to another. CMT diseases have no cure so far (Brennan et al., 
2015). 
 
A. Epidemiology 
 CMT diseases affect 1 in 2500 people worldwide with an estimated prevalence rate of 10-
28/ 100 000 in Europe (Braathen, 2012; Brennan et al., 2015; Pareyson, Saveri, & Pisciotta, 2017; 
Pisciotta & Shy, 2018; Saporta et al., 2011; Schenone et al., 2011). They often overlap with distal 
hereditary motor neuropathies (dHMN) and hereditary sensory/ autonomic neuropathies (HSN or 
HSAN). dHMN and HSN or HSAN occur less frequently than CMT disorders and involve 
predominantly motor nerves (dHMN) or sensory and autonomic nerves (HSN or HSAN). These 
three groups of inherited peripheral neuropathies are pooled as CMT diseases and related disorders 
(Pisciotta & Shy, 2018). Although clinical manifestations are very variable from one patient to 
another, in general signs and symptoms of CMT diseases start in the first two decades of life with 
a progressive course of gradual weakness and sensory loss (Pisciotta & Shy, 2018; A. S. D. Saporta 
et al., 2011).  
 CMT diseases can be inherited as autosomal dominant (AD), X-linked or autosomal 
recessive (AR) (Pisciotta & Shy, 2018; Saporta et al., 2011). The dominant forms are commonly 
present in Western Europe, North America and Japan whereas in other countries with an increased 
dominance of consanguineous marriages like in the Mediterranean basin, between 30 to 50% of 
all forms is autosomal recessive disorders (Tazir et al., 2014). CMT diseases are globally 
distributed without any ethnic predisposition (Pisciotta & Shy, 2018). 
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B. Classification 
 Based on neuropathology, CMT diseases show two main categories: primary 
demyelinating and primary axonal neuropathies. The first contain CMT1, CMT3 or Dejerine-
Sottas disease (DSD), congenital hypomyelinating neuropathy (CHN), and hereditary neuropathy 
with liability to pressure palsies (HNPP). The second category includes CMT2 (Schenone et al., 
2011). 
 Neurophysiological analysis and the pattern of inheritance further classify CMT diseases 
into many subtypes. Regarding the classification based on neurophysiological studies, slow nerve 
conduction velocities (NCV less than 38 m/s in the upper extremities) and pathological indication 
of a hypertrophic demyelinating neuropathy characterize CMT1.  On the other hand, rather normal 
nerve conduction velocities and sign of axonal degeneration are typically CMT2 neuropathies. In 
addition, intermediate nerve conduction velocities (less than and greater than 38 m/s) describe 
CMT intermediate group. For the classification based on genetics, CMT diseases can be inherited 
as autosomal dominant (CMT1, CMT2), autosomal recessive (CMT4), and X-linked (CMTX). 
Letters (A, B…) have been added to include the specific gene triggering the disease. For example, 
the myelin protein zero (MPZ) gene mutation cause CMT1B (Brennan et al., 2015) (Table 1). 
 There is a new classification proposed by Magy et al (2018). A 3-step approach was used 
for this purpose: 1) Mention the mode of inheritance as AD for autosomal dominant, AR for 
autosomal recessive, XL for X-linked and Spo for sporadic cases; 2) Indicate the phenotype (CMT) 
followed by the neurophysiologic hallmark: ‘De’ for demyelinating CMT instead of CMT1, ‘Ax’ 
for axonal CMT instead of CMT2 or ‘In’ for intermediate CMT; 3) Naming the gene causing the 
disease or putting ‘UNK’ for unknown in case of undiscovered gene or mutation. For example, 
CMT1A would be ‘AD-CMTDe-PMP22’. After conducting an online survey among more than 
300 CMT specialists from different background (clinicians and scientists) and from all over the 
world, responders preferred to start with the phenotype then the transmission mode and finally the 
gene involved with the precision ‘mutation’ or ‘duplication’ or ‘deletion’. Consequently, CMT1A 
would become CMTDe-AD-PMP22 duplication. Responders did not like mentioning ‘UNK’; they 
favored putting nothing when it was the case. This proposal requires further discussions with 
experts of the scientific and medical communities before modifications and validation (Magy et 
al., 2018). 
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 Murphy et al. established in their epidemiological study that CMT1 affect around 57% of 
all CMT patients (Murphy et al., 2012) while Braathen found that CMT1 and CMT2 are equally 
frequent in the general population (Braathen, 2012). Rearrangements or point mutations of PMP22 
and MPZ genes are the most frequent causes of CMT1 (Murphy et al., 2012). CMT1A till CMT1F 
are the different CMT1 subtypes whereas CMT2A till CMT2Q are the multiple CMT2 subtypes 
(Tazir et al., 2014)  (Table 1). 
 
C.  CMT1A 
1. Epidemiology  
 CMT1A, identified in 1991, was the first described genetic cause of CMT. It is an 
autosomal dominant demyelinating disorder with a 10% de novo mutation rate (Brennan et al., 
2015). CMT1A is a common subtype of CMT, 70-80% of CMT1 patients or 39.5% of all CMT 
patients are affected (Murphy et al., 2012). 
2. Genetics  
 CMT1A is commonly caused by the 1.5 Mb tandem duplication of the peripheral myelin 
protein 22 (PMP22) gene on the short arm of chromosome 17 (17p11.2-p12) resulting in an excess 
of PMP22 (protein with 4 transmembrane domains), peripheral nerve demyelination and secondary 
axonal loss (Brennan et al., 2015; de Carvalho Alcantara et al., 2015; Schenone et al., 2011). The 
PMP22 along with 8 other genes are duplicated (Li, 2017). Six exons (1a, 1b, 2-5) conserved in 
both human and rodents form the 40-kb PMP22 gene.  Exon 1a and 1b encode for two transcripts 
identical in their coding sequence but different in their 5’untranslated region. This suggests that 
two promoters - P1 and P2 - control the expression of each transcript. Exon 2 encodes the first 
transmembrane domain of PMP22, exon 3 the first extracellular loop and exon 4 the second 
transmembrane domain. The third transmembrane domain is encoded half by exon 4 and the 
second half by exon 5. Exon-5 also encodes the second extracellular domain, the fourth 
transmembrane domain, and the 3′ untranslated region. P1 and P2 promoters contain a TATA-box-
like DNA element with an increased GC island content. Circular adenosine monophosphate 
(cAMP) response element binding (CREB) protein silence the PMP22 promoter while the sterol 
regulatory element binding (SREB) protein improves PMP22 transcription in the presence of 
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steroid hormones. Transcription factors like EGR2, Sox10, and Oct6 regulate myelin protein 
expression including PMP22. For example, triggering of a G-protein coupled receptor, gpr126, 
increases cAMP levels and activates the expression of Oct6 which controls genes encoding myelin 
proteins (Li et al., 2013).  
3. Clinical features  
 CMT1A usually starts in the ﬁrst twenty years of life. Despite phenotypic variability even 
in monozygotic twins, symptoms include difficulty in walking, a steppage gait, distal weakness, 
muscular atrophy, sensory loss, hyporeﬂexia, foot deformity and respiratory problems (Brennan et 
al., 2015; de Carvalho Alcantara et al., 2015; Fledrich et al., 2017). de Carvalho Alcantara et al 
study suggested that the high respiratory weakness observed in CMT1A patients could be due to 
axonal degeneration of nerves directed to muscles of respiration (de Carvalho Alcantara et al., 
2015) (Figure 8) (de Carvalho Alcantara et al., 2015). 
 Most patients walk on time. They are usually slow runners and poor at sports during 
childhood. They develop highly arched feet and hammer toes during their teenage years and need 
orthotics for ankle support during adulthood. They can also present with foot weakness followed 
later on by hand weakness. Vibration and proprioception (large modalities) as well as pain and 
temperature (small modalities) are subject to sensory deficits. Balance problems often result from 
weak ankles and decreased proprioception. However, most of CMT1A patients stay ambulatory 
their whole life; their lifespan is not reduced by the disease. Absence of deep tendon reflexes is a 
main symptom of CMT1A present in almost all the patients. Roussy-Levy syndrome (postural 
tremor) and muscle cramps might also occur (Li et al., 2013).  
 In general, CMT1A children progress steadily through early childhood (3–10 years) and 
adolescence (11–20 years) (Cornett et al., 2017). CMT1A phenotype can be more severe if coupled 
to diabetes mellitus type II. As a matter of fact, it was previously shown that diabetes mellitus type 
II worsens electrophysiological features (decreased amplitude of ulnar compound motor action 
potential i.e. CMAP) and clinical outcomes (more severe motor and sensory impairments). It was 
hypothesized that diabetes mellitus could impair axonal transport and function of mitochondria 
(Jerath & Shy, 2017; Sheth et al., 2008). An increased body mass index also worsens lower 
extremity pinprick loss and lower extremity motor strength on examination but do not alter ulnar 
NCV (Jerath & Shy, 2017). 
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4. Electrophysiology  
 Nerve conduction velocity (NCV) depends on many factors including myelinated nerve 
fiber diameter, myelin thickness and internodal length. NCV was found to be linearly proportional 
to those factors over certain ranges (Li, 2015; Rushton, 1951). In CMT1A, NCV is usually around 
20 m/s much below the normal value of 38m/s. Sensory action potentials are decreased or non-
existent. Those two features are observed in the upper extremities median and ulnar nerves of 
CMT1A patients (Brennan et al., 2015; de Carvalho Alcantara et al., 2015; Fledrich et al., 2017; 
Li, 2015, 2017). Additionally, the typical feature of CMT1A being the reduced NCV, is 
generalized among nerves of the same limb or of another limb. This phenomenon of symmetry 
between limbs and nerves and low NCV is known as a ‘uniform slowing pattern of nerve 
conduction studies’.  A while ago, it was thought that demyelination was responsible for the slow 
NCV in CMT1A. Highly variable conduction velocities from one case to another along with 
temporal dispersion and conduction block usually characterize demyelination. Furthermore, 
demyelination results in a progressive steady decrease in conduction velocities. Yet, these 
attributes are not or seldom found in CMT1A patients suggesting that CMT1A is not simply due 
demyelination (Li, 2015, 2017; Manganelli et al., 2016). The investigations of R. Fledrich, R. 
Stassart and M. Sereda (2014) on a CMT1A rat model suggest that CMT1A is not only a 
demyelinating disease but also a developmental disease. Indeed a defect in Schwann cell 
differentiation induces a deficit in myelinated fibers very early on in CMT1A rat pups and this 
deficit can be corrected by administration of soluble NRG1 in mutant rats (Fledrich et al., 2014). 
5. Morphology  
 Nerve biopsy is rarely taken as it is invasive and not mandatory for diagnosing CMT1A. If 
done, it displays hypomyelination early on, in the first decade of life, onion bulb formation at later 
ages and a lowered density of myelinated fibers (Brennan et al., 2015; de Carvalho Alcantara et 
al., 2015; Fledrich et al., 2017; Gabreeels-Festen et al., 1995; Gabreëls-Festen & Van de Wetering, 
1999; Li, 2017). Demyelination occurs later on and diseased nerves show onion bulbs over time. 
It happens when many Schwann cells circle around an axon but fail to form compact myelin. Some 
SCs make contact with the axon and harvest a thin myelin sheath. In that case active demyelination 
leads to thin myelin and hence a higher g-ratio. This parameter is measured by dividing the inner 
fiber diameter over the overall fiber diameter with its myelin sheath.  Actually, despite active 
demyelination, the g-ratio is generally lower in CMT1A as the myelin sheath is thicker. This is 
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due to the focal myelin deposition which create heavy clump of myelin at paranodal loops in 
particular. Early on CMT1A patients Schwann cells fail to develop the large myelinated fibers. 
Consequently, myelinated fibers remain relatively homogeneous in their size with small diameters 
(Gabreëls-Festen & Van de Wetering, 1999; Li, 2015, 2017). In addition, internodal length is 
shortened in CMT1A patients (Li, 2015, 2017; M. A. Saporta et al., 2009). Subsequently, CMT1A 
myelinating Schwann cells do not attain their proper sizes both radially (nerve ﬁber diameter) and 
longitudinally (internodal length), suggesting a myelin sheath formation problem. Therefore, since 
in CMT1A myelin is abnormally developed, this neuropathy would be better termed as a 
dysmyelinating disease rather than a demyelinating disease (Li, 2017), but this remains 
controversial.  
 
Figure 8 : Signs and symptoms of CMT: Highly arched or very flat foot (Adapted from luckyfeetshoes.com/foot-
problems/flat-feet/), steppage gait (Adapted from cmt.org.uk/about-cmt/what-is-cmt/symptoms/), the use of a 
wheelchair in severe cases (Adapted from www.amsvans.com/blog/designer-is-giving-wheelchair-users-their-
personality-back/), numbness and muscle weakness in hands (Adapted from www.handandwristinstitute.com), feet 
and legs, inability to grasp objects (Adapted and modified from www.slideshare.net/lostpebble/susil-seminar-claw-
hand) and claw hand (Adapted from www.gettyimages.fr).   
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Table 1 : CMT types, mode of inheritance and characteristics 
CMT type Inheritance Gene Category NCV Onset 
(years) 
Specific 
characteristics 
CMT1A 
AD 
PMP22 
duplication 
17p11.2-p12 
Primary 
demyelinating 
neuropathy 
<38m/s 
All ages 
Classic CMT1: 
steppage gait, balance 
impairment, distal 
weakness, atrophy, 
sensory loss, 
hyporeﬂexia, foot 
deformity, claw hand 
CMT1B MPZ 0 to 20 
Clinically more severe 
than CMT1A 
CMT1C LITAF Childhood 
Unusual gait. 
Sometimes nerve 
hypertrophy. 
Infrequently deafness 
CMT1D EGR2 0 to 10 
Classic 
CMT1/DSN/CHN. 
Cranial nerve might be 
involved. Scoliosis 
CMT1E 
PMP22 point 
mutation 
Childhood 
Classic 
CMT1/DSN/CHN. 
Associated with 
deafness. 
CMT1F NEFL 1 to 13 
Early onset.  Severe 
disease 
CMT1 FBLN5 40 to 50 
Macular degeneration 
based on age. 
Hyperelastic skin 
HNPP 
PMP22 deletion 
or point mutation 
Normal or 
nearly normal 
but slowed at 
entrapment sites 
2 to 64 
Recurrent entrapment 
neuropathies. 
Multifocal 
neuropathies.  
Often predominantly 
length dependent large 
fiber neuropathy 
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CMT1X 
X-linked 
GJB1 
Males between 
25 and 45m/s, 
females >35m/s 
0 to 20 
Classic. Sometimes 
deafness. Males more 
severe phenotype than 
females.  
Males show the typical 
'split hand syndrome' 
CMTX 
dominant/ 
CMTX6 
PDK3 
Slow/ 
intermediate 
Childhood Classic CMT1 
CMTX 
recessive 
(Cowchock)/
CMTX4 
AIFM1 
Primary axonal 
neuropathy 
Normal 
Early 
childhood/ 
infantile 
Learning difﬁculties. 
Mental retardation. 
Deafness. 
CMTX5 X-linked PRPS1 
Primary axonal 
neuropathy 
Normal Childhood 
Mild–moderate 
neuropathy 
Deafness. Late optic 
atrophy 
AR 
CMT1 
AR 
PMP22 point 
mutation Primary 
demyelinating 
neuropathy 
<38m/s 
 Classic CMT1, DSN, 
CHN, HNPP 
AR 
CMT1-DSN-
CH 
MPZ  
CMT1, DSN, CHN, 
intermediate, CMT2 
CMT 
2A1 
AD 
KIF1B 
Primary axonal 
neuropathies 
>38m/s 
Childhood 
Faster disease 
progression in early 
childhood compared to 
adolescence. Faster 
progression rate than 
CMT1A. In CMT2A2, 
prominent distal 
weakness, late 
proximal weakness, 
optic atrophy and CNS 
involvement 
CMT 
2A2 
MFN2 6 to 50 
CMT2B RAB7A 20 to 30 
Severe sensory loss. 
Foot ulcers. 
Arthropathy and 
amputations 
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CMT2B1 LMNA Childhood 
Variable severity, 
distal muscle weakness 
and atrophy gradually 
progressing to the 
proximal muscles, 
sometimes sensory 
deficits, moderate or 
absent foot 
deformities, possibly 
proximal muscle 
atrophy of the pelvic 
and scapular girdle 
later in the disease 
course. 
CMT2B2 MED25 26 to 42 
Symmetric moderate to 
severe weakness of the 
distal muscles mostly 
the lower limbs. 
Important sensory 
impairments 
CMT2C TRPV4 Birth to 60 
More severe in 
younger patients. 
Motor predominance. 
Vocal cord, 
diaphragm, respiratory 
involvement/dHMN 
CMT2D GARS 16 to 30 
Mostly distal upper 
limb dHMN 
CMT2E NEFL 10 to 50 
Hearing loss. 
Hyperkeratosis 
CMT2F HSPB1 Adult Classic/dHMN 
CMT2G 
12q12–q13.2 
chromosome 
point mutation 
20 to 30 Classic 
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CMT2I/J MPZ Late 
Classic. Deafness and 
pupillary abnormalities 
in CMT2J 
CMT2H/K 
AD 
GDAP1 
Primary axonal 
neuropathies 
>38m/s 
Variable 
Vocal paralysis and 
pyramidal features 
CMT2L HSPB8 15 to 33 Classic/dHMN 
CMT2M DNM2 0 to 20 Tremor 
CMT2N AARS 15 to 50 Classic 
CMT2O DYNC1H1 
Early 
childhood 
Sometimes learning 
difficulties 
CMT2P LRSAM1 27 to 40 
Mild. Sometimes 
asymmetry 
CMT2Q DHTKD1 13 to 25 Classic 
HMSN-P TFG 17 to 55 
Proximal involvement. 
Tremor. Diabetes 
mellitus 
CMT2 HARS Late onset Sensory predominant 
CMT2 MARS Late onset Motor-sensory 
CMT2 MT-ATP6 0 to 20 
Motor predominant. 
Pyramidal signs 
ARCMT2A 
AR 
LMNA 20 to 30 
Severe course. Distal 
and proximal weakness 
ARCMT2B 
19q13.1–13.3 
chromosome 
point mutation 
28 to 42 Classic CMT2 
ARCMT2C NEFL 1 to 10 Severe form 
ARCMT2F/
dHMN 
HSPB1 Variable 
Sometimes proximal 
leg weakness 
ARCMT2H GDAP1 1 to 10 
Pyramidal 
involvement. Vocal 
cord involvement 
ARCMT2K 
AR (rarely 
AD) 
GDAP1 
Early-onset 
form 
Severe form. Vocal 
cord paralysis. Skeletal 
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deformities. 
Milder dominant form 
ARCMT2P AR LRSAM1 30 to 40 
Cramps. Erectile 
dysfunction 
CMT3-DSD AD or AR 
MPZ, PMP22, 
EGR2, PRX 
Primary 
demyelinating 
neuropathy 
<15m/s 
Severe 
early onset 
Most severe form of 
demyelinating CMT, 
motor delay, increased 
concentrations of 
proteins in the 
cerebrospinal fluid, 
nerve hypertrophy, and 
severe dysmyelination 
at nerve biopsy 
CMT 
4A 
AR 
GDAP1 
Variable 
< 2 
Severe and 
progressive, vocal cord 
and diaphragm 
paralysis in some cases 
CMT 
4B1 
MTMR2 3 
Severe CMT1, 
facial/bulbar weakness, 
focally folded myelin, 
scoliosis 
CMT 
4B2 
MTMR13(SBF2) 4 to 13 
Severe CMT1, 
glaucoma, focally 
folded myelin 
CMT 
4B3 
MTMR 5 (SBF1) 5 to 11 
Severe CMT, scoliosis, 
syndactyly, focally 
folded myelin, Pes 
planus 
CMT 
4C 
KIAA1985 
(SH3TC2)  
Early 
onset, 0 to 
20 
Severe CMT1, 
scoliosis, cytoplasmic 
expansions, deafness 
CMT 
4D/HMSNL 
NDRG1  < 10 
Severe CMT1, gypsy, 
deafness, tongue 
atrophy 
CMT 
4E 
EGR2  Birth 
Congenital hypotonia. 
Respiratory failure. 
Arthrogryposis 
44 
 
CMT 
4F 
PRX  Birth to 10 
CMT1, more sensory, 
focally folded myelin 
CMT 
4G/ HMSN-
Russe 
HK1  8 to 16 
Severe to moderate 
CMT1 
CMT 
4H 
FGD4  < 2 
Delayed milestones. 
Scoliosis. Severe 
course 
CMT 
4J 
FIG4  
Congenital, 
childhood 
or adult 
Severe CMT1±ALS 
(motor neuron disease) 
phenotype in 
adulthood  
CCFDN CTDP1  
Infancy 
Neonatal 
CMT1, gypsy, 
cataracts, dysmorphic 
features 
CMT 
4 
SURF Childhood 
Severe. Associated to 
cerebellar ataxia, brain 
MRI abnormalities and 
lactic acidosis 
CMT5-
HMSN type 
V 
AD 
MFN2 mostly               
BSCL2 and 
GJB1 to a lesser 
extent 
Primary axonal 
neuropathy 
>38m/s 
Adult 
The clinical phenotype 
is complicated by 
pyramidal involvement 
CMT6-
HMSN type 
VI 
MFN2 Early onset 
The clinical phenotype 
is complicated by optic 
atrophy 
DI-CMTA 
AD or AR 
10q24.1–25.1 
chromosome 
point mutation 
Dominant 
Intermediate 
(DI) 
< and >38m/s 
7 to 72 Classic 
DI-CMTB DNM2 0 to 20 
Classic with 
neutropenia and early 
onset cataract 
DI-CMTC YARS 7 to 59 Classic 
DI-CMTD  MPZ 30 to 50 
Sensory loss and 
weakness. 
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Deafness/pupil 
disorders 
DI-CMTE  YARS 5 to 28 
Glomerulosclerosis 
and proteinuria 
DI-CMTF  YARS 5 to 45 Classic 
Adapted from Angelo Schenone et al, 2011; Brennan et al, 2015; Pareyson and Marchesi, 2009; Tazir et al., 2014; Cornett et al, 2017 
Abbreviations: AARS, alanyl-tRNA synthetase; AD, autosomal dominant; AIFM1, apoptosis-inducing factor mitochondrion-associated 1; AR, autosomal recessive; 
BSCL2, Berardinelli-Seip congenital lipodystrophy type 2;CHN, congenital hypomyelinating neuropathy; CNS, central nervous system; CTDP1 ,CTD phosphatase 
subunit 1; DHTKD1, dehydrogenase E1 and transketolase domain-containing 1; DI, dominant intermediate; DNM2, dynamin 2; DSS, Dejerine Sottas Syndrome; 
DYNC1H1, dynein cytoplasmic 1 heavy chain 1; EGR2, early growth response 2; FBLN5, fibulin 5; FGD4, actin filament-binding protein frabin; FIG4, FIG4 
homolog SAC1 lipid phosphatase domain containing; GAN, Giant axonal neuropathy; GJB1, gap-junction protein β-1; GARS, glycyl-tRNA synthetase; GDAP1, 
ganglioside-induced differentiation-associated protein 1; HARS, histidyl-tRNA synthetase; HK1, hexokinase 1; dHMN, distal hereditary motor neuropathy; HMSN, 
hereditarymotor and sensory neuropathy; HNPP, hereditary neuropathy with liability to pressure palsies; HSPB1, heat shock protein B1; HSPB8, heat shock 
protein B8; KIF1B, Kinesin Family Member 1B ; LITAF, lipopolysaccharide-induced tumor necrosis factor; LMNA, lamin A/C; LRSAM1, leucine-rich repeats 
and sterile alpha motif-containing 1; MARS, methionyl-tRNA synthetase; MED25, meditor complex subunit 25; INF2, inverted formin 2; MFN2, mitofusin 2; MPZ, 
myelin protein zero; MT-ATP6, ATP6 subunit of the mitochondrial Adenosine Triphosphate synthase; MTMR2, myotubularin-related protein 2; MTMR5, 
myotubularin-related protein 5; MTMR13, myotubularin-related protein 13; NDRG1, N-myc downstream-regulated gene 1 protein; NEFL, neurofilament light 
chain; PDK3, pyruvate dehydrogenase kinase isoenzyme 3; PMP22, peripheral myelin protein 22; PRPS1, phosphoribosyl pyrophosphate synthetase 1; PRX, 
periaxin; RAB7, RAS-associated protein RAB7; SBF1, SET binding factor 1; SBF2, SET binding factor 2; SH3TC2, SH3 domain and tetratricopeptides repeats 2; 
SURF1, Surfeit 1; TFG, TRK-fused gene; TRPV4, transient receptor potential cation channel subfamily V member 4; YARS, tyrosyl tRNA synthetase.  
Split hand syndrome: dissociated muscle weakness in the hands (muscles on the side of the thumb wasted as compared to the muscles on the side of the little 
finger that are spared.
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D. CMT1A animal models 
1. Rodent models 
 Only one rat model and several mouse models were generated to mimic the human CMT1A 
peripheral neuropathy. All models overexpress the PMP22 gene (mouse or human). Those models are 
summarized in Table 2 : CMT1A murine models. Since I used the rat model for my thesis project, 
further details are exposed right after. 
2. CMT1A rat 
a) Generation of the model 
 In 1996, Sereda et al created a rat model for CMT1A, the PMP22-transgenic rat. The rat was 
specifically chosen as species because it is the favorite model system to test development of SCs in vivo 
and in vitro. From a 129SV mouse cosmid genomic library, cloning of the wild-type gene was performed. 
A restriction fragment of 43 kb with the transcription unit PMP22 was excised along with 7 kb upstream 
of exon 1A and 4 kb downstream of exon 5. Fertilized Sprague-Dawley rat oocytes were microinjected 
with DNA. This led to the generation of one founder male which could breed normally. This male was 
employed to launch a line of PMP22-transgenic rats  (M. Sereda et al., 1996) .  
b) Genetics 
 The heterozygous CMT1A rat carries three copies of the mouse PMP22 gene thus overexpressing 
the mouse PMP22 protein. They acquire a peripheral neuropathy representing the autosomal-dominant 
CMT1A human disease (Niemann et al., 1999; M. Sereda et al., 1996). Even before the first 
demyelination signs, SCs poorly differentiated at time points of early postnatal myelination. From 
Postnatal day 6 (P6) to P180, mRNA levels of myelination related genes Hmgcr, Prx and Mpz are 
decreased in CMT1A rats compared to WT. PMP22 mRNA is overexpressed very early on i.e. 2.1x at 
P1 and 1.2x at P6 and later on, i.e. 1.6x at P18. PMP22 mRNA is reduced during myelination peak i.e. 
from P28 to P180. Immature and dedifferentiated SCs markers Pou3f1, Ngfr, Notch1, Jun and Sox2 are 
increased in sciatic nerves (SN) of CMT rats from P18 to P180. From early postnatal development on 
(from P1on), CMT rat sciatic nerves display an important decrease in PI3K–v-Akt signaling pathway 
then trigger of the mitogen activated protein kinase kinase 1 (Mek)–mitogen activated protein kinase 
(Erk) signaling pathway at P6  (Fledrich et al., 2014) 
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Table 2 : CMT1A murine models 
Animal model Mutation in the animal 
model 
Copy 
number 
Characteristics 
CMT1A rat mouse PMP22 cosmid tg 3 Unsteady gait, clumsiness in walking, motor deficits, reduced NCV, 
hypo-, hyper-, de-, dys-myelination, axonal loss, onion bulb 
C22 
heterozygotes 
human PMP22 YAC tg 7 Unsteady gait, severe phenotype, progressive paralysis of the rear legs, 
very slow NCV and prolong distal motor latencies, Amyelinated or 
hypomyelinated large caliber axons, demyelination, onion bulbs, 
difficult to breed 
C61 mouse, 
heterozygotes 
human PMP22 YAC tg 4 Reduced performance in motor tests, some electrophysiological 
impairments de-, re-, hyper-myelination, onion bulbs 
TgN248 mouse PMP22 cosmid tg 16 Severe phenotype (slight shivering, unsteady gait, muscle atrophy and 
paralysis of the hindlimbs), do not live more than 8 months, poor 
breeding, high latencies and low CMAP amplitudes with temporal 
dispersion, low motor NCV. No myelin. 
My41 mouse PMP22 YAC tg  Severe phenotype (unstable gait since 3 weeks of age and weakness of 
the rear limbs), do not live long (rarely more than 5 months), breed 
poorly, a- or hypo-myelinated axons, demyelination. 
Double 
transgenic 
mice 
human, mouse PMP22 YAC 
tg + tetracycline 
 PMP22 overexpression is switched off by tetracycline and on by the 
absence of tetracycline, slight unsteady gait, little decrease of NCV, 
demyelination, onion bulbs 
C3-PMP 
mouse 
human PMP22 YAC tg 3-4 Mild neuromuscular problems, low NCV, hypo- and a-myelinated 
fibers, hypermyelination of small axons, rare axonal damage 
B6C3F1 mice PMP22 gene High Muscle weakness and atrophy, sensory loss, amyelinated large and 
medium axons and few small myelinated fibers, hypomyelinated axons, 
deficiency of large caliber axons 
Adapted from Fledrich, Stassart and Sereda, 2012. tg: transgenic. References: Fledrich et al., 2014; Huxley et al., 1996, 1998; Kobsar et al., 2005; Magyar et al., 
1996; Niemann et al., 1999; Norreel et al., 2001; Perea et al., 2001; Robertson, Huxley, King, & Thomas, 1999; Robertson et al., 2002; Sara Sancho, Magyar, 
Aguzzi, & Suter, 1999; M. Sereda et al., 1996; Verhamme et al., 2011
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c) Clinical phenotype and electrophysiology 
 CMT1A rats have an unsteady gait and they are clumsy when they walk as demonstrated by the 
outward position of their hind feet seen in footprint analysis. Loss of muscle strength is observed when 
rats attempt to right up at the cage wall and their hind limbs are unable to support their body weight. Like 
patients, CMT1A rats present motor deficits and decreased NCV in both motor and sensory nerves  
(Niemann et al., 1999; M. Sereda et al., 1996). Muscle weakness is more uniformly distributed in 
CMT1A rats as opposite to the length-dependent fiber loss in CMT1A patients (Zu Horste et al., 2007)  
d) Morphology 
 CMT1A rats display peripheral hypomyelination that is more obvious in large diameter fibers 
(presumably motor) compared to smaller fibers having normal or even higher thickness sheaths 
(hypermyelination). Hypomyelination is possibly due to reduced MPZ and MBP. Few SCs showed 
myelin debris. Endoneurial collagen was amplified. Degradation of axons was rare (less than 1% of 
fibers). The complicated combination of dysmyelination and superimposed progressive demyelination 
defines the phenotype of the rat (Niemann et al., 1999; M. Sereda et al., 1996). Hypermyelinated axons 
are observed at P6, P18 and P180. Amyelinated as well as hypomyelinated (thinly myelinated) axons are 
seen at P18 and P180. At postnatal day 18 (P18), CMT rats have the same total number of SN axons 
compared to wild-type (WT) controls. At P90 CMT1A rats show axonal loss (Fledrich et al., 2014). In 
young rats (5-week-old), amyelinated axons with no sign of myelin disruption as well as hypomyelinated 
axons and axons with normal myelin thickness were observed. Excessive Schwann cell processes and 
basal laminae surrounding hypomyelinated or amyelined axons i.e. onion bulbs increased in number with 
disease progression. As a matter of fact, electron micrographs of CMT1A rats’ sciatic and tibial nerves 
showed few onion bulbs at 2.5 month and numerous ones at 6 months. Onion bulb formation is more 
obvious in the ventral roots than in the dorsal roots. This might explain why motor functions are generally 
more damaged than sensory functions in CMT1A (Niemann et al., 1999; M. Sereda et al., 1996). One 
limitation of the rat model is that contrarily to what is seen in CMT1A patients, axonal loss in CMT1A 
rats is not distally pronounced when comparing tibial and sciatic nerves (Zu Horste et al., 2007).   
e) Homozygous rat 
 Homozygous PMP22-Transgenic rats were more harshly affected. In fact, light and electron 
microscopy analysis revealed an absolute absence of PNS myelin. Highly overexpressed PMP22 
Schwann cells do not complete differentiation; they stop at the promyelin stage. Abnormal spasticity, 
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hind limb paralysis, uncoordinated movements and absence of motor development are displayed by 
homozygous rats. Hind limb paralysis and spasticity are fatal at 4-6 weeks of age in those rats  (Niemann 
et al., 1999; M. Sereda et al., 1996). 
 From now on, “CMT1A rat” will refer to the heterozygous PMP22-trangenic rat model 
created by Sereda in 1996. 
f) Biomarkers analysis 
 Fledrich et al (2012) searched for indicators of disease severity while studying the CMT1A rat. 
This research team demonstrated that sciatic nerve messenger RNA expression for genes associated with 
lipid metabolism such as peroxisome proliferator-activated receptor gamma (PPARG) were sometimes 
downregulated (63-day-old rats) and other times upregulated (7-day-old rats) in severely affected rats 
compared with mildly affected rats. Consequently, there is inversed proportionality between messenger 
RNA expression for genes associated with lipid metabolism of the early disease stage and of the late 
disease stage. Lipid metabolism contributes to the myelination and demyelination process. Nerve 
conduction velocities determined at 9 weeks of age, were significantly lower in CMT1A rats than in 
wild-type rats. However, mildly and severely affected rats presented similar results. Hence, axonal loss 
rather than demyelination might be an indicator of disease severity. Contrarily to nerve conduction 
velocities, sensorial impairments can be an indicator of disease severity. Indeed, compared to wild-type 
and mildly affected CMT rats, severely affected animals had an important sensory impairment after 
testing the response to heat pain with a nociceptive hot plate. Fledrich et al (2012). proposed an important 
indicator of disease severity while studying rat models:  the combination of age and cutaneous messenger 
RNA levels of glutathione S-transferase theta 2 and cathepsin A (Fledrich, Schlotter-Weigel, et al., 2012). 
 
E. Peripheral Myelin Protein (PMP22) 
1. PMP22 generalities 
 Inherited peripheral neurological disorders including Charcot Marie Tooth disease type 1A 
(CMT1A), hereditary neuropathy with liability to pressure palsies (HNPP) and severe childhood onset 
demyelinating neuropathies (Tyson et al., 1997) have been associated with duplications (CMT1A) 
(Lupski et al., 1991; Pentao et al., 1992; Raeymaekers et al., 1991), deletions (HNPP) (Chance et al., 
1993)and point mutations of the Peripheral Myelin Protein 22 (PMP22) gene (CMT1E) (Giambonini-
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Brugnoli et al., 2005; Gregson et al., 2007). Loss-of-function phenotype is a consequence of deletion 
whereas gain-of-function phenotypes are consequences of overexpression and point mutations of the 
PMP22 gene (Li et al., 2013). 
 PMP22 is also known as growth arrest specific gene-3 (gas-3) due to the fact that it was first 
discovered as a decreased transcript in mouse NIH-3T3 fibroblasts upon growth arrest (Li et al., 2013; 
Snipes, Suter, Welcher, & Shooter, 1992). However, so far the exact function of PMP22 protein remains 
unknown. 
2. PMP22 transcript  
 In humans, PMP22 mRNAs are mainly found in Schwann cells of the peripheral nerves. They 
are also expressed at low level postnatally and in young adults in the central nervous system (brain and 
brainstem) (Li et al., 2013; Ohsawa et al., 2006). More detailed studies have been done on rats and mice  
(de Leon, Nahin, Mendoza, & Ruda, 1994; Li et al., 2013; Parmantier, Cabon, Braun, D’Urso, Müller, 
et al., 1995; Snipes et al., 1992; Welcher, Suter, De Leon, Snipes, & Shooter, 1991; Wulf & Suter, 1999) 
(Table 3). 
 PMP22 possess 6 Alternative Splicing Variants (ASVs) (variants 1-6). A single gene using 
alternate exon-intron inclusions and exclusions cause alternative splicing hence creating several 
messenger RNA (mRNA) isoforms (Taneri, Asilmaz, & Gaasterland, 2012; Visigalli et al., 2016). In 
both humans and rodents, two alternatively transcribed exons (1a and 1b) results in two different 
transcripts (refer to Introduction III.C.2 for more details). This might explain the difference in PMP22 
mRNA distribution among tissues. Exon 1b is mostly present in the brainstem, spinal cord, skeletal 
muscle, heart and SN while exon 1a is mainly found in SN. Those alternatively transcribed exons are the 
variants 1, 2 and 3 coding for the same PMP22 protein of 18 kDa, the “classical” PMP22. On the other 
hand, variants 5 and 6 code for a new PMP22 protein isoform of 13 kDa. This smaller isoform is mostly 
found in the endoplasmic reticulum in opposition to the classical PMP22 protein that is expressed at the 
plasma membrane. Variant 4 do not code for any PMP22 protein (Visigalli et al., 2016). 
3.  PMP22 protein 
 PMP22 is a membrane-bound 18-kDa polypeptide which is modified by glycosylation after 
translation to form the mature glycoprotein of 22 kDa (Giambonini-Brugnoli et al., 2005). The peripheral 
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myelin protein (PMP22) is constituted of 160 amino acid glycoproteins (Hayasaka’ et al., 1992) with 
four hydrophobic regions (Jetten & Suter, 2000).  
 PMP22 has four transmembrane domains with two extracellular domains and one intracellular 
domain (Figure 9). Transmembrane domain 1 comprising amino acids 1-30 is depicted as a long α-helix, 
extracellular loop 1 (amino acids 31-57) as a largely unstructured loop, transmembrane domains 2- 4 as 
a molten globular helical bundle and extracellular loop 2 as a short loop between transmembrane domains 
3 and 4. Seven potential metal ion-coordinating sites have been identified in the extracellular loops. 
Those sites might be involved in the Zinc (Zn) (II) binding ability of PMP22. Extracellular loop 1 is 
responsible for interactions between two PMP22 proteins while extracellular loop 2 regulates interaction 
between PMP22 and MPZ (Hasse,et al., 2004; Li et al., 2013). 
 
 
Figure 9 : PMP22 molecular structure: 4 transmembrane domains, 
160 amino acids. Mutations sites are represented. Taken from 
Watila & Balarabe, 2015 who adapted it from Li et al., 2013.
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Table 3 : Distribution of PMP22 postnatally/ in young adults 
 Human Rat Mouse 
Organ mRNA Protein mRNA Protein mRNA Protein 
Brain Low NA Low Low Low NA 
Brainstem Low NA 
Medium (motor nuclei). 
Absent in sensory nuclei 
NA 
High (motor 
nuclei). Absent 
in sensory nuclei 
NA 
Spinal cord High 
Detected in ventral and dorsal 
roots, motor neurons and 
preganglionic sympathetic 
neurons in spinal cord 
Medium in spinal cord’s 
motor neurons and not in 
sensory counterparts 
Medium in dorsal and 
ventral horn, detected 
in motor neurons 
High in spinal 
cord motor 
neuron 
High in spinal cord 
motor neuron 
Dorsal Root 
Ganglion 
Detected but 
not 
quantified 
NA 
Absent in neurons but 
medium in satellite cells 
Medium in neurons and 
satellite cells 
Absent NA 
Sciatic Nerve High High High High High High 
Cranial nerve NA NA High Absent High Absent 
Skeletal muscle NA NA Medium Undetectable NA NA 
Heart NA NA Medium Undetectable Low NA 
Liver NA NA Detected in bile canaliculi Low in bile canaliculi NA NA 
Kidney NA NA Low Undetectable NA NA 
Gastro-
intestinal tract 
NA NA High High High NA 
Lung NA NA High Undetectable High NA 
Testes NA NA Low NA NA NA 
NA=Not Applicable. Adapted from : Baechner et al., 1995; de Leon et al., 1994; Li et al., 2013; L. Notterpek et al., 2001; Ohsawa et al., 2006; Parmantier, Cabon, 
Braun, D’Urso, Muller, et al., 1995; Snipes et al., 1992; Wulf & Suter, 1999  
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 PMP22 is mostly found in the peripheral nervous system of mammals (Gregson et al., 
2007) especially in myelinating Schwann cells (Giambonini-Brugnoli et al., 2005) like PMP22 
mRNA (Li et al., 2013). Although PMP22 mRNA was identified in the cranial nerve motor nuclei 
of mouse (Parmantier, Cabon, Braun, D’Urso, Muller, et al., 1995) and rat (Snipes et al., 1992), 
the protein was not expressed in this tissue (Gregson et al., 2007; Parmantier, Cabon, Braun, 
D’Urso, Muller, et al., 1995; Snipes et al., 1992). Contrarily to Gregson et al (2007) who did not 
find PMP22 in the central nervous system, Snipes et al (1992) have detected low levels of PMP22 
in the central nervous system both in the adult (Table 3) and during embryonic development 
(Giambonini-Brugnoli et al., 2005; Gregson et al., 2007; Snipes et al., 1992). Snipes et al findings 
correlate with PMP22 mRNA low levels detected in the brain of humans and rodents (Li et al., 
2013; Snipes et al., 1992). In the mammalian peripheral nervous system, this protein is the second 
most abundant protein after myelin protein zero (P0) (Gregson et al., 2007).  
4. PMP22 protein synthesis and transport 
 Newly produced PMP22 is transiently retained in the endoplasmic reticulum and Golgi 
compartments for post-translational modification like glycosylation. Culturing rat Schwann cells 
or co-culturing rat Schwann cells with neurons results in approximately 70% of newly produced 
PMP22 to be degraded and only a small portion is transported to the cell surface. Consequently, it 
has been suggested that PMP22 protein glycosylation stabilize the protein structure preventing 
protein degradation and allowing transport to the cell surface (Li et al., 2013).   
5.  PMP22 Function 
 The function of PMP22 protein is neither clear nor well-defined. Several hypotheses have 
been presented including PMP22 involvement in cell proliferation, apoptosis and myelination. 
However, PMP22 gene dosage (over-, under-expression and point mutation) has different effects 
depending of the cell type. In addition, contradictory results have been found between in vivo and 
in vitro studies (Li et al., 2013). Since PMP22 is highly relevant in myelinating Schwann cells 
(Mittendorf et al., 2017), I will only present studies related to its function in the peripheral nervous 
system. 
a) Cell proliferation  
 The important increase of PMP22 expression during NIH3T3 cell starvation suggested a 
role of PMP22 in cell proliferation. However, in vitro and in vivo studies have shown contradictory 
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effects. Indeed, overexpression of PMP22 decrease proliferation in Schwann cells (Hanemann et 
al., 1998; Li et al., 2013; Mittendorf et al., 2017; Zoidl et al, 1995) or fibroblasts  (Li et al., 2013; 
Zoidl et al., 1997) in culture while in vivo PMP22 overexpression in young adult transgenic mice 
increases Schwann cell proliferation (Li et al., 2013; Sancho et al., 2001). Nonetheless, in CMT1A 
patients cell proliferation is decreased (S. Lee et al., 2018). In addition, point mutations decrease 
proliferation of fibroblasts in vitro (Zoidl et al., 1997) but increase proliferation of Schwann cells 
in vivo (transgenic mice aged 21-days onward) (Li et al., 2013; Sancho et al., 2001). On the other 
hand, deficiency of PMP22 increase proliferation of Schwann cells in vitro (Li et al., 2013; Zoidl1 
et al., 1995) and in vivo in transgenic (Li et al., 2013; Sancho et al., 2001).  
b) Apoptosis 
 Extensive research has been done on the apoptotic effect of PMP22 on Schwann cells, but 
contradictory results were found. Duplication, deletion and point mutation of PMP22 lead to a 
higher apoptotic rate of Schwann cells (Sancho et al., 2001) and of cultured fibroblasts (Fabbretti 
et al., 1995; Sancho et al., 2001) of transgenic mice. However, this rate is decreased in case of 
several PMP22 point mutations (L16P, S79C, T118M, and G150D) (Fabbretti et al., 1995; Sancho 
et al., 2001). 
c) Myelination 
 PMP22 protein is essential for the structure, the development and the maintenance of 
peripheral nerve myelin (Mittendorf et al., 2017; Suter & Snipes, 1995). Concerning myelin 
structure, recent studies conducted on an in vitro model of lipid bilayers concluded that PMP22 is 
involved in organizing the ultrastructure of compact myelin. Indeed, spiral wrapping around a 
central cylindrical vesicle similar to the wrapping of myelin around an axon was observed in 
presence of PMP22 (Mittendorf et al., 2017). 
 Regarding myelin development and maintenance, the abnormal dosage of PMP22 impairs 
different stages of myelination. Over- or under-expressing PMP22 in Schwann cells in vitro 
indicated that PMP22 is involved in controlling myelin thickness and stability (Suter & Snipes, 
1995). Despite the previously described experiments, the structure of myelin lamellae was similar 
in over- or under-expressed PMP22 Schwann cells (D’Urso et al., 1997). Amici et al (2007) 
demonstrated that PMP22 plays a role in the initiation of myelination in vitro and in vivo, in PMP22 
-/- knockout mice (PMP22 -/- mice). Moreover in the absence of PMP22, expression of several 
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markers of myelination was disturbed (Amici, Dunn, & Notterpek, 2007). Dysmyelination features 
were also observed in these mutant mice: increased number of promyelinating Schwann cells 
surrounding axons without wrapping them, hypermyelinated axons, reduced fiber diameter and 
increased in g-ratio. All of those findings suggested a delayed myelination (S. A. Amici, 2006). 
Furthermore, histological studies of peripheral nerves from transgenic rodent models harboring 
extra copies of PMP22 show amyelinated, hypomyelinated and/or hypermyelinated axons (Table 
2) (Fledrich, Stassart, & Sereda, 2012) further illustrating PMP22 crucial role in the myelination 
process.  
 
F.  Pathomechanisms of CMT1A 
1. Imbalanced activity of signaling pathways  
 CMT1A is both a dysmyelinating and demyelinating disease, which etiology remains 
unclear. Many hypotheses have been proposed including imbalanced activity of signaling 
pathways, dysregulation of critical genes expression, alteration of cholesterol biosynthesis, 
increase in calcium levels, PMP22 aggregates formation and toxicity toward axons (Fabbretti et 
al., 1995; Fledrich et al., 2014; Giambonini-Brugnoli et al., 2005; Kinter et al., 2013; Li et al., 
2013; Nobbio et al., 2009; S Sancho et al., 2001; Vigo et al., 2005; Visigalli et al., 2016).
 Imbalanced activity of the signaling pathways PI3K-Akt and Mek-Erk contributes to 
CMT1A pathogenesis. Indeed, in the CMT1A rat, there is a decreased signaling of PI3-Akt 
pathway followed by a stimulation of Mek-Erk pathway. This leads to a persistent differentiation 
defect of Schwann cells in this rat model, during early postnatal development (Fledrich et al., 
2014). 
2. Downregulation of cholesterol genes 
 Studies on PMP22-overexpressing transgenic mice (CMT1A transgenic mice) showed 
downregulation of genes involved in cholesterol biosynthesis especially the ones encoding the 
rate-limiting key enzymes HMG-CoA reductase and HMG-CoA synthase. This most probably 
explains the decreased activity of sterol regulatory element binding protein 2 (SREBP-2) 
transcription factor. SREBP-2 is a master regulator of the cholesterol pathway genes (Giambonini-
Brugnoli et al., 2005; Horton, Goldstein, & Brown, 2002; Sakakura et al., 2001). Cholesterol is an 
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essential lipid that constitutes a large amount of myelin lipids. It also controls the transferring of 
major myelin proteins (P0) from the Schwann cell endoplasmic reticulum to myelin membrane. 
Cholesterol deficiency in Schwann cells disrupts this process leading to the loss of peripheral 
myelin compaction and the modification in the stoichiometry of myelin membrane components 
(Li et al., 2013; Saher et al., 2009; Vigo et al., 2005). During myelination genes driving cholesterol 
biosynthesis are highly expressed in WT while in CMT1A transgenic mice, their expression 
remains low. This could explain the severe hypomyelination seen early on in CMT1A 
(Giambonini-Brugnoli et al., 2005).   
3. Downregulation of genes influencing the cytoskeleton and extracellular 
matrix 
 Expressions of genes whose products affect the cytoskeleton such as Ankyrin 3 and the 
extracellular matrix such as integrins beta 4 and 5 are downregulated in CMT1A transgenic mice. 
This could be associated with the remodeling of the extracellular matrix seen in CMT1A patients. 
As the interaction of the myelinating Schwann cell with the basal lamina is critical for myelination 
(Cornbrooks et al., 1983; McKee et al., 2012) the severity of nerve fiber loss and the duration of 
the pathology could be linked to these gene expression defects (Giambonini-Brugnoli et al., 2005; 
Palumbo et al., 2002). 
4. Upregulation of Schwann cells differentiation and myelination factors 
 Schwann cells differentiation and myelination require transcription factors such as Krox20 
(refer to Introduction I.D.1). These genes are highly expressed at the start of myelination both in 
CMT1A transgenic mice and controls. However, at adult age, the expression of some markers of 
differentiating Schwann cells such as Oct 6 remains high in CMT1A transgenic mice but not in 
controls. This suggests a defect in the differentiation program of the Schwann cells in CMT1A 
disease (Giambonini-Brugnoli et al., 2005; Jaegle & Meijer, 1998).  
5. Increase in calcium levels 
 Excess of PMP22 has been shown to increase P2X7, a purinoceptor who lead to 
extracellular calcium influx into Schwann cells. Increased levels of calcium have been shown to 
impair myelin synthesis in Schwann cells (Nobbio et al., 2009) and to trigger segmental 
demyelination (Li et al., 2013; K. J. Smith & Hall, 1988). As high calcium levels are normally 
present in immature developing Schwann cells (Fields & Stevens, 2000), this mechanism likely 
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works after development of myelin. Studies have demonstrated that inhibiting P2X7 prevents 
demyelination in Schwann cell/neuronal co-culture with PMP22 overexpression (Li et al., 2013; 
Nobbio et al., 2009). 
6. PMP22 aggregates formation 
 Culturing dermal fibroblasts from CMT1A patients and from age-matched controls show 
fewer mitotic cells as well as a decreased proliferation rate in CMT1A cells compared to controls. 
This is in line with the hypothesis of inverse relationship between increased PMP22 protein levels 
and decreased cell proliferation in vitro (refer to Introduction III.F.5.a). PMP22 distribution in 
cultured fibroblasts differs between patients and controls cells. Indeed, PMP22 excess results in 
perinuclear accumulation of the protein located in aggresomes in Schwann cells (Fortun et al., 
2006; Lee et al., 2018; Notterpek et al., 1999; Rangaraju & Notterpek, 2011). As a large amount 
of PMP22 is misfolded, PMP22 is actively catabolized through protein degradation pathways 
including the ubiquitin proteasome system and the endosomal-lysosomal compartment (Fortun et 
al., 2006; Lucia Notterpek et al., 1999). In CMT1A cells there were significantly higher levels of 
polyubiquitinated molecules compared to controls indicating a deficient proteasome activity in 
diseased cells. Furthermore, in CMT1A cells there was significantly higher levels of autophagy 
and lysosomal proteins lysosome-associated membrane protein 1 (LAMP1) and microtubule-
associated protein light chain 3 (LC3) compared to controls indicating the activation and 
recruitment of autophagy lysosomes to clear and process PMP22 aggregates in diseased cells 
(Fortun et al., 2006; S. Lee et al., 2018; Lucia Notterpek et al., 1999). It can be concluded that 
PMP22 overexpression leading to the formation of aggregates is a possible mechanism for 
CMT1A. PMP22 excess overloads the proteasome system hence inducing demyelination (Fortun 
et al., 2006; S. Lee et al., 2018; Lucia Notterpek et al., 1999).  
7. Axonal loss 
 Axonal loss even at early age is a feature of CMT1A patient and rat model. Why these 
axons die remains unclear. Many hypotheses have been stated.  
 First, abnormal mitochondrial transport along the axon is a characteristic of the most 
frequent forms of CMT in which axonal loss is severe (M. A. Saporta et al., 2009) such as dominant 
CMT2A and recessive CMT4A (Baxter et al., 2002; Pareyson et al., 2015). High mitochondrial 
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density was observed in myelinated axons of CMT1A dermal biopsies suggesting a defective 
mitochondrial transport (M. A. Saporta et al., 2009).  
 Second, in sciatic nerves of rat overexpressing PMP22 cntf (ciliary neurotrophic factor) 
mRNA expression was dramatically downregulated whereas in CMT1A patients’ sural nerve 
biopsies cntf transcript was completely absent. cntf is a neurotrophic factor, which is produced and 
secreted by Schwann cells to support the survival of motor and sensory neurons (Sleeman et al., 
2000). CNTF protein levels were also decreased suggesting the deficient support of Schwann cells 
to axons lead to axonal atrophy in late stages of CMT1A (Vigo et al., 2005).  
 
G. Clinical features  
 Despite the large variability from one patient to another, the most common symptoms 
include muscle weakness in the feet, ankles, legs and hands, loss of proprioception and pinprick 
sensation, amyotrophy of the legs giving an aspect of “jambes de coq” and of the hands leading to 
the famous “mains en griffes” or claw hand symptom, an awkward way of walking (steppage gait) 
and highly arched i.e. pes cavus and hammertoes or very flat feet i.e. pes planus. In a study by 
Ribiere et al (2012) patients with CMT1A appear to feel less pain than other CMT patients (Ribiere 
et al., 2012). In severe cases, patients use a wheelchair (Brennan et al., 2015; Tazir et al., 2014) 
(Figure 8) 
 
H. Diagnostic tools 
 When a patient shows the above clinical features i.e. signs and symptoms of a chronic 
sensorimotor polyneuropathy, CMT diseases must be seriously considered as one of the 
differential diagnoses. First, a detailed family history must be taken to identify the mode of 
inheritance. Then, electrophysiological testing is performed followed by molecular analyses to 
determine the gene causing the disease and for some cases, nerve biopsy (Murphy et al., 2012; 
Paasen et al., 2014; Pareyson & Marchesi, 2009; A. S. D. Saporta et al., 2011). New emerging 
techniques in neuroimaging are also becoming more widely used for the diagnosis of CMT 
diseases (Padua et al., 2017). 
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1. Family history 
 Asking the patient if there are other family members presenting similar signs or symptoms 
helps the physician in determining the mode of inheritance (AD, AR or X-linked). If one parent is 
affected, AD or X-linked (in cases of no male-male transmission) inheritance is probable. If many 
siblings are affected but not the parents or if consanguineous marriages occurred, AR inheritance 
is considered. Family history can be confusing since symptoms are very variable from one patient 
to another and some patients may go undiagnosed. Therefore, carefulness is required when taking 
family history. Clinical as well as electrophysiological examination of first-degree relatives is 
often necessary to establish the inheritance pattern. Family history gives clues towards the most 
probable type of CMT. For example, in case of AD inheritance, the disease is likely to be CMT1 
and in case of AR, CMT4 (Pareyson & Marchesi, 2009; Pisciotta & Shy, 2018; A. S. D. Saporta 
et al., 2011). 
2. Electrophysiological testing  
 Nerve conduction velocity (NCV) under 38m/s in upper-limb motor nerves with a diffuse 
and homogeneous pattern points toward CMT1 and CMT4 (demyelinating CMT). Normal or 
mildly low NCV (NCV > 38m/s in median or ulnar motor nerves) with decreased amplitudes of 
compound muscle and sensory action potential indicates CMT2. NCV ranging from 25-45m/s in 
upper limbs (intermediate NCV) are a bit problematic. Those NCVs hint at the possibility of 
CMT1X in men or dominant intermediate CMT in both men and women (Murphy et al., 2012; 
Paasen et al., 2014; Pareyson & Marchesi, 2009).  
3. Molecular analyses 
 Electrophysiological test allows determining the CMT type (1-6 or X) and directs toward 
subsequent genetic tests required to define the CMT subtype such as A-F for CMT1 (Pareyson & 
Marchesi, 2009). Around 61% of CMT patients are diagnosed by molecular tests at the moment. 
Approximately 93% of molecular diagnoses are made based on 4 genes: PMP22, GJB1, MFN2 
and MPZ (Murphy et al., 2012).  
4. Nerve biopsy 
 Neuropathology is seldom examined due to recent advances in genetic testing. Nerve 
biopsy analysis using electron microscopy is useful in sporadic cases or in inherited cases when 
the main genetic investigations are negative (Pareyson & Marchesi, 2009). 
60 
 
 As an example, nerve biopsies from CMT1A patients display abnormal myelination over 
the whole nerve length (dysmyelination): onion bulbs occurring usually after the age of six, a 
reduced g-ratio and a low density of myelinated nerve fibers. In sural nerves of 3 years patients, 
around 7 000 myelinated fibre/mm2 can be found while it is around 13 000 in control. While 
pathological features were seen in proximal nerves and in roots, the most severe pathological 
changes occurred distally in nerves (Hanemann, Gabreëls-Festen, Stoll, & Müller, 1997; Jacobs & 
Love, 1985; Paasen et al., 2014). 
5. Neuroimaging 
 Peripheral nerve imaging to diagnose neurological diseases is an evolving research field. 
It has known many advances in recent years. Many techniques can be used such as ultrasound 
(US), magnetic resonance imaging (MRI), MR neurography and spectral confocal reflectance 
microscopy (SCoRe) (Deffieux et al., 2018; Heckel et al., 2015; Noto et al., 2015; Padua et al., 
2017; Schain, Hill, & Grutzendler, 2014; Zhang, Guo, & Lee, 2018).  
a) Ultrasound (US) imaging  
 Ultrasound (US) imaging of peripheral nerves is becoming more and more useful in 
differentiating axonal (CMT2) from demyelinating neuropathies (CMT1). Contrarily to CMT2 
patients, CMT1 patients show a significant enlargement in their nerves in US imaging. US imaging 
can also be used to study the disease progression (Padua et al., 2017). US imaging abnormalities 
of CMT1A patients’ median nerve positively correlated with clinical features and negatively 
correlated with NCV (Noto et al., 2015).  
 US imaging is a fast advancing field in neuroscience. New techniques like ultrafast US 
(UFUS) imaging are being developed. This method is based on replacing image acquisitions of 10 
frames per second for US imaging by thousands frames per second for UFUS imaging. At first, 
image quality, resolution, contrast and signal-noise-ratio were worse than regular US imaging due 
to the lack of focus of UFUS imaging. Therefore, a new technique was recently added aiming at 
increasing all the UFUS imaging resolution: cascaded dual-polarity waves relying on a pulse wave 
with positive and negative polarities. This method did not affect the frame rate. It was tested in 
vivo on human back muscle (Deffieux et al., 2018; Y. Zhang et al., 2018). Unfortunately, UFUS 
imaging has not yet been applied to CMT diseases diagnostic.  
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b) Magnetic Resonance Imaging (MRI) and Neurography (MRN)  
 MRI is a type of medical imaging relying on the magnetic properties of hydrogen atoms 
(“spin”properties) found in all tissues of the human body (Grover et al., 2015). Patients with 
peripheral neuropathies can be currently diagnosed by Magnetic Resonance Neurography (MRN), 
a newly developed MRI technique for peripheral nerves. Nevertheless, the resolution of MRN is 
not very high compared to other photon-based imaging techniques. It cannot distinguish the axon 
compartment from the myelin compartment in peripheral nerves making it difficult to differentiate 
demyelinating from axonal neuropathies. The recent development of diffusion tensor imaging 
(DTI) technique to complete MRN analysis can solve this problem. DTI relies on the diffusion of 
water molecules in tissues to depict microstructural modifications. The parameters commonly used 
in DTI are: Fractional Anisotropy which shows the directional preference of water diffusion, Axial 
Diffusivity indicating diffusion parallel to fiber orientation and Radial Diffusivity evaluating 
diffusion perpendicular to fiber orientation. In peripheral nerves, Fractional Anisotropy and Radial 
Diffusivity can be used as imaging markers of myelin sheath integrity whereas Axial Diffusivity 
can be used as an imaging marker of axon integrity (Heckel et al., 2015). 
c) Spectral confocal reflectance microscopy (SCoRe)  
 In addition, several in vivo imaging procedures are still under research. One of these 
methods is called spectral confocal reflectance microscopy (SCoRe). It has been tested on mouse 
brain in vivo and on postmortem human cerebral cortex. SCoRe is based on a common laser-
scanning confocal system, which is relatively easy to implement for clinical applications. Images 
results from the reflectance signals of a scanning laser at different wavelengths. The light is 
reflected by myelin itself so there is no need for an endogenous labeling or staining. Each 
myelinated fiber show a unique striking color pattern due to the combination of its spatial 
orientation and of the light wavelength that is reflected. The resolution is high enough to detect 
nodes of Ranvier and Schmidt-Lanterman incisures. So it is possible to use SCoRe technique for 
identifying many myelin defects. Indeed, the reflectance signal was found to be decreased in case 
of reduced myelination in the brain of shiverer mice, a model having a MPZ gene mutation 
resulting in no formation of compact myelin in the CNS (Schain et al., 2014). Further research 
need to be done to find a suitable imaging technique for in vivo diagnosis of neuropathies.  
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I. Outcome measures for clinical trials 
 CMT diseases gradually progress and worsen with time. To evaluate therapeutic strategies 
in clinical trials, finding reliable and strong outcome measures allowing for the detection of 
relatively small changes over time is crucial. The previously described method for diagnostic can 
of course be used but several additional methods for outcome measures have been developed.  
 For adults, simple, consistent and validated standardized assessment tools are the 
following: the CMT neuropathy score (CMTNS) versions 1 and 2, the most recent Rasch analysis-
based weighted version, rCMTNS, and the subscales rCMTES (r CMT examination score) and 
rCMTSS (r CMT symptom score) (Cornett et al., 2017; Grandis & Shy, 2005; Murphy et al., 2012). 
 For children only one disease-specific scoring system is available: the CMT Pediatric Scale 
(CMTPedS). This scale includes 11 items evaluating fine and gross motor function, strength, 
sensation, and balance in 3 to 20-year-old- children (Burns et al., 2012; Cornett et al., 2017). 
 Beyond these classical clinical scores several novel outcome measures have been proposed 
recently. First, biochemical biomarkers found in the patients’ skin have been investigated. 
Cutaneous transcripts of GSTT2(Glutathione S-transferase theta-2), CTSA (Cathepsin A), PPARG, 
CDA (Cytidine Deaminase) and ENPP1(ecto-nucleotide pyrophosphatase/phosphodiesterase 1) 
(involved in metabolism, negative regulation of cell growth, regulation of fat cell differentiation, 
vacuolar/lysosomal membrane and exopeptidase activity) were found not only to characterize 
patients with CMT1A but also to reliably indicated disease severity and progression. Those 
transcripts represent a potential tool to speed up the finding of a CMT1A therapy in clinical trials 
(Fledrich et al., 2017). 
 Second, gait analysis through the characterization, quantification and following over time 
of locomotor and postural deﬁcits is promising in CMT diseases (Ferrarin et al., 2013; Kennedy, 
Carroll, & McGinley, 2016; Lencioni et al., 2014, 2015, 2017; Õunpuu et al., 2013). Spatio-
temporal parameter (i.e. walking speed), kinematic, related to joint ﬂexion– extension degree (i.e. 
ﬂexion–extension of the ankle, linked to the CMT locomotor deﬁcit of foot drop due to anterior 
tibialis weakness) and kinetic, related to muscle strength (i.e. ankle generated power, linked to 
push-off deﬁcits of CMT patients due to the weakness of the triceps surae) are the three most 
important parameters of gait analysis to assess patients with CMT. According to Lencioni et al 
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(2017), gait analysis including the ability to ascend and descend stairs should be part of the clinical 
evaluation to better characterize impairment when conducting clinical trials (Tiziana Lencioni et 
al., 2017). 
 
IV. Treatment for CMT1A 
 So far, no specific treatment is available for CMT1A disease, but several are being 
developed at preclinical or clinical stages. Meanwhile, at the moment, physical therapy and 
rehabilitative measures are the only option to alleviate the symptoms of the patients. 
 
A. Physical therapy and associated rehabilitative measures 
 Surgery used to be the key choice in the past to correct foot deformities in CMT1A. 
Nowadays, patients undergo less invasive procedures such as physical therapy and associated 
rehabilitative measures (Kenis-Coskun & Matthews, 2016; Tazir et al., 2014). CMT1A patients 
are often prescribed ankle-foot arthroses with or without special shoes. In order to prevent osteo-
articular problems, patients are advised to exercise moderately (Chetlin, Gutmann, Tarnopolsky, 
Ullrich, & Yeater, 2004; Tazir et al., 2014) and to do some stretching. In order to enhance quality 
of life, pain medications, psychological support and counseling are given to patients (Tazir et al., 
2014). Mobility, ambulation and upper limb function are enhanced by orthotic devices ideally 
custom crafted for the needs of patients. Ankle foot orthoses (AFOs) fabricated from 
thermoplastics, metal, leather or carbon fiber material are examples of orthoses (Kenis-Coskun & 
Matthews, 2016) (Figure 10).  Nonetheless, CMT patients think that AFOs are uncomfortable and 
non-esthetic. Thus, anterior elastic AFOs (A-AFOs) were created to boost comfort in patients. 
Those AFOs are a “footup splint” consisting of a detachable cuff that can be worn around the ankle 
and tied into the shoes laces, a “Push brace” made of a preformed foam with three elastic straps 
and a “Multifit Achilles drop foot orthosis”, comprising a half foot plate, a cut-out heel section 
and an adjustable back stem reaching the calf (Kenis-Coskun & Matthews, 2016; Ramdharry, Day, 
Reilly, & Marsden, 2012) (Figure 10). CMT1A patients with anterior elastic AFO can walk for a 
longer time and with less physical effort resulting most probably from decreased steppage gait 
64 
 
(Kenis-Coskun & Matthews, 2016; Menotti et al., 2014). The previously mentioned three types of 
AFOs can decrease foot drop, one typical feature of CMT1A.  
 
 
Figure 10 : AFO (Ankle Foot Orthoses): A: Solid; B: Footup splint; C: Push brace; D: Multifit Achilles drop foot 
orthosis. Adapted from Kenis-Coskun & Matthews, 2016; Ramdharry et al., 2012. 
 Other than orthotic devices, orthopedic shoes were created to avoid foot drop, to alleviate 
pain, to enhance gait and to improve walking distance. Those special shoes  were produced as 
weightless as possible (400 g, lighter than regular shoes) (Bensoussan et al., 2016). Furthermore, 
focal mechanical vibration (fMV) on lower limbs in particular quadriceps and triceps surae 
improved the balance of CMT1A patients enrolled in the study done by Pazzaglia et al. (Pazzaglia 
et al., 2016). Upper extremities are often affected in CMT. Their function could be enhanced by a 
thumb opposition splint. (Kenis-Coskun & Matthews, 2016). 
 
B. Treatment at preclinical stages  
 Several approaches such as pharmacological and gene therapy have been tested at 
preclinical level in animal models (Table 4). 
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1. Pharmacological treatments 
a) NRG1  
 According to studies done on transgenic mouse models (Fricker et al., 2011; Michailov et 
al., 2004; Stassart et al., 2013; Taveggia et al., 2005), soluble NRG1, already used in human trials 
for heart failure treatment, was suggested as  an effective therapeutic candidate to promote nerve 
regeneration (Gambarotta et al., 2014). 
 Fledrich et al (2014) tested the efficacy of soluble NRG1 as an experimental therapy in the 
CMT1A rat and they found that soluble NRG1 was successful in overcoming impaired peripheral 
nerve development and restoring axon survival into adulthood when dispensed at early age 
between postnatal days 6 and 18. Therapy enhanced motor performance in a dose-dependent 
manner; the greatest gain in grip strength without affecting body weight was at the dose of 1 μg/kg. 
Moreover, soluble NRG1 increased the number of myelinated axons in sciatic nerves reaching 
wild-type levels and restitutes the lowered axonal caliber. In treated rats, CMAP was corrected 
(increased levels) but NCV did not change. Treatment restored the balance between pro-
myelinating Akt pathway and demyelinating MAPK pathway and also lowered the expression of 
dedifferentiation markers cJun and Sox2. However, soluble NRG1 therapy neither influenced the 
differentiation-associated genes nor altered the thickness of myelin sheath in the CMT1A rat. 
Treatment starting at later ages (from P18 to P90) was not as efficient in CMT1A rats. The clinical 
phenotype improved but the number of myelinated axons in sciatic nerves and the CMAP showed 
minor ameliorations and the NCV did not change (Fledrich et al., 2014). Finally, while NRG1 
could be used as treatment for human patients, it has serious side effects like an increased risk of 
cancer (Jabbour et al., 2011). 
b) Progesterone antagonist 
 Progesterone promotes PMP22 gene expression in Schwann cell cultures and increases 
PMP22 mRNA of wild-type rats in vivo. In the CMT1A rat, Onapristone, a selective progesterone 
receptor antagonist originally synthesized for primary breast cancer therapy, was found to decrease 
PMP22 mRNA and improve the clinical, electrophysiological and morphological phenotype when 
injected from 5 days till 7 weeks of age or at a later age (from 5 till 18 weeks of age). Indeed, grip 
strength as well as CMAP amplitudes were significantly increased in the Onapristone-treated 
group compared to placebo-treated group. In addition, Onapristone increased the number of mid-
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to large caliber myelinated axons (3-4 µm) in the tibial nerve while in the sciatic nerve the number 
of axons was increased by 7% in the Onapristone-treated group compared to placebo-treated 
diseased rats after 5 months of treatment. Hence, Onapristone prevented axonal loss. Nevertheless, 
treatment did not change NCV or myelin thickness. No toxicity signs were observed (M. W. 
Sereda, Meyer Zu Hörste, Suter, Uzma, & Nave, 2003; Zu Horste et al., 2007). 
c) Inhibition of the P2X7 receptor  
 Intracellular calcium is abnormally increased in Schwann cells from CMT1A rat. Those 
high concentrations were found to be due to PMP22-associated overexpression of the P2X7 
purinoreceptor/channel resulting in extracellular calcium influx into CMT1A Schwann cells (refer 
to Introduction III.F.5). Pharmacological inhibitors of P2X7 (example KN-62, oxidized ATP) can 
correct calcium levels in CMT1A Schwann cells, therefore restoring the migration and the 
secretion of CNTF by Schwann cells. In addition, myelination is improved in co-cultures of 
CMT1A Schwann cells with dorsal root ganglion sensory neurons (Nobbio et al., 2009). An in 
vivo study in CMT1A rats showed that 3 mg/kg of the P2X7 receptor pharmacological antagonist 
A438079 given intraperitoneally every day at the age of one month and for 11 weeks was well 
tolerated and improved the behavioral as well as the morphological phenotypes. Grip strength was 
higher in the A438079-treated group compared to vehicle-treated diseased rats. The expression of 
Schwann cell differentiation markers Mpz and Hmgcr were significantly increased and de-
differentiation markers c-jun along with Ki67 were significantly decreased in A438079-treated 
CMT1A rats. Macrophage-mediated myelin degeneration and axonal damages were reduced by 
A438079 treatment. Nevertheless, treatment did not improve the NCV or CMAP (Sociali et al., 
2016). 
d) Wlds transgene and nicotinamide  
 Wlds (Wallerian degeneration slow) is a phenotype that spontaneously occurred in a mouse 
strain in London, UK. After nerve injury these mice showed a delayed axonal degeneration and 
demyelination due to the recombination of a gene expressed in axons (Coleman et al., 1998). Wlds 
gene is a chimeric gene between Ubiquitination factor 4B and nicotinamide mononucleotide 
adenylyl transferase 1 (Nmnat1) enzyme (Coleman et al., 1998; T. G. Mack et al., 2001). The 
mechanism of action is still unknown but the expression of Wlds gene in rat, drosophila and even 
human neurons in culture preserve axonal degeneration. Meyer zu Horste et al (2011) tested 
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whether Wlds and nicotinamide prevent axonal loss in CMT1A. CMT1A rat were crossbred with 
rat expressing Wlds in neurons. A heterozygous double transgenic (PMP22 and Wlds) rat called 
“CMDS” rat was generated. CMDS rats presented improved clinical impairments (higher grip 
strength, NCV and CMAP amplitude) and decreased axonal loss of mainly larger caliber axons 
versus CMT1A rats. However, Wlds transgene did not affect dysmyelination since like in the 
CMT1A rat, hypermyelination of small caliber axons and hypomyelination of larger ones were 
observed in tibial nerves’ histological sections (Meyer zu Horste et al., 2011).  
  The neuroprotective effect of Nicotinamide was observed after nerve crush injury in young 
adult wild-type rats. However, nicotinamide therapy from 5 till 13 weeks of age didn’t prevent 
axonal loss and impairment in strength in CMT1A rats (Meyer zu Horste et al., 2011). 
2. Gene therapy  
a) Neurotrophin 3 for CMT1A and CMT1E 
 Neurotrophin-3 (NT-3) is a neurotrophic factor that preserves axon from generation. Both 
Schwann cells and muscles express NT-3 (Meier et al., 1999; Sahenk et al., 2014). NT-3 levels 
decrease following nerve injury and are upregulated during peripheral nerve regeneration 
(Frostick, Yin, & Kemp, 1998). In addition NT-3 belongs to an autocrine survival loop which 
contributes to survival and differentiation of SCs without the axon (Meier et al., 1999; Mirsky et 
al., 2002; Zarife Sahenk et al., 2014). NT-3 administration was shown to enhance axonal 
regeneration and remyelination process. Nevertheless, NT-3 possesses a short half-life and needs 
to be continuously administrated. Hence, a more beneficial way of conveying NT-3 is through an 
adeno-associated virus (AAV) gene transfer. Sahenk et al (2014) tested this possibility first using 
the trembler J (TrJ) mouse, a naturally occurring animal model of CMT showing a point mutation 
in the gene PMP22 (Zarife Sahenk et al., 2014). TrJ mice were injected intramuscularly with a 
single injection of 1x1011 vector genome (vg) of AAV1.CMV.NT3. NT-3 was injected in the 
muscle because the goal of the therapy was to preserve axons and muscle allows for a long-lasting 
biological systemic effect due to a continuous discharge (CMV: Cytomegalovirus) (Zarife Sahenk 
et al., 2014). Treated mice showed a signiﬁcant improvement of grip strength starting around 10 
weeks after injection and rotarod performance between 20 and 40 weeks post injection compared 
to PBS-injected controls. Improved myelin thickness and CMAP amplitude were mostly seen in 
small and medium sized fibers 20 weeks post injection (Table 4). This NT3 therapeutic strategy 
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has currently moved to clinical trials (NCT03520751). For further details refer to Introduction 
IV.C. 4. 
b) PMP22 antisense oligonucleotides (ASO) 
 ASOs are single-stranded synthetic deoxynucleotides that bind target mRNA via Watson-
Crick base pairing, resulting in degradation of target mRNA by RNAse H, a ubiquitously 
expressed mammalian enzyme (Rinaldi & A Wood, 2017; Zhao et al., 2017). Zhao et al showed 
that treating weekly intraperitoneally C22 mice and CMT1A rat (two CMT1A murine models, 
Table 2) with ASOs after start of disease effectively decreases PMP22 mRNA in affected nerves. 
NCV and CMAP were increased in both CMT1A rodent models. Moreover, ASO therapy 
improved rotarod and grip test performance in treated diseased mice (Zhao et al., 2017). However, 
no effect was shown on behavioral performance of CMT1A rats and the treatment strategy was 
inconsistent as rats overexpressing mouse PMP22 were treated with an ASO targeting endogenous 
rat PMP22, while an ASO targeting mouse PMP22 was available. A comparison of my work with 
the data presented in this article is shown in the discussion part.  
 
C. Clinical trials  
1. Ascorbic acid and creatine (vitamin trials)  
 Ascorbic acid and creatinine did not show improvements in treated CMT1A patients 
(dowling, 2018). Ascorbic Acid is critical to trigger myelination in vitro and in vivo. Lack of 
ascorbic acid is associated with femoral peripheral neuropathies. In a preclinical study treatment 
of the C22 mouse model of CMT1A with high doses of ascorbic acid improved the grip test and 
rotarod performance, as well as the number of myelinated fibers (Passage et al., 2004). As ascorbic 
acid relatively easy to produce and is approved for human treatment, a phase 2 clinical trial was 
organized. Although the treatment was indeed safe and well-tolerated, no significant improvement 
could be found in treated patients versus placebo treated (Lewis et al., 2013; Mandel et al., 2015; 
Pareyson et al., 2011) (Table 4). 
 Creatine is a natural substance that plays an important role in the energy metabolism of 
muscle. Creatine supplements improve repeated maximal exercise performance and recovery from 
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exercise. It was given orally to a small cohort of 20 patients. No difference was observed between 
treated CMT1A patients and placebo groups (Chetlin et al., 2004) (Table 4). 
2. PXT3003  
 PXT3003 is a three-drug-combination therapy or what is named as ‘pleotherapy’ by 
Pharnext. The drugs, baclofen, naltrexone and D-sorbitol are given at a low dose and they are 
already approved (Tazir et al., 2014). Baclofen (BCL) is an agonist of GABAb receptor. It reduces 
the activity of adenylate cyclases including intracellular cAMP which positively regulate PMP22 
expression. BCL is a safe drug since it is already utilized as spasticity therapy. Naltrexone (NTX) 
is an opioid receptor antagonist. It also decreases intracellular levels of cAMP. Like BCL, it is safe 
and currently on the market to treat drug addiction. Finally, D-sorbitol (SRB) plays a role in energy 
production/storage (polyol pathway). It might improve PMP22 protein folding that is impaired 
when overexpressed in CMT1A Schwann cells (Chumakov et al., 2014). 
 In vitro testing proved the efficacy of PXT3003 and the synergy of the three-drug 
combination.  Treating with PXT3003 myelinating co-cultures of dorsal root ganglion (DRG) 
neurons with Schwann cells derived from CMT1A rats improved myelination. In CMT1A rats, 
PXT3003 decreased PMP22 mRNA. Treatment also ameliorated the clinical electrophysiological 
and morphological phenotype of CMT1A rats (Chumakov et al., 2014). 
 As demonstrated by clinical trial phase 2, PXT3003 therapy is safe and tolerable. Most of 
treatment-emergent adverse events including gastrointestinal disorders, nausea and nervous 
system disorders were mild and not dangerous. The highest dose showed the best improvements 
of the clinical phenotype in the four functional measures done (6MWT=6 Minute Walk Test, Ankle 
dorsiflexion, Hand Grip and 9HPT=9-Hole Peg Test). Electrophysiological measures suggested a 
possible improvement of myelin function, but no imaging of myelin has been possible. Distal 
motor latency was slightly but significantly lower in the high dose group comparing to placebo 
and motor conduction velocity increased even if it is not statistically significant (Attarian et al., 
2016). PXT3003 significantly improved disease progression in CMT1A patients measured with 
classical clinical scores CMTNS and ONLS (Overall Neuropathy Limitations Scale) (Mandel et 
al., 2015). PXT3003 is in phase III clinical trial since December 2015 (check the website cited 
after the bibliography and enter this number NCT02579759) (Table 4).  
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3. ACE-083 for CMT  
 ACE-083 is a therapeutic candidate acting on myostatin (GDF8) and other members of 
TGF-beta superfamily to improve skeletal muscle growth. When this drug is injected in some 
muscles, it increases their mass and strength. This was initially demonstrated in a mouse model of 
neuromuscular diseases, but it is also beneficial in the CMT mouse model Trembler-J. This 
treatment can be applied to CMT patients displaying a mild-moderate disease phenotype involving 
specific muscles (Glasser et al., 2018) (Table 4). 
 A phase 1 clinical trial study in healthy volunteers resulted in significantly dose-dependent 
higher muscle volume. However, no significant effect was detected in muscle strength. 
Furthermore, ACE-083 was safe and well-tolerated (Glasser et al., 2018); NCT02257489). 
Adverse events were mild and similar between placebo and treated individuals. The administration 
route being a local injection in muscles, injection site pain was the most frequent adverse effect. 
Most of those effects were reported at the time or right after dosing and resolved shortly after.  
Since 31 July 2017, there is an ongoing phase 2 clinical trial in CMT1A or CMTX patients with 
the foot drop symptom (mild-moderate ankle dorsiflexion weakness and mild plantar flexion 
weakness). This trial is expected to end in July 2019 (NCT03124459) . 
4. Gene therapy approach  
 In a pilot clinical trial, recombinant methionyl human NT-3 (r-metHuNT-3) was tested on 
8 CMT1A patients. Participants received either placebo or 150 µg/kg r-metHuNT-3 three times a 
week for 24 weeks. Improvement of motor, reflex and sensory abilities was seen in NT3-treated 
group versus placebo. Sural nerve biopsies were collected before and after treatment on treated 
and on placebo patients. Axonal regeneration improved after NT3 treatment (Z. Sahenk et al., 
2005).  
 The following phase I/ IIa clinical trial has been setup using recombinant virus 
AAV1.tMCK.NT-3 (NCT03520751). Triple muscle-specific creatine kinase (tMCK) is the 
promoter controlling the coding sequence (Zarife Sahenk et al., 2014). The goal was to assess a 
gene therapy approach to treat CMT1A in an open-label (both the researchers and participants 
know which treatment is being administered), one-time injection ascending dose study. 
AAV1.tMCK.NTF3 was administered intramuscularly into both legs muscles of 9 CMT1A 
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subjects aged 15 to 35 years old. The patients are injected with 2x1012vg/kg or 6x1012vg/kg 
(NCT03520751) (Table 4). 
5. Other Ongoing clinical trials 
 The anti-progestin Ulipristal Acetate (EllaOne®) is a drug that antagonizes progesterone 
activity. It has been developed and tested for long-term safety in the frame of endometrial fibroma 
treatment. As progesterone promotes PMP22 expression in SCs (Désarnaud et al., 2000; M. W. 
Sereda et al., 2003; Zu Horste et al., 2007), the anti- progestin EllaOne drug was also evaluated in 
a clinical trial phase 2 in order to improve the phenotype of CMT1A patients. No results are 
available yet, but the trial has been terminated prematurely in 2017 because serious hepatic side 
effects occurred in some patients treated for fibroma (NCT02600286) (Table 4). 
 MD1003, a high-dose pharmaceutical-grade biotin drug, has been assessed for effect on 
motor and sensory conduction in demyelinating neuropathies patients including CMT1A. No 
results for CMT1A are available yet. Biotin is a cofactor for an enzyme involved in fatty acid 
synthesis, which is critical for the myelin sheath. Biotin treatment had been suggested to be 
efficient for the treatment of multiple sclerosis. (NCT02967679; Tourbah et al., 2018) (Table 4).  
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Table 4 : Treatment options for CMT1A.  
Name Aim Design 
Animal 
model 
Results 
NRG1 
Restore 
axonal 
survival 
· P6-P18 IP injection every 
2 days. 
· Different doses: 0; 0.1; 1; 
10; 50 µg/ kg 
CMT1A rat 
· Better motor performance. 
· Increased number of myelinated axons in sciatic 
nerves. 
· CMAP corrected but not NCV. 
· Restored balance between Akt and MAPK pathway. 
· No effect on differentiation genes. 
· No effect on myelination. 
Onapristone 
Decrease 
PMP22 
excess 
· Progesterone receptor 
antagonist 
· Subcutaneous time-
release pellets 5 days - 7 
weeks or 5 till 18 weeks 
· 20mg/kg/day 
CMT1A rat 
· Increased muscle strength, CMAP, mid-large 
myelinated axons in tibial and sciatic nerves. 
· No change in NCV. 
· No effect on myelination. 
 
A438079 
Correct 
calcium 
levels 
· P2X7 receptor antagonist 
· IP daily injection from 1-
2 month of age 
· 3mg/kg 
CMT1A rat 
· Increased muscle strength and Schwann cell 
differentiation markers. 
· Decrease de-differentiation markers, myelin 
degradation and axonal loss. 
· No change in NCV or CMAP. 
 
Wlds trangene 
 
Prevent 
axonal loss 
 
CMDS 
(CMT1Ax 
Wlds) 
· Higher grip strength, NCV and CMAP amplitude. 
· Decreased axonal loss of mainly larger caliber 
axons. 
· No effect on dysmyelination. 
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Nicotinamide 
Prevent 
axonal loss 
Daily IP injections from 5-10 
week of age, 500 mg/kg 
CMT1A rat No effect on axonal loss or on muscle strength. 
NT-3 
Preserve 
axon from 
degeneration 
Single intramuscular injection 
of 1x1011 vg of 
AAV1.CMV.NT3 
TrJ mice 
Improvement of grip strength and Rotarod performance, 
thickness of myelin and CMAP amplitude mostly in small 
and medium sized fibers. 
ASO 
Decrease 
PMP22 
excess 
Intraperitoneal injections 
CMT1A rat 
and C22 
mouse 
· Increased NCV and CMAP in both animal models. 
· Improved motor phenotype in treated C22 mice. 
Ascorbic acid 
Trigger 
myelination 
110 individuals initially, 
aged 13 to70 years, 
randomized, double masked, 
controlled trial with 
4:1allocation to oral ascorbic 
acid or matching placebo, 
4g/day for 2 years. Not all 
completed the study (3 
withdrawals) due to adverse 
event 
C22 mice 
(pre-vious 
studies) 
· In mice, improved motor performance and increased 
number of myelinated fibers. 
· No effect on patients. 
Creatine 
Important 
role in the 
energy 
metabolism 
of muscle. 
Double blind trial, 20 
patients, daily oral 
administration, 5g/day, with 
resistance training during 12 
weeks 
 
No difference between treated CMT1A patients and 
placebo. 
PXT3003 
Decrease 
PMP22 
excess 
323 participants. Randomized 
triple masking phase 3 
clinical trial. Combination of 
3 drugs: baclofen, naltrexone 
and D-sorbitol 
(NCT02579759). 
Preclinical 
studies in 
vitro and in 
CMT1A 
rats 
· In vitro improvement of myelination 
· Decreased PMP22 and better clinical, 
electrophysiological and morphological phenotype in 
rats and in patients except for myelin function, no 
possible imaging in humans. 
· Safe and tolerable in humans. 
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References cited in the text above. 
ACE-083 
Improve 
skeletal 
muscle 
growth 
Phase 1 non-randomized, 
open-label clinical trial 
(NCT02257489) completed 
and ongoing randomized, 
double-blind and placebo-
controlled phase 2 
(NCT03124459). 42 
participants.                          
Bilateral tibialis anterior 
intramuscular injection of 
maximum 250 mg/muscle, 
once every 3 weeks for up to 
17 doses. 
Pre-clinical 
studies in 
TrJ mice 
and mouse 
model of 
neuro-
muscular 
disease 
· Dose-dependent higher muscle volume in healthy 
volunteers (phase 1 results). 
· Safe and well tolerated treatment; mild adverse events 
mostly related to administration route. 
EllaOne 
(Ulipristal 
Acetate) 
Progesterone 
antagonist 
23 participants, randomized, 
triple masking phase 2 
clinical trial (NCT02600286) 
 
Long term safety tested for endometrial fibroma treatment        
CMT1A trial terminated due to serious hepatic side effects 
occurred in some patients treated for fibroma. 
MD 1003 
(Biotin) 
Critical for 
myelin sheath 
15 participants, open label 
phase 2 for CMT1A and other  
Peripheral Neuropathy 
 Efficient for the treatment of multiple sclerosis. 
AAV1. tMCK. 
NT-3 
Preserve 
axon from 
degeneration 
9 CMT1A subjects aged 15 to 
35 years old                                                        
Open-label label, one-time 
injection phase I/IIa clinical 
trial.  Intramuscular injection 
into both legs muscles of 
2x1012 vg/kg or 6x1012 vg/kg 
(NCT03520751). 
Refer to 
above 
Improvement in motor, reflex and sensory abilities as well 
as axonal regeneration. 
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V. Gene therapy 
 Gene therapy or the concept of treating an inherited disease with no cure by correcting or 
replacing a defective gene within the affected cells has long captivated scientists, clinicians and 
the general public (Naldini, 2015; Piguet, Alves, & Cartier, 2017). However, this approach still 
raises concerns and fears towards safety and possible consequences (Wirth, Parker, & Ylä-
Herttuala, 2013). There are two types of gene therapy (germline and somatic). Gene therapy went 
through a long and difficult journey from concept to clinical application in several fields of 
medicine (Dunbar et al., 2018). In order to translate to clinical trial, finding the safest and most 
efficient delivery method of the therapeutic gene is essential (Naldini, 2015). 
 
A. Types of gene therapy 
 In germline gene therapy, the therapeutic or modified gene is passed along to the next 
generation. This category of gene therapy is not allowed by current legislation. In somatic gene 
therapy, the therapeutic or modified gene is inserted in some target cells without passing along to 
the next generation (Wirth et al., 2013). 
 For ex vivo somatic gene therapy, diseased human cells are isolated, cultured and 
genetically altered outside the body through non-viral or viral-mediated gene transfer (Naldini, 
2015; Wang & Gao, 2014). In this way, safety and target cell specificity are improved since the 
body is not directly exposed to gene delivery vectors. Furthermore, the genetically-altered cells 
are autologous cells from the patient him/herself, hence avoiding the risk of graft-versus-host 
disease frequently observed in hematopoietic stem cell transplantation between two persons. Stem 
or progenitor cells with transgene integrated into host genome in addition to integrating viral 
vectors are most widely used for ex vivo gene therapy.  For in vivo somatic gene therapy, vectors 
(viral and non-viral) are used to deliver the therapeutic or modified gene to patients (Wang & Gao, 
2014). I will develop further the in vivo somatic gene therapy in the following paragraphs. 
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B. Delivery methods 
 Vectors (gene delivery vehicles) are divided into two main categories: non-viral and viral 
(Wang & Gao, 2014). 
1. Non-viral vectors (DNA vectors) 
 A therapeutic gene expression cassette including a gene transcription promoter, the 
transcript of interest and a termination signal ending gene transcription can be enclosed in a 
circularized, double stranded DNA molecule, plasmid DNA (pDNA) serving as a delivery vehicle. 
Several direct in vivo injection techniques exist. The most efficient one is rapidly injecting a large 
amount of pDNA solution in major organs while temporarily causing pores in cell membrane. This 
method is known as hydrodynamic injection (D. Wang & Gao, 2014; Wang, et al., 2013). In order 
to help negatively charged pDNA molecules entering the hydrophobic membranes of cells, pDNA 
can be compressed into lipoplexes and polyplexes respectively by cationic lipids and cationic 
polymers. Those cationic lipids and polymers protect pDNA from degradation by nuclease and 
help penetration into target cells (Jin et al., 2014; Wang & Gao, 2014). To obtain a successful 
transgene expression, pDNA has to pass through important cellular surveillance mechanism 
barriers leading for example to a destructive innate immune response when Toll-Like Receptor 9 
detects unmethylated CpG dinucleotides in pDNA (Barton, Kagan, & Medzhitov, 2006; D. Wang 
& Gao, Guangping, 2014). To avoid this, minicircle DNA (mcDNA) that do not possess CpG-rich 
backbone sequences have been designed  (Mayrhofer et al., 2009; Wang & Gao, 2014). This 
mcDNA also leads to safer, higher and more sustainable transgene expression than classic pDNA 
(Gill et al., 2009; Wang & Gao, 2014). A part of DNA vector goes to the nucleus and form a non-
integrating, episomal DNA leading to transgene expression. Nevertheless, this non-replicable 
DNA is lost when cells are dividing. Moreover, this DNA tends to be degraded in cells. 
Consequently, transgene expression is temporary. A scaffold matrix attachment region (S/MAR) 
might be added to the vector to replicate and retain episomal DNA in daughter cells (Argyros et 
al., 2011; Wang & Gao, 2014)  
 The advantages of DNA vectors are an easy production, the large cassette of expression, 
and the absence of a viral component thus low immunotoxicity. However, DNA vectors are 
relatively easily degraded and much less effective in gene delivery than viral vectors (D. Wang & 
Gao, Guangping, 2014). 
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2. Viral vectors 
 Viruses, naturally evolved microorganisms, have developed many ways to infect cells 
where they could use the host machinery to replicate their viral genetic material and produce viral 
proteins. One way for viruses to enter the cell is endocytosis (Vannucci et al., 2013; Wang & Gao, 
2014). This concept has encouraged scientists to explore viruses as gene delivery vectors for 
therapy and in particular viruses that can be manipulated to be non-replicative (they infect but 
cannot reproduce themselves).  A wild-type viral genome is composed of several viral genes and 
signal sequences that serve for viral life cycle. Viral vectors can be produced in cells in cultures. 
The majority of viral genes are replaced by a therapeutic cassette in order to limit viral toxicity 
and pathogenesis, whereas the signal sequences are kept to synthesize a sufficient amount of vector 
particles. The current most frequently utilized viral vectors for gene therapy are the retrovirus, the 
herpes simplex virus (HSV), the adenovirus (AdV) and the adeno-associated virus (AAV) 
(Herzog, Cao, & Srivastava, 2010; Vannucci et al., 2013; Wang & Gao,  2014) (Table 5). 
a) Retrovirus 
 Retroviruses include gammaretroviruses and lentiviruses. They are single-stranded RNA 
viruses. They use virus-derived reverse-transcriptase and integrase enzymes for inserting their 
proviral complementary DNA into the host genome. Gammaretrovirus only transduce replicating 
cells whereas lentivirus transduce both replicating and non-replicating cells (Sakuma, Barry, & 
Ikeda, 2012; D. Wang & Gao, Guangping, 2014). The glycoproteins present on the envelope of 
those two types of virus could be altered hence allowing specific tissue/cell tropism (Vannucci et 
al., 2013; D. Wang & Gao, 2014). Retroviral vectors are capable of integrating the host genome. 
This is not only an advantage of ensuring the stability of transgene and persistence of transgene 
expression to daughter cells following genome replication and cell division but also a 
disadvantage: the threat of insertional mutagenesis (Fehse & Roeder, 2008; Wirth et al., 2013) and 
the risk to cause cancer by possibly disrupting tumor suppressor genes or activating oncogenes 
(Hacein-Bey-Abina et al., 2010; D. Wang & Gao, Guangping, 2014). To avoid insertional 
mutagenesis, targeted integration of transgenes to predefined genomic sites has been the topic of 
many research studies. Zinc finger nucleases, meganucleases or transcription activator-like 
effector nucleases have been used to cleave genomic DNA at a specific site so that targeted 
integration occurs (Marcaida et al., 2010; Mussolino & Cathomen, 2012; Urnov et al., 2010). To 
elude the cancer risk, self-inactivation vectors in addition to modifying the viral integrase have 
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been created (Lombardo et al., 2007; Provasi et al., 2012; D. Wang & Gao, 2014; Yáñez-Muñoz 
et al., 2006; Zufferey et al., 1998) (Table 5). 
b) Herpes simplex virus (HSV)  
 HSV is a double-stranded DNA virus. Being naturally neurotropic, it is suitable for treating 
neurological disorders. As HSV is retrogradely transported in neurons; their uptake at sensory 
nerve terminals following skin or mucous membrane infection, allows gene modifications in 
neuronal nucleus in the cell body. Some HSV have been designed to produce cell death factor and 
they are used to treat cancer by inducing oncolysis in transduced tumor cells (Manservigi et al., 
2010; D. Wang & Gao, 2014) (Table 5). 
c) Adenovirus (AdV)  
 AdV are double stranded DNA viruses. Contrarily to retroviruses, Adv do not integrate the 
host genome and thus do not cause insertional mutagenesis. AdV form an episomal DNA in the 
host nucleus. AdV can transduce a large range of cells going from quiescent to proliferating cells 
and passing by tumor cells. However, the main downside of this vector is its strong 
immunogenicity in many mammals and in human in particular injection (Lehrman, 1999; D. Wang 
& Gao, 2014). AdV are still used for infecting and killing tumor cells (oncolysis like HSV) and 
for vaccination, which requires activation of the immune system (Table 5). 
d) Adeno-Associated Virus (AAV)  
 AAV are single stranded DNA viruses. Nowadays, AAV vectors are among the most 
commonly used viral vectors for gene therapy. Formerly, since it has not been classified as a 
pathogen, not much was known about this virus. The absence of disease associated with this  virus, 
the persistence of the virus in cells in vivo, the ability to transduce non-dividing cells and the 
diversity of the serotypes have improved the potential of AAV as a delivery tool for gene therapy 
applications (Daya & Berns, 2008; Grieger & Samulski, 2012; Okada, 2013) (Table 5). 
i. AAV physical properties 
 Wild-type AAV is a small (20-26nm), single-stranded encapsulated DNA, non-enveloped 
parvovirus.  Its linear genome is composed of two open reading frames containing the rep and cap 
genes bordered by inverted terminal repeats (ITRs) (Grieger & Samulski, 2012). The ITR can pair 
with themselves through a T-shaped hairpin structure, contain cis elements required for replication 
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and packaging (Koczot et al., 1973). Four non-structural proteins (Rep78, Rep68, Rep52, and 
Rep40) and three capsid proteins (Cap: VP1, VP2, and VP3) are encoded by those two genes 
(Grieger & Samulski, 2012; Okada, 2013; Young et al., 2000). 
 The large Rep proteins (Rep78 and Rep68) regulate viral replication through the production 
of DNA binding, site-specific and strand-specific endonuclease activities and DNA-RNA and 
DNA-DNA helicase activities. Rep78 and Rep68 are essential for facilitating targeted integration 
into the human genome on chromosome 19 at the AAVS1 designated locus (Grieger & Samulski, 
2012; Okada, 2013; Young et al., 2000). 
 The small Rep proteins (Rep52 and Rep40) play a role in accumulating the single-stranded 
viral genome in order to package within AAV capsids (Grieger & Samulski, 2012; Okada, 2013). 
Transcripts utilizing p5, p19 and p40 promoters produce respectively the large Rep proteins 
(Rep78 and Rep68), the small Rep proteins (Rep52 and Rep40) and capsid proteins (Grieger & 
Samulski, 2012; Okada, 2013; Qiu & Pintel, 2008; Young et al., 2000). 
 The three capsid proteins differ in their N-terminus residues. The VP1 protein comprises 
phospholipidase that is necessary for infectivity while the VP2 and VP3 proteins form the structure 
of the envelope coat, the capsid (Girod et al., 2002; Grieger & Samulski, 2012). 
ii. AAV infection cycle 
 Wild-type AAV uses the host cell polymerase for its own replication since it does not 
encode any (K I Berns, 1990). AAV enters the host cell via receptor mediated endocytosis and it 
is then transported to the nucleus by clathrin coated vesicle (Bartlett et al., 2000). In the nucleus, 
the virion sheds its capsid and releases its genome (Ding et al., 2005; Srivastava, 2008). The 
particularity of AAV is that viral genome of wild-type AAV replicates only in the presence of a 
co-infected helper virus such as an adenovirus. In the absence of this helper virus, AAV integrates 
into the host cell genome on the specific locus AAVS1 of human chromosome 19. This integration 
occurs because the Ying Yang 1 (YY1) transcription factor prevents p5 viral promoter to produce 
viral proteins (Berns & Linden, 1995; Pereira et al., 1997) (Figure 11).  
 Specific genes of the helper adenovirus are required for AAV replication such as: E1A, 
E2A, E1B 55, E4 (ORF6) and viral associated proteins.  E1A associates with the YY1 repressor 
thus p5 can initiate the expression of large amounts of Rep68/Rep78. E2A promotes AAV 
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replication in vitro. The E1B 55 and E4 (ORF6) proteins stimulate AAV replication and second 
strand DNA synthesis (Fisher et al., 1996; Samulski & Shenk, 1988; Ward et al., 1998). By 
blocking the phosphorylation of EIF2 alpha translation factor, the viral associated proteins trigger 
AAV expression. This factor inhibits AAV gene expression when phosphorylated (Nayak & 
Pintel, 2007). In addition, UV radiation and hydroxyurea that lead to cell stress naturally intensify 
AAV replication (Yalkinoglu et al., 1988). 
 
Figure 11 : AAV infection cycle: AAV enters the cell via endocytosis and is transported to the 
nucleus. In the nucleus it sheds its capsid and releases its genome. It replicates only in the 
presence of a helper virus (lytic cycle). In the absence of the helper virus, AAV integrates into 
the host cell genome (lysogenic cycle) .Adapted from 
https://www.abmgood.com/marketing/knowledge_base/Adeno_Associated_Virus_Introductio
n.php#14 
 
iii. Recombinant AAV (rAAV) 
 In 1984, some researcher replaced the viral genome of AAV by a simple transgene and 
transfected it into cells infected with adenovirus. This led to the generation of modern days AAV 
adaptations: recombinant AAV (rAAV) (Carter, 2004; Grieger & Samulski, 2012). 
 Modern day rAAV vectors are now produced by substituting the entire AAV viral genome 
between the ITRs with an expression cassette of approximately 5 kb. Afterwards, the essential 
81 
 
genome of AAV is provided by two plasmids: one delivering the rep and cap genes in trans 
(separate from the ITR/Transgene cassette) and the other carrying the adenoviral helper genes. 
These three plasmids are co-transfected in packaging cells to produce infectious viral particles. 
These viral particles are non-replicative because they lack the replication gene rep (Grieger & 
Samulski, 2012). 
 It is now possible to control the rAAV tropism by switching the serotype through the 
alteration of the rep and cap genes. It is important to note that since the rAAV does not possess 
the rep gene along with its cis-active intercistronic expression element that are both needed for site 
specific integration, rAAV stays as an extra chromosomal element in the cell, as an episome 
(Carter, 2004; Daya & Berns, 2008; Grieger & Samulski, 2012). 
iv. AAV serotypes and tropisms 
 At least 10 serotypes of AAV have been characterized each with its own unique traits and 
tropisms. Tropism is determined based on differences between cell surface receptors of AAV 
serotypes. It might as well be affected by cellular uptake, intracellular processing, nuclear delivery 
of the vector genome, uncoating, and second strand DNA synthesis (Wu et al., 2006). AAV1 and 
AAV5 transduce almost the same cells (vascular endothelial cells). However, AAV5 efficiently 
transduces astrocytes, whereas AAV1 effectively transduces retina, heart and lung tissue (Chen et 
al., 2005). AAV 1 and AAV7 transduce efficiently murine skeletal muscle while AAV2, the most 
widely studied AAV serotype is able to infect various tissues with a preference towards skeletal 
muscles (Manno et al., 2003), neurons (Bartlett et al., 1998), vascular smooth muscle cells (Richter 
et al., 2000) and hepatocytes (Koeberl et al., 1997). AAV2 can also kill breast cancer cells without 
affecting normal mammary epithelial cells (Alam et al., 2011; C. Gao, Zhang, Zheng, & Wang, 
2018). AAV3 targets CNS/retina, heart and liver. AAV4 tropism is towards heart and lung cells 
because it is present mostly in the chest of the host after infection. AAV6 highly transduce airway 
epithelial cells with a lower immunogenicity compared to AAV2 (G.-P. Gao et al., 2002; Halbert, 
Allen, & Miller, 2001; Rabinowitz et al., 2004). AAV7 and AAV 8 both transduce hepatocytes 
with a higher efficiency for AAV8 (Zincarelli et al., 2008). Intravenous injection of AAV8 in dogs 
transduced most tissues including skeletal muscles, diaphragm, heart and liver but not the brain 
nor the pancreas nor the thymus cells (Mack et al., 2017). AAV9 targets CNS, heart, lung, liver 
and skeletal muscle (Armbruster et al., 2016; Zincarelli et al., 2008).  AAV9 can cross the blood 
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brain barrier after intravenous injection (Armbruster et al., 2016; Foust et al., 2009; Gray et al., 
2010; Haurigot et al., 2013). After intracerebral injections, AAV10 efficiently transduces the 
central nervous system (injected hemisphere, cerebellum and cervical spinal cord) but is also 
detected in other organs such as the liver, the spleen, the lymph nodes and blood but not the gonads 
(Zerah et al., 2015). AAV viral vector tropism is different depending on animal species. For 
example, in dogs, AAV8 vector infection of the liver is much lower than in mice and nonhuman 
primates (Bell et al., 2011; Mack et al., 2017; Nathwani et al., 2007; Nietupski et al., 2011; L. 
Wang et al., 2011). 
v. AAV Pseudotyping 
 Pseudotyping is defined as the substitution of the capsid of one serotype (usually AAV2) 
with the capsid of another serotype. This process could lead to different transduction efficiency 
and tropism profiles (Auricchio, 2003; Balaji et al., 2013). Furthermore, pre-existing immune 
response against one serotype could be avoided with a capsid from another serotype (Auricchio, 
2003). For example, rAAV2/5 designates a virus holding the genome of serotype 2 packaged in 
the capsid from serotype 5. After brain injections, thanks to the serotype 5 capsid this pseudotyped 
virus targets neurons that are not transduced by rAAV2; the primary neurons in pyramidal layers 
of the hippocampal brain area. In addition, rAAV2/5 is more widely distributed in some brain areas 
than rAAV2. Furthermore, transduction frequencies are higher for rAAV2/5 compared to rAAV2  
(Burger et al., 2004). Another example of a more efficient transduction of pseudotyped virus 
compared to classic one is AAV2/9 after stereotaxic brain surgery for viral injection (Vincent, 
Gao, & Jacobson, 2014). 
vi. AAV advantages and disadvantages: 
 In comparison to other viral vectors such as lentivirus and adenovirus which both infect 
most diving/non-dividing cells with a high transduction rate in particular for adenovirus, AAV 
serotypes are  more cell-specific, while they also infect both dividing and quiescent cells (Vannucci 
et al., 2013) (Table 5). 
 While 10% of wild-type (WT) AAV may integrate the genome, recombinant AAV (rAAV) 
usually do not integrate the genome; which prevent the insertional mutagenesis characteristic of 
lentivirus. Nevertheless, the episomal double-stranded DNA of AAV persist in non-dividing cells 
for a long time without damaging the host cell (R. H. Smith, 2008). 
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 Furthermore, contrarily to lentivirus and adenovirus which both cause respectively a high 
or very high immune response, AAV only causes a very mild immune response and an almost 
negligible pathogenicity. Even though AAV is highly found in the human population and that more 
than 80% of adults aged 20 years and more have neutralizing antibodies to AAV serotypes 1, 2, 3 
and 5, no known illness is linked to AAV (Giacca & Zacchigna, 2012; Vannucci et al., 2013).  
 On the other hand, the main disadvantage of AAV is its relatively small genome size (5Kb) 
that restricts the inserted gene size to less than 4.5 kb in length compared to lentivirus (9Kb) and 
adenovirus (7.5Kb). However, some alternatives have been developed such as an oversized AAV 
transduction. This is possible via DNA repair pathways using an oversized reporter of 6.2kb and 
resulting in “fragment” AAV genomes of 5.0, 2.4, and 1.6 kb (Hirsch et al., 2013). This method is 
efficient as shown in mouse and dog models (Allocca et al., 2008; Monahan et al., 2010). 
 Another disadvantage for rAAV is being single stranded DNA hence needing to synthesize 
or recruit the complementary strand before gene expression. After single stranded DNA is 
converted to double stranded, an important loss of gene expression could occur due to transient 
instability of the vector genome. This loss affects the overall efficiency of the vector. 
Consequently, using self-complementary AAV avoid this problem. Self-complementary AAV is 
generated from packaging two halves of single stranded DNA molecules which fold and base pair 
to produce a double stranded DNA molecule. Those two halves could be obtained when dimeric 
inverted repeat genomes are formed during AAV replication cycle. However, self-
complementation reduces the inserted gene size of an already small viral vector (McCarthy, 2008).
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Table 5 : Viral vectors characteristics. Adapted from Chamcheu et al., 2015; Vannucci et al., 2013; McCarthy, 2008 
Vector 
Genetic 
material 
Packaging 
capacity (kb) 
Tropism Vector genome form Advantages Disadvantages 
Gamma-
retrovirus 
ssRNA 8 Dividing cells Integrated 
Long-term transgene 
Expression, low immunogenic 
Do not transduce non-dividing cells; 
random integration into host genome; 
high risk of insertional mutagenesis. 
Lentivirus ssRNA 9 
Dividing/ 
nondividing 
cells 
Integrated 
Long-term transgene 
expression 
Pathogenic; random integration into 
host genome; complicated production 
procedure 
Herpes 
Simplex 
Virus 
dsDNA 50 Wide Non-Integrated Neurotropic, oncolytic 
Transient expression of the 
transgene, high level of pre-existing 
immunity, potential remaining 
cytotoxicity 
Adenovirus dsDNA 7.5 
Dividing/ 
nondividing 
cells 
Non-integrated 
Transduce 
most tissue/cells; oncolytic 
Highly immunogenic transient 
transgene 
Expression, high levels of pre-
existing immunity 
Adeno-
associated 
virus 
ssDNA 5  
Dividing/ 
nondividing 
cells 
Non-integrated 
(90%) 
Integrated 
Only WT (>10%) 
Non-inﬂammatory; 
Nonpathogenic, low 
immunogenic; possible site-
specific integration 
Possible loss of gene expression, low 
packaging capacity 
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C. Safety concerns 
 The fear and concerns towards gene therapy and its possible consequences have long 
delayed the clinical translation of this approach. Viral vectors risk of integrating into gene 
regulatory regions or into transcriptionally active domains have presented a threat of insertional 
mutagenesis and oncogenesis in patients (Donsante et al., 2001; Fehse & Roeder, 2008; Wirth et 
al., 2013). To avoid these problems, targeted integration of transgenes to predefined genomic sites 
has been the topic of many research studies. Immunogenicity of adenoviruses has been another 
concern. However, many studies demonstrate that those viruses have a safety profile in humans 
(Hedman et al., 2009; Muona et al., 2012; Wirth et al., 2013). The major concern has been the risk 
of uncontrolled genetic modifications that could be passed onto next generations in worst case 
scenario. It is always forgotten that other approved and extensively used agents like radiotherapy 
also cause genetic changes (Wirth et al., 2013). The ethical aspects and rationality of gene therapy 
have long been discussed (Beutler, 2001; Friedmann, 2000; Friedmann & Roblin, 1972; Wirth et 
al., 2013) and attending that the right safety and toxicity studies are done in large animals, gene 
therapy can reach clinical trials with success (Colle et al., 2009; Le Guiner, Moullier, & Arruda, 
2011; Rapti et al., 2012). 
 
D. Clinical trials 
 As already mentioned, gene therapy faced many difficulties before to be accepted as being 
a safe way to treat patients (Dunbar et al., 2018). Now several have been successful and many more 
are under course. 
1. First trials and drawbacks 
a) Retrovirus vector gene therapy for X-linked Severe combined 
Immunodeficiency (SCID-X1)  
 Children with SCID-X1 have been treated with Moloney murine leukemia virus–based γ-
retrovirus vector expressing interleukin-2 receptor γ-chain complementary DNA. The therapy 
successfully restored immunity in the majority of patients. However, vector-induced leukemia 
appeared in 25% of patients. Therefore, a modified γ-retrovirus vector was designed. It was found 
efficient in treating SCID-X1 and the long-term effect on leukemia genesis is still under 
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investigation (ClinicalTrials.gov numbers: NCT01410019, NCT01175239, and NCT01129544; 
Hacein-Bey-Abina et al., 2014). 
b) Ornithine transcarbamylase (OTC) deficiency 
 OTC deficiency safety clinical trial used the human adenovirus type 5 which carried human 
OTC cDNA. The viral vector was injected into the right hepatic artery. In 1999, one 18-year-old 
patient died 98 h after gene transfer following an anaphylactic shock due to strong adenovirus 
infection (Raper et al., 2003). This tragic event led to many interrogations and both the Food and 
Drug Administration (FDA) and the National Institute of Health (NIH) stopped recommending any 
policy alterations or clinical holds (Lehrman, 1999). 
2. New trials and successes 
 Only a selection of successful trials is presented here.  
a) Glybera to treat lipase familial deficiency: 
 Glybera was the first authorized gene therapy product in the Western marketing world. It 
is a rAAV1 vector for treating a rare disease called Lipoprotein Lipase (LPL) Deficiency (LPLD) 
(Wang & Gao, part II, 2014; Ylä-Herttuala, 2012). LPLD causes life threatening pancreatic 
inflammation (Gaudet, Méthot, & Kastelein, 2012; Wang & Gao, part II, 2014). A single 
intramuscular injection at different sites is enough for transduced muscular cells to synthesize LPL 
into blood thus the disease severity is diminished (Gaudet et al., 2012; Stroes et al., 2008; Wang & 
Gao, part II, 2014). Three days before and twelve weeks after treatment, immune suppression is 
advised to prevent the viral vector from being attacked or cleared by the host immune defense 
(Ferreira, Twisk, et al., 2014; Ferreira, Petry, & Salmon, 2014; Wang & Gao, part II, 2014). 
b) Gencidine to treat head and neck carcinomas 
 Gencidine was the first gene therapy approved for human use. It is available on the market 
in China since 2004. It combines Adenovirus type 5 vector with a p53 expression cassette (Ad-
p53). A Chinese clinical trial reported that the majority of patients treated with intratumoral 
injections of Ad-p53 in combination with radiation therapy (70 Gy/8 weeks) showed complete 
remission compared to the patients receiving radiation therapy alone. Those results were highly 
significant, thus the China State Food and Drug Administration approved this product for treating 
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head and neck cancer (https://www.inserm.fr/en/health-information/health-and-research-from-
z/gene-therapy; Vattemi & Claudio, 2009). 
c) CNS neuropathies gene therapy 
 CNS neurological diseases are among the hardest to treat for multiple reasons such as the 
limited diffusion of therapeutics through the blood brain barrier (BBB), the unclear 
pathomechanisms of neuropathies and the lack of suitable outcome measures after treatment 
(Piguet et al., 2017). Despite those difficulties, many clinical trials have been done or are ongoing. 
Some are presented thereafter. 
i. Spinal Muscular Atrophy (SMA) type 1  
 SMA type 1 is a severe, autosomal recessive, progressive motor neuron infancy disease 
caused by a loss or dysfunction of the gene encoding survival motor neuron 1 (SMN1). The 
degeneration and loss of lower motor neurons result in muscle atrophy and death. It is the most 
common genetic cause of death among infants. After successfully testing for viral vector safety, 
tolerability and effectiveness in preclinical trials in mice and dogs, intravenous injection of self-
complementary AAV9 (scAAV9) containing DNA coding for SMN gene therapy approach moved 
to clinical trials on children of up to 6 months of age (“AveXis”and other funds, NCT02122952). 
Longer survival, higher achievement of motor milestones and ameliorated motor function were 
attained after a single dose injected in affected babies. Improved motor behavior milestones 
included sitting unassisted for a few seconds, roll over, crawl and ability to speak. However, high 
serum aminotransferase levels without any other liver enzyme abnormalities were found in treated 
patients. This has been categorized as serious adverse events due to AAV infection in the liver. 
Liver enzymes increase was decreased by prednisolone treatment (Armbruster et al., 2016; Mendell 
et al., 2017; Piguet et al., 2017).  
ii. Lysosomal storage disease (LSD)  
 LSD is caused by a lysosomal function deficiency resulting in undigested or partially 
digested materials in cells. This leads to metabolic dysfunctions, neurodegeneration and 
neuroinflammation. Twenty eight AAV-based gene therapy clinical trials exist for LSD with the 
majority based on intraparenchymal injection and some intrathecal (Batten disease) and one 
intravenous injection (MPSIIIA) (Piguet et al., 2017). 
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iii. Metachromatic leukodystrophy (MLD) 
 MLD is a very severe autosomal recessive infantile disease with a survival rate of maximum 
seven years. It is caused by a deficiency in arylsulfatase A (ARSA) resulting in severe motor and 
cognitive impairment. This impairment has been linked to demyelination of both the peripheral and 
the central nervous system (Colle et al., 2010; Piguet et al., 2017; Zerah et al., 2015). Efficacy and 
toxicology studies in Macaca fascicularis nonhuman primates proved that intracerebral injection of 
AAVrh.10cuARSA (AAV serotype rh10 with human ARSA cDNA coding for Arylsulfatase A 
enzyme) is safe and well-tolerated except for a few minor lesions attributed to the surgical 
procedure itself and for a dose-dependent inflammatory response against human ARSA. 
Inflammation was expected since human ARSA and Macaca ARSA differ by 17 amino acids. No 
significant adverse events neither clinical nor biochemical were detected in Macaca. Moreover, 
ARSA enzyme expression is maintained in the brain (Zerah et al., 2015). Efficacy tests included 
cognitive, behavioral and neuromotor tests (Ciron et al., 2009), whereas toxicity assessment 
comprised neutralization antibodies against the viral  capsid, neuropathology and pathology of 
peripheral organs as well as biodistribution of the viral vectors in tissues and fluids (Zerah et al., 
2015). This gene therapy approach was translated to clinical trial (NCT01801709) that is still 
ongoing (Piguet et al., 2017; Zerah et al., 2015). 
iv. Sanfillippo syndrome type A 
 Sanfillippo syndrome type A, also called mucopolysaccharidosis (MPS) type IIIA, is an 
infantile disease appearing before the age of two with a survival rate of 20-30 years. It is caused by 
an autosomal recessive mutation in the N-sulfoglycosamine sulfohydrolase (SGSH) enzyme gene. 
Symptoms are mostly neurological and include a progressive deterioration of cognitive and motor 
abilities. Furthermore, children progressively develop severe mental retardation. Two clinical trials 
are ongoing for this disease: one with the intracerebral injection of AAVrh10 encoding both the 
SGSH and the sulfatase modifying factor 1 (SUMF1) cDNAs (clinical trial NCT02053064) and 
the second with intravenous injection of a scAAV9.U1A-hSGSH coupled with immunosuppressive 
therapy (prednisolone) (clinical trial NCT02716246). The first therapy was found to be safe, well 
tolerated and the neurosurgery was uneventful. Patients displayed improvements in their behavioral 
disorders and in their hyperactivity and sleep disorders after 1 year. A study with a longer follow-
up period (5 years) is ongoing to evaluate the safety and tolerability. Preliminary results 6 months 
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post treatment showed some improvements in cognitive abilities and nonverbal IQ assessment 
(Piguet et al., 2017). 
v. San Fillippo syndrome type B 
 San Fillippo syndrome type B, also called MPS type IIIB, is caused by the accumulation of 
partially degraded heparin sulfate oligosaccharides consecutive to the deficiency in alpha-N-
acetylglucosaminidase (NAGLU) enzyme. MPSIIIB is characterized by progressive impairments 
of cognitive capacities after 2-4 years. Two clinical trials are ongoing for this disease: one with the 
intracerebral injection of AAV5 encoding the NAGLU cDNAs (clinical trial ISRCTN19853672) 
coupled with an immunosuppressive therapy (tacrolimus and mycophenolate mofetil) and the 
second with intravenous injection of rAAV9-CMV-NAGLU (NCT03315182). The first therapy 
was well tolerated and cognitive benefits were clearly seen after a two-year-follow-up study. No 
details are available yet for the second clinical trial (Piguet et al., 2017). 
vi. Canavan disease 
 Canavan disease, a childhood genetic disorder, is caused by a defective aspartoacylose 
(ASPA) enzyme resulting in higher levels of its substrate N-acetyl aspartate (NAA) in the CNS. 
Consequently, myelination is disturbed and the brain degenerate in a spongiform way. A gene 
therapy clinical trial consisting in the intravenous injection of AAV2 expressing ASPA resulted in 
lower NAA concentrations in the brain after a 10-year-follow-up period. In addition, it was 
observed an improved myelination, a decreased water content in the splenium of the corpus 
callosum as suggested by MRI, a stabilization of brain atrophy and relatively fewer seizures in 
treated patients (Ciron et al., 2009; Janson et al., 2002; McPhee et al., 2006; Piguet et al., 2017). 
vii. Late Infantile neuronal Ceroid Lipofuscinosis (LINCL)  
 LINCL also called Batten disease results from a deficiency in tripeptidyl peptidase 1 (TPP-
1), a proteolytic enzyme encoded by the CNL2 gene. Less frequently LINCL is due to mutations in 
CLN6 gene, which encodes a transmembrane protein of the endoplasmic reticulum. Symptoms 
include progressive destruction of retinal pigmented epithelial cells and central nervous system 
neurons. This results in progressive loss of vision and neurological decline starting at 
approximately 3 years of age. Other symptoms are cognitive defects, seizures and impaired motor 
skills causing a vegetative state and death in middle to late childhood (Haltia & Goebel, 2013; 
Sondhi et al., 2005);  AAV2 expressing CNL2 was injected intracranially (NCT00151216) and this 
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led to a slower decline of neurological symptoms after a 6-month-follow-up period (Crystal et al., 
2004). Nevertheless, the progression of the disease could not be stopped. AAVrh.10-CAAG-
hCLN2 clinical trial NCT01161576 and NCT01414985 were launched in 2011 with no results 
available yet. A recent clinical trial (NCT02725580) with intrathecal injection of AAV9-CAG-
CLN6 is still ongoing (Piguet et al., 2017). 
viii. Alzheimer’s disease  
 Alzheimer’s disease, the most common neurodegenerative disease in humans, has unclear 
causes. However, nerve growth factor (NGF) supply has been shown to be beneficial to prevent 
neuron degeneration. Thus, a clinical gene therapy trial (NCT00087789) has been initiated based 
on an AAV2 expressing NGF, which is injected intracerebrally. It was found to be safe and well 
tolerated 2 years after the injections. The therapy decreased the cognitive decline. A phase II 
clinical trial (NCT00876863) is ongoing (Piguet et al., 2017).   
 In Alzheimer’s disease, brain cholesterol homeostasis seems to be impaired. Indeed, in 
normal conditions, cholesterol 24-hydroxylase, an enzyme encoded by the CYP46A1 gene, convert 
brain cholesterol into 24S-hydroxycholesterol to allow cholesterol transport through the BBB. This 
is critical to discard cholesterol excess from the brain. In Alzheimer’s disease patients, the level of 
brain cholesterol is increased while the level of 24S-hydroxycholesterol is decreased (Ayciriex et 
al., 2017; Burlot et al., 2015). In THY-TAU22 mice, an Alzheimer’s disease -like mice model, 
AAV-CYP46A1 injections in the hippocampus increased the levels of CYP46A1 and restored 
normal level of 24S-hydroxycholesterol. Consequently, memory capacities, synaptic impairments 
as well as neuronal morphology and function were improved (Burlot et al., 2015). This gene 
therapy approach will enter clinical trials soon. 
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VI. CMT1A gene therapy approach  
 Considering a gene therapy approach for CMT1A (my thesis project) appears to be an 
interesting option. Since this disease is caused by an overexpression of the PMP22 gene, the most 
logical therapeutic strategy is to decrease this excess. Gene downregulation can be achieved 
through mRNA downregulation via antisense oligonucleotides (ASO) or RNA interference 
(RNAi). 
A. Antisense Oligonucleotides (ASO) 
 ASO are short single stranded nucleic acids made of 13-25 nucleotides. They bind to their 
complementary mRNA either to restore protein synthesis or to inhibit the production of a mutant 
protein (Mustonen, Palomäki, & Pasanen, 2017; Pirmohamed, 2018). Exon splicing is the 
mechanism of ASO that results in restoring protein production (Mustonen et al., 2017; 
Sierakowska, Sambade, Agrawal, & Kole, 1996; van Deutekom, 2001). Stimulating RNase H and 
thus degrading mRNA as well as inhibiting ribosomes binding and thus stopping translocation of 
mRNA (steric block) are two mechanisms used by ASO for preventing protein synthesis (Bennett 
& Swayze, 2010; Evers et al., 2015; Fattal & Bochot, 2006; Mustonen et al., 2017) (Table 6). 
 Chemical modifications improved the capacity of ASOs to recognize and bind to their target 
RNA. Those include substituting a nonbridging phosphate oxygen atom with a sulfur atom to be 
more resistant against nucleolytic degradation (first generation ASO) and altering sugars to 
enhance binding affinity (Bennett et al., 2017; Monia et al., 1993; Stein et al., 1988).  
B. siRNA 
 RNAi is a strong tool for highly specific and selective gene silencing (Burnett, Rossi, & 
Tiemann, 2011; Rao, Vorhies, Senzer, & Nemunaitis, 2009). The first experimental study reported 
in 1998 by Fire et al received the 2006 Nobel Prize in Physiology/Medicine (Pushparaj et al., 2008). 
It is based on double-stranded RNA designed to be the same as the host sequence it targets for 
mRNA degradation. Many methods exist such as small interfering RNA (siRNA) and short hairpin 
RNA (shRNA) (Moore et al., 2010; Pushparaj et al., 2008; Rao et al., 2009). It is possible to directly 
deliver siRNA into the cytosol. Several cell types are possibly targeted by siRNA but with limited 
efficiency to only cells that can be transfected (Moore et al., 2010). 
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1. siRNA properties 
 21-25 base pairs (bp) constitute siRNAs (Pushparaj et al., 2008). Within 15 min after 
delivery, double stranded siRNAs are present in the nucleus and goes to the cytoplasm during the 
next 4 hours in both an unmodified form and a dissociated one (Rao et al., 2009). ATP-dependent 
helicase enzyme converts synthetic siRNAs into single strands (Nykänen et al., 2001). Those 
strands link to a protein complex called the RNA-induced silencing complex (RISC) (Hammond, 
et al., 2000) in order to bind the specific target sequence mRNA and degrade it (Grishok et al., 
2001; Hutvágner et al., 2004; Pushparaj et al., 2008; Timmons et al., 2003) (Table 6). 
 Usually, siRNA are designed by carefully selecting the coding sequence for regions free of 
translational or regulatory proteins. Approximately 65-75% of designed siRNAs result in 50-65% 
gene silencing (Bernstein et al., 2001). This is often not significant biologically or therapeutically. 
To improve efficiency, siRNAs were chemically altered to increase their stability or several 
siRNAs can be used in parallel for silencing target genes. More than 80% gene silencing was 
obtained with multiple siRNAs (Pushparaj et al., 2008; Reynolds et al., 2004).  
2. siRNA delivery 
 Non-viral vectors could be used to deliver siRNA in vivo (Pushparaj et al., 2008). Examples 
include polymer particles and cationic liposomes (Zhang et al., 2007). Normally, the majority of 
siRNA is degraded 48 hours post injection (Pushparaj et al., 2008; Rao et al., 2009).  
 
C. shRNA 
 Short hairpin RNA (shRNA) is a technological method of gene knockdown with high 
effectiveness when introduced in a viral vector, sustainable outcomes, low copy numbers and very 
little off-target effects. shRNAs consist of sense and antisense sequences separated by a loop 
sequence. shRNAs are transcribed by the RNA polymerase enzyme II or III and cleaved by the 
dicer enzyme to form double-stranded RNA. One of the two RNA strands is removed (the 
“passenger” strand) and the second (the “guide” strand) binds to targeted mRNAs resulting in their 
degradation or sequestration (Rao et al., 2009; Moore et al., 2010). 
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1. shRNA properties 
 shRNAs are composed of two complementary 19–22 bp RNA sequences linked by a short 
loop of 4–11 nucleotides (Moore et al., 2010). 
 shRNA could be used to obtain stable knockdown cell lines without multiple rounds of 
transfection and with high reproducible results. Nevertheless, this task is time-consuming. Several 
months are usually needed to prepare the construct and select the shRNA positive cells by drug 
resistance or fluorescent markers (Moore et al., 2010) (Table 6). 
  To get a successful gene knockdown, it is most crucial to properly choose the target 
sequence. Minimum two target sequences must be designed for each gene to maximize the chances 
of obtaining a significant gene knockdown. After selecting the target sites, shRNA vectors are built 
mainly by oligonucleotide-based cloning or by PCR-based cloning (Moore et al., 2010).   
 Synthesis of shRNAs occurs in the nucleus of cells. Since they can be continuously 
produced by the host cell, their effect is durable. After that, they are processed, taken to the 
cytoplasm and incorporated into the RISC to degrade the targeted mRNA (Rao et al., 2009). 
2. shRNA life cycle inside of transfected cells 
 RNA polymerase II or III can transcribe shRNA via promoters of RNA polymerase II or III 
on the expression cassette. RNA polymerase II promoter produces a primary transcript.  This 
transcript is processed in the nucleus by a complex including the RNase III enzyme Drosha  (Lee 
et al., 2003) and the double-stranded RNA-binding domain protein DGCR8. Pre-shRNA is the 
processed primary transcript. Exportin 5, a Ran-Guanosine Triphosphate-dependent mechanism, 
carries the pre-shRNA to the cytoplasm (Rao et al., 2009; Yi et al., 2003). There, it is inserted into 
another RNase III complex. This complex is formed of the RNase III enzyme Dicer and double-
stranded Tat–RNA-binding protein (TRBP) or PACT (RNA-dependent protein kinase (PKR) 
activating protein). The loop of the hairpin is removed to form a double-stranded siRNA: the 
mature shRNA (Lee et al., 2003; Rao et al., 2009). Afterwards, mature shRNA/siRNA in the 
Dicer/TRBP/PACT complex is linked to Argonaute protein 2 (Ago2), the main constituent of 
RISC. The double-stranded RNA/ Dicer/ TRBP/Ago-2/ RISC form the RISC loading complex 
(RLC)  (Rao et al., 2009) (Figure 12). 
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 In the RLC, RNase-H like activity of Ago-2 separates the two strands of the RNA leading 
to the departure of the passenger strand. Following that, Ago protein complexes loaded with guide 
strand RNA search for complementary target sites in mRNAs, where Ago-2 cleaves mRNA 
resulting in mRNA degradation. Other Ago protein containing complexes predominantly associate 
with partially complementary target sites for translation repression through mRNA sequestration 
in processing bodies (p-bodies). Finally, the active RNA loaded complex is released for additional 
rounds of gene silencing activity (Rao et al., 2009) (Figure 12). 
 
Figure 12 : shRNA life cycle: shRNA is delivered to the cytoplasm. After that, it is transported to the nucleus 
where it is transcribed to pri-shRNA. It is converted to the primary transcript pre-shRNA by 
Drosha/DGCR8. Exportin5 carries pre-shRNA ton the cytoplasm. There, pre-shRNA is processed into 
mature shRNA by Dicer/TRBP/PACT complex. This complex and shRNA bind to the Ago protein of the 
RISC. The double stranded shRNA is then converted to a single strand shRNA. Finally, shRNA complexed 
with Ago/RISC degrade the targeted mRNA. Other Ago complexes could also sequestrate mRNA in 
processing (p-bodies) in order to repress translation. Adapted from Rao et al, 2009. 
 
3. shRNA delivery 
 Two main methods exist for delivering shRNA: transfection as plasmid vectors transcribed 
by RNA pol III or modified pol II promoters and infection of cell with viral vectors (Moore et al., 
2010). 
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D. Clinical trials 
 
ASO and RNAi-based therapies are recently widely used in clinical trials for cancer, infections and 
other inherited diseases (Burnett et al., 2011). Some examples are developed thereafter. 
1. ASO 
 Chemically modified antisense oligonucleotides (ASOs) are being used in clinical trials for 
Huntington disease (NCT02519036) (Piguet et al., 2017).  Safety and tolerability profile has been 
demonstrated. In addition, ASO gene therapy decreased the toxic huntingtin protein that initiates 
the pathology (van Roon-Mom, Roos, & de Bot, 2018). 
 Nusinercen is a recently licenced ASO to treat spinal muscular atrophy. This drug targets 
the SMN2 gene thus synthesizing a full-length protein. Therapy administered early in life 
importantly decreased mortality and enhanced motor function (Finkel et al., 2017; Pirmohamed, 
2018).   
2. siRNA 
 The long and difficult journey of RNAi-based therapy might have come to an end. Alnylam 
Pharmaceuticals, pioneer in the field of RNAi, have submitted all regulations to the Food and Drug 
Administration (FDA) and the European Medicines Agency for the therapy of hereditary 
transthyretin-mediated amyloidosis (ATTR), patisiran (C. Morrison, 2018). Hereditary 
Transthyretin Amyloidosis is an autosomal disorder caused by mutations in the gene coding for 
transthyretin (TTR), a protein produced by the liver. In the disease, this protein form amyloid in 
peripheral nerves, the heart, kidney and gastrointestinal tract (Adams et al., 2018; Hawkins et al., 
2015; Ruberg & Berk, 2012). It is a life-threatening, multisystem disorder. It causes important 
sensorimotor defects, hypotension, diarrhea, impotence, bladder impairments and cardiac 
manifestations such as heart failure (Adams et al., 2018; Ando et al., 2013; Conceição et al., 2016). 
Alnylam published the results of the RNAi-based therapy phase 3 clinical trial (APOLLO 
ClinicalTrials .gov number: NCT01960348). Patisiran, a double stranded siRNA targeting TTR 
mRNA, was injected intravenously in lipid nanoparticles for liver delivery. The dose of o.3 mg/kg 
was administered for approximately 80 minutes once every 3 weeks for 18 months. Patisiran-
treated patients showed an ameliorated quality of life and improvements in walking, in nutritional 
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status as well as in cardiac manifestations. The only adverse event was mild-to-moderate and 
related to injections. It diminished with time (Adams et al., 2018). 
 Another pharmaceutical company, Quark, is assessing QPI-1007, a siRNA treatment for 
NAION in a phase 3 clinical trial (NCT02341560). NAION (Non Arteritic Anterior Ischemic Optic 
Neuropathy) is caused by damage to the optic nerve with in general painless visual loss evolving 
over many hours to days as the main symptom (Atkins et al., 2010). 3mg of QPI-1007 are 
administered as single or multi-dose intravitreally (naked siRNA). The expected completion date 
is October 2020 (NCT02341560). 
3. shRNA 
 Lentiviral-delivered shRNA as a treatment for Human Immunodeficiency Virus (HIV) 
infection is currently recruiting patients for a phase 1 clinical trial since May 2018 
(NCT03517631). Briefly, peripheral blood mononuclear cells are taken from patients, modified by 
transducing with lentivirus shRNA and reinfused into patient. This is an autologous cell therapy 
approach aiming at assessing the efficacy and safety of the treatment (NCT03517631; Burnett et 
al., 2011). 
 AAV shRNA as a treatment for Hepatitis C (drug TT-034) is currently in a follow-up study 
to a phase I/II clinical trial until 2022 (NCT01899092; NCT02315638). The strategy consists in 
delivering 3 sequences of anti-Hepatitis C Virus into the liver of patients with 3 different shRNAs 
included in an AAV vector. Administration of the drug is by single intravenous injection. 5 dose 
levels were tested: 4x1010, 1.25x1011, 4x1011, 1.25x1012, and 4x1012 vg/kg. Headache was the most 
common adverse events. Transduction varied from one patient to another with the same dose (Patel 
et al., 2016). 
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Table 6: Gene silencing tools 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ASO: antisense oligonucleotides; siRNA: small interfering RNA; shRNA: Short hairpin. 
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Thesis objectives  
 
I just presented the shRNA tools and the different gene therapies that are clinically 
developed at the moment. Considering a shRNA gene silencing approach for CMT1A (my thesis 
project) appears to be an interesting option since CMT1A is caused by an overexpression of 
PMP22. There are several murine models for CMT1A; we have chosen to work on the CMT1A rat 
because we believe it mimics best the human disease. For my thesis project, I studied the 
effectiveness of the following gene therapy approach on CMT1A rats: AAV-9 shRNA mouse 
PMP22 injected bilaterally in sciatic nerves at 6-7 days of age, time at which myelination starts 
and when first myelination deficits appear in the sciatic nerves of CMT1A rats.  
The efficacy of the therapy was assessed by (Figure 13): 
1. Molecular and biochemical techniques 
2. Histological procedures 
3. Behavioral analysis 
Those methods are presented right after.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 : Summary of tests used
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Chapter 1: Gene Therapy Project 
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Material and Methods 
 
I.  Therapeutic tools production and validation 
 
A. Recombinant AAV (rAAV) manufacturing and purification  
Done at the Center for production of vector (CPV)-UMR1089, Nantes 
1. Cell amplification, transfection, harvest and supernatant Polyethylene 
glycol (PEG)-precipitation  
 Human embryonic kidney (HEK) 293 cells cultured with Dulbecco's Modified Eagle 
Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS) and 1% Penicillin 
Streptomycin (Pen/Strep) are co-transfected with the vector plasmid and helper plasmid 
(containing helper genes from adenovirus and the rep cap genes according to the capsid serotype) 
using the Calcium orthophosphate (CaPO4) precipitate technique. The cells were incubated 6 to 15 
hours at 37 +/- 1°C and 5 +/- 1% CO2 with only the transfection medium. This medium was then 
removed and replaced by fresh exchange medium (DMEM, 1% Pen/Strep) prior to a 3 days 
incubation at 37 +/- 1°C and 5 +/- 1% CO2. After that, the transfected cells were harvested. The 
supernatant is precipitated at 5 +/- 3°C overnight with PEG, centrifuged and discarded. The PEG-
pellet was resuspended in Tris-buffered saline (TBS) before benzonase digestion.  
2. Vector purification  
 The viral suspension is purified by two successive cesium chloride (CsCl)-gradient 
ultracentrifugation of respectively 24 hours, 28 000 rpm and 48 hours, 38 000 rpm. The viral 
suspension is then subjected to 4 successive rounds of dialysis against Dulbecco's phosphate-
buffered saline (DPBS) 1X. The purified vector is finally collected, sampled for vg titer and purity 
assay, and stored at <-70°C. 
3. Vector titration 
 Quantitative polymerase chain reaction (qPCR) was used to titer the rAAV vector genome. 
The target amplicons correspond to PolyA (Polyadenylation) or ITR-2.  
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B. Animals 
 Sprague Dawley rats and Swiss mice (Janvier) of different ages (pups and adults) as well 
as non-human primates (NHP, macaca fascicularis) served for transduction efficiency of AAV 
CAG GFP viral vectors serotypes 9 and rh10 (Figure 14, Table 7).  
 
Figure 14 : AAV CAG GFP cassette. ITR= Inverted Terminal Repeat. 
GFP (Green Fluoresent protein) transgene under the control of a CAG 
promoter (CMV enhancer fused to chicken beta actin promoter). Adapted 
and modified from Figure 1 of Masat et al, Humoral Immunity to AAV 
Vectors in Gene Therapy: Challenges and Potential Solutions. Discovery 
Medicine; ISSN: 1539-6509; Discov Med 15(85):379-389, June 2013.  
 
C. Injected viral solution 
 The viral solutions were prepared by diluting virus with sterile phosphate buffer saline 
(PBS) 1x and filtered 0.05% fast green to inject into sciatic nerves of mice, rats and macaques 
according to the following criteria (Table 7).
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Table 7 : Injection parameters for transduction efficiency: vg=vector genome  
 Rat Mice 
Non-human primate (NHP) : 
macaqus fascicularis  Pups Adults Pups Adults 
Vectors AAV9_CAG_eGFP 
AAV9 and 
AAVrh10 
AAV9_CAG_eGFP AAVrh10_CAG_eGFP 
Injection Unilateral in the right sciatic nerve Unilateral in the left sciatic nerve 
Vector 
Quantity 
(vg/nerve) 
1x1011 1.8x1011 1.15x1010 4.6x1010 5x1011 5x1012 
Volume 
injected per 
nerve (µl) 
8 30 2 8 40 400 
Injection 
time (min) 
15 15 3-4 15 10 30 
Number of 
animals per 
vector 
3 
6 (+ 1 
PBS-
injected 
control) 
6 (+ 1 PBS-
injected 
control) 
9 (+ 1 PBS-
injected control) 
1 
Injection 
Age 
P6-P7 1 month P3-P4 2 months 2 years 
Sacrifice 1-month post injection 
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D. Injection of AAV9 CAG eGFP in rodents’ sciatic nerves 
Injection needles were pulled using borosilicate glass capillary (GC 100-10, Harvard 
number 30-0016, 1 mm O. Dx0.58mm I.D) with the “Nichrome Coil Filament P30N4” machine. 
For the surgery, each rodent was anesthetized using the anesteo anesthesia system: inside an 
isoflurane box with isoflurane set at 4% and air flow adjusted to 3L/minute. A few minutes later, 
the animal was placed on the surgery table, under a microscope with inclined and rotatable 
binocular stereo heads and on a 37̊ C-heating plate. Its head was introduced inside a mask cone 
with decreasing isoflurane to 2%, setting O2 flow to 0.5% and nose cone aspiration flow to around 
1.8 LPM (liter per minute). The region of incision was shaved for adult animals and disinfected 
for both adults and pups with betadine solution and ethanol 70%. Skin was cut at the sciatic nerve 
location, at the level of the thigh. The connective tissue and fat connecting the two muscles gluteus 
superficialis and biceps femoris were carefully torn apart to expose the small cavity containing the 
sciatic nerve.  The nerve was gently lifted out using a spatula. The needle filled with the appropriate 
volume of viral solution (Table 7) was carefully lowered into the nerve using a microinjector 
(WPI=World Precision Instruments, Europe). Over several minutes (Table 7), the viral solution 
was injected using a pulse generator (GW INSTEK GIG8215A) with a 0.9 frequency and a 50 Ω 
output, as well as a pneumatic picopump (PV820 WPI) with 100 ms amplitude and a 10 psi 
pressure. At the end of the injection, the sciatic nerve was replaced inside its cavity and muscles 
were pushed back around it. The wound was closed by suturing and using histoacryl tissue glue 
(B/Braun Aesculap, cat. no. 1050060) for pups and surgical clips for adults. 
 
E. Injection of AAV9 CAG eGFP in macaques’ sciatic nerves 
Local anesthesia was by Ketamine (10mg/kg) + Xylazine (0.5mg/kg) for induction and by 
Propofol (1ml/kg/h) for maintenance. Injection of AAV into the sciatic nerve of 2 year-old-
macaques (macaca fascicularis) was done at the MIRCEN facility of the CEA Fontenay aux roses 
by the neurosurgeon Dr Michel Zerah, with the help of Benoit Gautier and Claire-Maëlle. 
Macaques were anesthetized and injected using a capillary fiber linked to a 26 G Hamilton syringe 
(Gastight, PTFE Luer Lock) right above the split of the sciatic nerve into common fibular and 
tibial nerves. 40µL were injected for AAV9 and 400µL for AAV10 over 10 minutes for AAV9 
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(5x1011 vg/nerve) and 30 minutes for AAV10 (5x1012 vg/nerve). There was some viral leak with 
AAV9 (Table 7, Figure 15).  
 
 
Figure 15 : AAV injection in sciatic nerve of macaca fascicularis 
 
F. Dissections and Immunostaining of sciatic nerve 
 One month after injections, animals were sacrificed by lethal dose of sodium Pentobarbital, 
and their injected sciatic nerve was dissected to study the virus transduction efficiency. Macaques 
were perfused first by phosphate buffer saline then by paraformaldehyde (PFA).  
Some dissected sciatic nerves of rodents were teased in small fibers bundles in order to 
determine the type of cells transduced by the viral vector (GFP marker on AAV). The percentage 
of transduced myelinating Schwann cells, non-myelinating Schwann cells and axons was 
determined. Minimum 300 cells were counted. Other dissected sciatic nerves of rodents were fixed 
in PFA 4% for 1.5 h at room temperature and incubated in successive sucrose baths 6 and 30 % 
for 1-2 days each at 4°C.  
Peripheral nerves of macaques (radialis, median, sciatic, common fibular and tibialis) were 
incubated in successive baths of sucrose 10% for 3-4 days then sucrose 30% for 4 days with 
changing the medium every 2 days. Rodent sciatic nerves were embedded in OCT and stored at    
-80°C until coronal sections were cut using the cryostat (Leica cryostat 3050) and placed on 
Superfrost slides (Thermo scientific, reference J1800AMN2) stored at -20°C. Nerves of macaques 
were embed in paraffin. Slides were fixed again for 3-4 min in PFA 4%, washed by PBS and 
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blocked in 5% Normal Donkey Serum (NDS), 0.1% Triton 1x buffer for 45 min at room 
temperature. Primary antibodies (1/1 000 dilution) against Myelin Basic protein (MBP- SMI-99, 
Millipore, reference NE1019) and against β-Tubulin III (Tuj1, Sigma reference T2200) were 
incubated overnight at 4°C. On the next morning, the nerve sections were incubated with 
corresponding secondary antibodies (1/1 000 dilution) donkey anti-Mouse, Alexa Fluor 594 
(Thermofisher, reference A-21203) and donkey anti-rabbit Alexa Fluor 647 (Thermofisher, 
reference A-31573) and with DAPI (Sigma, reference SI-D9542-5MG) for 1 h at room 
temperature, in the dark. The sections were mounted in Dako fluorescent Mounting medium 
(Reference S3023). ‘Nanozoomer Hamamatsu’ slide scanner was used to obtain images.  
 AAV9-CAG-GFP transduction rate in % was calculated by dividing the number of 
myelinated SCs that are transfected by the total number of myelinated SCs. A minimum of 1000 
cells were counted. 
 
G. In vitro validation of shRNA PMP22 
1. Reverse Transcriptase quantitative real time Polymerase Chain Reaction 
(RT-qPCR PMP22 mRNA)  
Done by our collaborators Burkhard Gess and Peter Young at the University Hospital 
Münster, Department of Sleep Medicine and Neuromuscular Diseases, Germany 
 After transfecting the mouse Schwann cell line MSC80 with scramble shRNA or shRNA 
PMP22-49 (Plasmid from Sigma, TRCN0000087949) or shRNA PMP22-50 (Plasmid from Sigma, 
TRCN0000087950) plasmids, RNA was extracted, and reverse transcribed into cDNA using 
commercial kits according to common laboratory practice at the Department of Sleep Medicine 
and Neuromuscular Diseases in Germany. Next, quantitative real-time PCR was performed in 
triplicate. Gapdh was used as the reference gene. Sequences as well as PCR parameters are detailed 
in the table below (Table 8). For quantitation, mRNA of PMP22 was normalized against GAPDH. 
The relative expression software tool (REST) was used for quantifications. Results were expressed 
according to the following relative expression equation (Pfaffl, Horgan, & Dempfle, 2002):  
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E= real time PCR efficiency; CP= crossing point= point at which the fluorescence is significantly 
higher than the background fluorescence; Δ= difference; control=reference gene (ref). 
Table 8 : PCR conditions for in vitro validation of shRNA PMP22  
Name of 
primers 
Sequences of primers 
Concentrations 
in qPCR mix 
(µM) 
PCR program 
Mouse 
Pmp22-F 
GACAAACCCCAGACAGTTGA 0,4 
Sybr Green 
10 min at 95°C, 40 
cycles of (15s at 
95°C, 30 s at 60°C 
and 30s at 72°C 
Mouse 
Pmp22-R 
CAGGAGCCACCAGCTATTACT 0,4 
GAPDH: F GTCTTCACTACCATGGAGAAGG 0,4 
GAPDH: R TCATGGATGACCTTGGCCAG 0,4 
F= forward primer, R= reverse primer 
2. Western Blot 
 MSC80 cells were seeded in DMEM (Gibco/Thermo Fisher, reference 31966021) with 
10% FBS (HyClone reference SV30160.03) and 1% Pen/Strep (HyClone reference SV30010, 
J160026) until reaching 70-90% confluency (400 000 cells/well in a 6-well-plate). Cells were 
transfected using Lipofectamine 3000 reagent (Thermo Fisher, reference L3000015) according to 
manufacturer recommendations with scramble shRNA (scr.sh) or shRNA PMP22-49 (sh49) or 
shRNA PMP22-50 (sh50) plasmids (2.5 µg of DNA/well in a 6-well-plate, plasmids produced in 
Nantes-CPV-UMR1089 and containing U6 and CMV promoters as well as a GFP marker) (Figure 
16). Proteins were extracted with a radioimmunoprecipitation assay (RIPA) lysis buffer (Thermo 
Scientific reference 89901). Protease (Thermo Scientific Halt Protease Inhibitor Cocktail reference 
78430)  as well  as phosphatase (Thermo Scientific Halt Phosphatase Inhibitor Cocktail reference 
78420) inhibitors were  added. After that, proteins were quantified using the bicinchoninic acid 
(BCA) protein assay kit (Thermo Scientific, reference: 23225) based on colorimetric detection. 20 
µg of proteins were separated in 10% precast polyacrylamide gels (Bio Rad, reference: 4568034). 
After that, proteins were transferred to Polyvinylidene difluoride (PVDF) membranes by rapid (7 
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min), semi-dry blotting process (Bio Rad Trans blot transfer pack, reference: 1704157 and Bio 
Rad Trans-Blot Turbo system). Membranes were blocked for 1 hour at room temperature using a 
commercial buffer (Odyssey Blocking buffer (PBS) LI-COR 927-40000). The following primary 
antibodies were incubated overnight, at 4ºC, in blocking buffer, on a shaker: rabbit anti-PMP22 
(Sigma, Reference SAB4502217, 1/750 dilution) and mouse anti-Tubulin (Millipore, reference 
MABT205, 1/7 000 dilution). Following washing with TBS-0.1% Tween (TBST), secondary 
antibodies were incubated for 1 hour at room temperature at a 1/12 000 dilution: IRDye 800CW 
donkey anti-rabbit (Li-Cor, green fluorescence, reference 925-32213), IRDye 800CW donkey anti-
goat (Li-Cor, green fluorescence, reference 925-32214) and IRDye 680RD donkey anti-mouse (Li-
Cor, red fluorescence, reference 925-68072). After washing in TBST, results and quantifications 
were obtained by the Odyssey CLX Li-Cor Imaging System and its “Image Studio” software. 
Samples were run in triplicates with the following conditions: non-transfected cells, cells 
transfected with sh.scr, cells transfected with sh49 and cells transfected with sh50 so that three 
blots were performed in total.  
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Figure 16 : shRNA: plasmid map (A) and sequences for sh49 (B) and sh50 (C).  
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II. CMT1A rat model characterization 
A. Animals 
 PMP22 transgenic  rats called CMT1A rats (M. Sereda et al., 1996) were used for this 
study. Wild-type (WT) littermates served as controls. Genomic DNA was extracted from tail 
biopsies  for genotyping by polymerase chain reaction with mouse transgene-specific primers 5’-
GACAAACCCCAGACAGTTG–3’ and 5’–CCAGAAAGCCAGGGAACT-3’ previously 
described (M. Sereda et al., 1996). All experiments were performed based on the French 
regulations for animal experimentation (French decree 2013-118, Directive 2010/63/EU).  
 Equal number of males and females served for model functional characterization. Tests 
were performed every 1-2 months until 6 months of age of rats then at 12 months right before 
sacrifice except for nerve conduction velocity measurements which was only done at 12 months 
(Table 10,  Table 11). 22 WT and 20 CMT1A rats were tested for motor deficits by rotarod and 
grip test, for locomotion impairments Catwalk and for nerve conduction velocity by 
electrophysiological measurements. Those tests are detailed thereafter. 
 
B.  Behavioral Analysis 
  All tests were performed by the same investigator who was blinded toward genotype and 
treatment.  
1. Rotarod 
 The rotarod test (Bioseb) was used to assess motor coordination and balance in rats. The 
animal is placed on the rotating bar of the apparatus and the timer is started. As soon as the animal 
drops, the latency to fall (minutes and seconds) and the rotation speed (rpm) are automatically 
recorded. Rats were first given a one-day training to familiarize them with the rotating bar. Their 
ability to stay for a minimum of 2 minutes at constant speed (4 rpm) was verified. For the actual 
measurements, latency to fall and rotation speed of rats were recorded by accelerating the speed 
from 4 till 40 rpm over a 5 minutes period. Each animal underwent three trials. Data of the latency 
to fall were averaged for each rat and then averaged for each group.  
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2.  Grip test 
 The grip test (Bioseb) was used to study muscular strength in rats’ rear paws. The animal 
is placed on a grid and pulled by its tail. The measure is done by a sensor connected to an electronic 
device recording the force in Newtons. Each rat underwent three trials. Data were averaged for 
each rat and then averaged for each group.  
3. Catwalk 
 The Catwalk test was used to analyze gait characteristics in rats. The animal crossed from 
one side to the other on an enclosed walkway on a glass plate. Green light enters the plate and is 
scattered at the areas where the animal’s paws contact the glass plate. The paws are captured by a 
video camera located underneath the walkway and connected to a computer with the CatWalk 
software (Noldus Information Technology , 2015). Minimum three runs having a constant and 
homogeneous speed of crossing were analyzed per rat. The automatic classification of runs i.e. 
assigning labels to paws (RF=right front, LF=left front, RH=right hind, LH=left hind) was verified 
manually. After that, the catwalk software calculated a huge number of parameters related to 
individual footprints, positions of footprints and time-based relationships between footprints. Data 
were averaged per animal and per group.  
Statistically significant parameters were (Noldus Information Technology , 2015):  
· Max contact max intensity (max contact): parameter measuring maximum intensity at 
maximum contact of a paw. Intensity ranges from 0 to 255 arbitrary units (a.u). The 
intensity of a print depends on the degree of contact between a paw and the glass plate. It 
is usually used to assess the effects of neuropathic pain. 
· Regularity index: number of normal step sequence patterns relative to the total number of 
paw placements in percentage (%). 
· Phase dispersions: temporal relationship between placements of two paws. It is used as a 
measure of inter-paw coordination. It ranges from -50 to 75%. 
· Couplings: Like the phase dispersions parameter, couplings describe the temporal 
relationship between placements of two paws within a step cycle. It is used as a measure 
of inter-paw coordination. The value of Couplings ranges between 0 and 100 %. 
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· Single Stance: duration (in seconds) of ground contact for a single hind paw (Coulthard et 
al., 2002). It is used for gait analysis in pain models. In CatWalk, Single Stance is the part 
in the step cycle of a hind paw where the contralateral hind paw does not touch the glass 
plate. 
 
C.  Electrophysiology  
 Proximal as well as distal electrophysiological measurements on both sciatic nerves of rats 
were performed at 12 months in non-injected rats and every 1-3 months starting one month after 
injection (Table 11). Rats were anesthetized with isoflurane (anesteo) and placed on a heating plate 
at 37̊ C. On the rat’s thigh, along the nerve at the sciatic notch, a pair of 12 mm-steel needle 
electrodes with 2 mm pin plugs (AD Instruments, MLA1304, Oxford, UK) was positioned 
subcutaneously for proximal stimulation. Compound muscle action potentials (CMAPs) were 
recorded from the intrinsic foot muscles using 12 mm-steel electrodes with 1.5 mm safety socket 
plugs (AD Instruments, MLA1303, Oxford, UK) placed on the rat’s paw’s muscle, middle toe and 
the ground electrode on the tail for safety. CMAP is defined as the sum of activity in muscle fibers 
following motor nerve stimulation. Supramaximal square wave pulses, a biphasic stimulation 
lasting 0.2ms (200µs) were given using a PowerLab 26T machine connected to the LabChart 
software (AD Instruments, Oxford, UK). Stimulation was delivered by increasing current intensity 
beginning with 1mA then higher until no more change in amplitude (maximum 7mA). The highest 
response measurement was selected. The same process was repeated for distal stimulation. Above 
the ankle, along the tibial nerve, a pair of electrodes was positioned in addition to the electrodes 
on the intrinsic foot muscles. Both amplitudes and latencies of CMAP were determined using the 
LabChart software program. Latency is the time at which there is a change in the baseline meaning 
there is a stimulation response. The distance between the proximal and distal sites of stimulation 
was measured with a ruler with the limb as extended as possible. Nerve conduction velocities 
(NCVs) were calculated from sciatic nerve latency measurements:  
NCV (m/s) =distance/ (Proximal Latency - Distal Latency) (Table 11). 
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III. Gene therapy approach in CMT1A rats 
A. Animals 
 CMT1A rats and their WT littermates were injected with AAV9 shRNA at 6-7 days of age 
(P6-P7) in sciatic nerves. They were divided into 2 cohorts subdivided into 4 groups each. The 2 
cohorts are termed “long term cohort or LTC” and “short term cohort or STC”. LTC served to 
study the efficiency of the gene therapy on the long run (until 1 year of age) while STC was used 
to correlate behavioral analysis and electrophysiological measurements with biochemical studies. 
Rats of STC were sacrificed at 2.5 months (Figure 17). 
 
The 4 groups are: 
· WT injected with AAV9 scramble shRNA (8 animals) 
· CMT1A injected with AAV9 scramble shRNA (8 animals) 
· CMT1A injected with AAV9 shRNAPMP22-49 (8 animals) 
· CMT1A injected with AAV9 shRNAPMP22-50 (8 animals) 
 The efficiency of the AAV9 shRNA PMP22 gene therapy was assessed by behavioral 
analysis and biochemical studies as detailed below (Figure 17). 
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Figure 17: Summary of experimental design 
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B. Injected AAV9 viral solution 
 For rat pups, the sequence of scramble shRNA is confidential (CPV-UMR1089, Nantes). 
The sequences of shRNA PMP22 sense strands are the following: 
CGCGGTGCTAGTGTTGCTCTT (49) and CACTGACTACTCCTATGGCTT (50) (Figure 16). 
The AAV9 viral solutions were prepared by diluting virus with sterile phosphate buffer saline 1x 
(PBS) and filtered 0.01% fast green to inject 8μl of 1x1011 vg/nerve giving a concentration of 
1.25x1010vg/μl.  
C. Injection of AAV9 shRNA in rats’ sciatic nerves (SN) 
 Refer to Material and Methods I. D. Both sciatic nerves were injected but not successively 
since it takes a long period of time and pups dye one day later. Pups were first injected in one 
sciatic nerve, woken up and after a while injected in the second nerve. 
D. Behavioral Analysis 
 The efficacy of AAV9shRNA PMP22 gene therapy was assessed by motor behavioral test 
in rats each 1-3 month starting one month after injections. Those tests included: rotarod, grip test 
and Randall Selitto (Table 10). All tests were performed by the same investigator who was blinded 
toward genotype and treatment.  
1.  Rotarod 
Refer to Material and Methods II. B.1. 
2. Grip test 
Refer to Material and Methods II. B.2. 
3. Randall Selitto  
Performed by Antoine Jouvenel, PhD student “Pain assessment” team 
 The Randall Selitto test (Bioseb) was used to assess the nociceptive threshold of 6 and 11-
month-old rats. The rat hind paw is placed on a small plinth under a cone-shaped pusher with a 
rounded tip. An increasing pressure force is applied to the animal paw by the operator who presses 
a pedal switch initiating the mechanism exerting the force. The maximum force applied to prevent 
injuring the skin is 600 g. When the rat reacts orally, the operator stops pressing the pedal and 
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records the force at which the animal felt pain (the nociceptive threshold of the animal).  Each rat 
was first trained to get used to the test and the experimenter for 10 days. The training consisted of 
handling rats every day, restraining them and carefully immobilizing them to apply the pressure 
on both of their hind paws.  
 
E. Electrophysiology 
Refer to Material and Methods II.C (Table 11). 
 
F. Dissections 
 The 32 AAV9 shRNA-injected rats of STC were sacrificed at 2.5 months of age (Figure 
17). First, each rat was administered intraperitoneally with the drug Pentobarbital sodium used for 
anesthesia and euthanasia (54.7 mg/mL, 100 mg/kg, CEVA Santé animale, reference 6742145). 
Second, blood (600 µL) was collected by cardiac puncture for neutralization assay (refer to 
Material and Methods III.I) for 5 WT injected with AAV9 scramble shRNA and 5 CMT1A rats 
injected with AAV9 scramble shRNA and after centrifugation serum was recuperated and frozen 
at -80 °C. In addition, whole blood was collected in EDTA tubes for AAV vector biodistribution 
for 4 WT injected with AAV9 scramble shRNA, 2 CMT1A rats injected with AAV9 scramble 
shRNA, 1 CMT1A rats injected with AAV9 shRNA PMP22-49 and 1 CMT1A rats injected with 
AAV9 shRNA PMP22-50. Third, each rat was perfused with around 100 mL of 1x PBS (Gibco, 
reference 10010023). Finally, the following organs and nerves were dissected: heart, liver, spleen, 
kidney, muscle closed to sciatic nerve, lumbar (L) spinal cord, dorsal root ganglions (DRG) L4 
and L5 as well as brainstem for AAV biodistribution and both sciatic nerves cut in multiple pieces 
for RT-qPCR (refer to Material and Methods III. G.1), AAV biodistribution (refer to Material and 
Methods III. J) and Western Blot (refer to material and Methods III. G.2) (Table 11). Two small 
pieces of each organs were cut: one was snap frozen in liquid nitrogen then stored at -80°C for 
biochemical analysis and the second fixed for 24 h in PFA 4% at 4°C then placed in sucrose 6 and 
30 % for around 48h at 4°C and embed in Optimal Cutting Temperature (OCT, NEG-50, reference 
650-2) for histological studies. 
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29 out of 31 of AAV9 shRNA-injected rats of LTC (1 rat euthanized due to paw’s infection 
and another one died due to visceral tumor) were sacrificed at 12 months of age (Figure 17). First, 
each rat was administered intraperitoneally with the drug Pentobarbital sodium used for anesthesia 
and euthanasia (54.7 mg/mL, 100 mg/kg, CEVA Santé animale, reference 6742145). Second, each 
rat was perfused with around 100 mL of 1x PBS (Gibco, reference 10010023). Third, the following 
organs and nerves were dissected: lumbar (L) spinal cord, dorsal root ganglions (DRG) L4 and L5 
and both sciatic nerves cut in multiple pieces for RT-qPCR (refer to Material and Methods III. 
G.1), CARS microscopy (refer to Chapter 2: Label-Free non-linear microscopy Project) and 
Western Blot (refer to material and Methods III. G.2) (Table 11). Finally, the spinal cord and DRG 
from one side of the spinal cord were snap frozen in liquid nitrogen then stored at -80°C for 
biochemical analysis. DRG from the other side of the spinal cord were fixed for 24 h in PFA 4% 
at 4°C then placed in sucrose 6 and 30 % for around 48h at 4°C and embed in Optimal Cutting 
Temperature (OCT, NEG-50, reference 650-2) for histological studies. 
 In order to avoid contamination, dissection instruments were cleaned between each tissue 
and each rat. The following reagents were used in this order for the cleaning: tap water to remove 
the blood, 10% Sodium dodecyl sulfate solution (SDS, Sigma, reference L4522), PBS (2 baths), 
RNAse Away (Thermo Scientific, reference 10666421 and PBS (2 baths).  
 
G. Molecular and biochemical techniques  
1. RT-qPCR  
Translational gene therapy for genetic diseases- UMR1089, Nantes, France 
 TRIzol® reagent (Thermo Fisher Scientific, reference 15596026) was used to extract total 
RNA, according to the manufacturer's instructions. After treating total RNA (150 ng) with RNAse-
free DNAse I (ezDNAse, Thermo Fischer Scientific, reference 11766051), random primers, oligo 
(dT)18 (Thermo Fischer Scientific, reference SO131) and SuperScript IV Vilo Master Mix 
(Thermo Fischer Scientific, reference 11756050) served to synthesize cDNA from total RNA in a 
final volume of 20 µL. Afterwards, quantitative PCR (qPCR) analysis was done on 5 µL of cDNA 
(diluted 1/15) in duplicate using primers for Pmp22, Mpz and rat Hprt1. Sequences as well as PCR 
parameters are detailed in the table below (Table 9). For quantitation, mRNA of PMP22 and MPZ 
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were normalized against rat HPRT1 mRNA, co-amplified as an endogenous control. "cDNA-like 
samples" analysis confirmed the absence of DNA contamination for each RNA sample. This was 
acquired by excluding reverse transcriptase from the reaction mix. Analyzing serial dilutions of 
cDNA sample (1/10 to 1/100000 for Pmp22 or Mpz and 1/5 to 1/60 for HPRT1) from a sciatic 
nerve of a transgenic rat injected with AAV9 shRNA scramble defined the efficiency, linearity 
and absence of qPCR inhibition. Results were expressed in relative quantities (RQ): RQ = 2-ΔCt 
= 2 - (Cycle threshold Ct target - Ct endogenous control). The limit of quantification (LOQ) of our 
test was for mouse Pmp22 RQ =2.4 and for Mpz RQ=0.5. 
Table 9 : PCR conditions for in vivo validation of shRNA PMP22  
Name of 
primers 
Sequences of primers 
Concentrations 
in qPCR mix 
(µM) 
PCR program 
Mouse 
Pmp22-F 
GACAAACCCCAGACAGTTGA 0,25 
Sybr Green 
30s at 95°C, 40 
cycles of (5s at 95°C 
and 30s at 64 °C) + 
melt curve 
Mouse 
Pmp22-R 
CAGGAGCCACCAGCTATTACT 0,25 
Mpz: F TGTTGCTGCTGTTGCTCTTC 0,25 Sybr Green 
30s at 95°C, 33 
cycles of (5s at 95°C 
and 30s at 60 °C) + 
melt curve 
Mpz: R TTGTGAAATTTCCCCTTCTCC 0,25 
Rat HPRT 
F 
GCGAAAGTGGAAAAGCCAAGT 0,2 Taqman 
30s at 95°C, 33 
cycles of (5s at 95°C 
and 30s at 60 °C) + 
melt curve 
Rat HPRT 
R 
GCCACATCAACAGGACTCTTGTAG 0,2 
Rat HPRT 
P 
CAAAGCCTAAAAGACAGCGGCAAGTTGAAT 0.2 
F= forward primer, R= reverse primer, P= TaqMan probe 
 
2. Western Blot 
 Western Blot biochemical technique was used to quantify PMP22 protein in rat sciatic 
nerves. At the time of dissection, rats were 2.5 months old. Proteins were extracted and quantified 
using the BCA protein assay kit (Thermo Scientific, reference: 23225) based on colorimetric 
detection. 20 µg of proteins were separated in 10% precast polyacrylamide gels (Bio Rad, 
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reference: 4568034). After that, proteins were transferred to Polyvinylidene difluoride (PVDF) 
membranes by rapid (7 min), semi-dry blotting process (Bio Rad Trans blot transfer pack, 
reference: 1704157 and Bio Rad Trans-Blot Turbo system). Membranes were blocked for 1 hour 
at room temperature using a commercial buffer (Odyssey Blocking buffer (PBS) LI-COR 927-
40000). The following primary antibodies were incubated overnight, at 4ºC, in blocking buffer, on 
a shaker: Rabbit Anti-PMP22 (Sigma, Reference SAB4502217, 1/500 dilution), goat anti-MPZ 
(Invitrogen, reference PA5-18773, 1/500 dilution) and mouse anti-alpha tubulin (Millipore, 
reference MABT205, 1/7 000 dilution). On the next morning, membranes were washed for 3-5x7 
min in Tris-buffered saline, 0.1% Tween 20 (TBST). Following the washing, secondary antibodies 
(Li-Cor) were utilized at a 1/12 000 dilution: IRDye 800CW Donkey anti-rabbit (green 
fluorescence, reference 925-32213), IRDye 800CW Donkey anti-goat (green fluorescence, 
reference 925-32214) and IRDye 680RD Donkey anti-mouse (red fluorescence, reference 925-
68072). After washing in TBST, results and quantifications were obtained by the Odyssey CLX 
Li-Cor Imaging System and its “Image Studio” software. Statistical analysis was done using 
Graphpad Prism 7 software. Three blots were performed with on each, samples from 2 WT rats 
injected with scramble shRNA, 2 CMT1A rats injected with scramble shRNA, 2 CMT1A rats 
injected with shRNA PMP22-49 and 2 CMT1A rats injected with shRNA PMP22-50. The first 
blot was chosen as reference and the other blots were corrected using a factor for each based on 
the average value of the WT samples. Statistical analysis was done using Graphpad Prism 7 
software. Western Blots were reprobed using different antibodies (rabbit anti-Akt Cell Signaling, 
reference: 9272, 1/1 000 dilution, mouse anti-Anti-Glyceraldehyde-3-Phosphate Dehydrogenase 
Antibody, clone 6C5 (GAPDH, Millipore, reference MAB374, 1/1 000 dilution).  
 
H. AAV9 Neutralizing factors  
 Gene Therapy Immunology (GTI) core - UMR1089, Nantes, France 
 An inhibition assay was used to detect neutralizing factors (NF) against the viral vector 
AAV9 (Table 11). The aim of this technique is to measure cell transduction efficiency of the viral 
vector. In practice, serial dilution of serum (1/50, 1/500, 1/5 000, 1/50 000 and 1/500 000) were 
incubated with cells and AAV9 expressing the reporter gene Lac Z. A chemiluminescent method 
119 
 
(Galacto star kit, Life Tech, reference) was used to detect gene expression. Cell number range, 
AAV9 transduction level in the absence of serum, limit of detection (LOD) and a neutralizing 
serum positive control constitute some of the acceptance criteria of the neutralization assay. The 
positive test is equivalent to more than 50% of transduction inhibited in the presence of AAV9 NF 
in serum; the 100% corresponding to the transduction control with AAV9 alone. 
 
I. AAV9 biodistribution  
Virginie François at the Preclinical Analytics core (PAC) - UMR1089, Nantes, France 
 For AAV biodistribution i.e. the spreading of the viral vector away from the injection site 
(Le Guiner et al., 2011), DNA was extracted and quantified by qPCR. Analyzed samples enclosed: 
the injection site (sciatic nerve), the lumbar dorsal root ganglion 4 and 5 (DRG L4 and L5), the 
lumbar spinal cord, the heart, the liver, the spleen, the kidney, the muscle close to the sciatic nerve, 
the brainstem and the blood  (Table 11). Whole blood was collected in tubes containing EDTA as 
an anticoagulant. All samples were collected in DNA-free, RNAse/DNAse-free and PCR 
inhibitors-free certified microtubes and stored at -80°C before DNA extraction. 
 First DNA was extracted from blood and tissues according to manufacturer’s 
recommendations (Gentra Puregene, Qiagen, reference 1042606). Briefly, red blood cells were 
discarded from whole blood samples using the “Red Blood Cell Lysis Solution” (Gentra Puregene) 
and tissues were grinded with TissueLyserII from qiagen. Then, in the presence of the proteinase 
K enzyme and of a DNA stabilizer to limit the activity of intracellular along with environmental 
DNases, an anionic detergent lysed tissues and cells. After that, contaminants were removed with 
an RNA digesting enzyme for RNA and salt precipitation for proteins. Next, precipitation with 
isopropanol and drying with 70% ethanol recovered the genomic DNA and the hydration solution 
(1 mM EDTA, 10 mM Tris·CI pH 7.5) dissolved it (Gentra Puregene, Qiagen handbook, 2014). 
Lastly, the DNA concentration was measured by a nanospectrophotometer. 
 Second, a PCR internal control was prepared using a linearized DNA to avoid interference 
with PCR efficiency from supercoiled DNA. The linearized DNA enclosing one copy of the 
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sequence to analyze was purified. The following formula was utilized to calculate the weight of 
one copy of the plasmid: 
Weight of one copy of the plasmid = Weight of 1bp (g/mol) x size of the plasmid (bp) 
                                                            Avogadro’s number (molecules/mol) 
                                                        = 660 x size of the plasmid (bp) 
                    6,022E23 
A dilution at 1011 copies of plasmid in a final volume of 5 µL was made.  
Afterwards, serial dilutions of this linearized DNA plasmid were prepared to get a range from 107 
to 25 copies for Gfp and from 106 to 100 copies for reference gene (Le Guiner et al., 2011). 
 Third, TaqMan qPCR was performed on 50 ng DNA in duplicates for each sample.  Primers 
and probe designed to amplify and match the GFP marker of AAV9 shRNA and an endogenous 
gene were used to determine vector DNA copy numbers expressed at the end as vector genome 
per diploid genome (vg/dg).  For Gfp gene: 
Forward: 5’-ACTACAACAGCCACAACGTCTATATCA-3’  
Reverse: 5’- GGCGGATCTTGAAGTTCACC-3’ 
Probe: 5’-FAM-CCGACAAGCAGAAGAACGGCATCA-TAMRA-3’ 
For rat Hprt1 gene: 
Forward: 5’- GCGAAAGTGGAAAAGCCAAGT -3’ 
Reverse: 5’-GCCACATCAACAGGACTCTTGTAG-3’ 
Probe: 5’- JOE- CAAAGCCTAAAAGACAGCGGCAAGTTGAAT-TAMRA-3’ 
 For each sample, Ct values were compared with those obtained with different dilutions of 
linearized standard plasmids (containing either the Gfp expression cassette or the rat Hprt1 gene). 
The absence of qPCR inhibition in the presence of gDNA was checked by analyzing 50 ng of 
gDNA extracted from tissues samples from a control animal, spiked with different dilutions of 
standard plasmid. The limit of quantification was calculated by dividing 25 copies over the mean 
of the reference gene. Results were expressed in vector genome per diploid genome (vg/dg). The 
sensitivity of the test was 0.002vg/dg. The efficiency of the amplification reaction was between 95 
and 105% (Le Guiner et al., 2011). 
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Table 10: Summary of behavioral tests 
1: 2WT rats jumped from rotating bar as soon as placed on it; 2: 2WT rats jumped from rotating bar as soon as placed on it + 1 WT with wounded paw; 3:  1 WT 
rat with wounded paw; 4:1 CMT1A rat euthanized due to paw infection and 3 CMT1A jumped from rotating bar as soon as placed on it; 5:  1 CMT1A euthanized 
due to paw ; 6: 1 CMT1A rat died from a visceral tumor; 7 : 1 CMT1A rat drags right hindpaw  
Dissections: At 6 months for non-injected rats, 10 WT and 8 CMT1A were dissected, at 12 months all rats of LTC are going to be dissected, at 2.5 months all rats 
of STC dissected. m=month 
 
Cohort Group 
Total 
initial 
Number 
Rotarod (month) Grip test (month) Catwalk (month)  
Randall 
Selitto 
Dissection 
1 2  3  4 6  9 12 1  2  3  4  6  9  12  1 2  4  6  12  6  11  Age Nb 
Non-
injected 
WT 22 22 201  192 201  12 22 22  213 22  12 22 22 213 22 12   6m 10 
CMT1A 20 20 20  20 20  12 20 20  20 20  12 20 20 20 20 12   6m 8 
Long 
term 
cohort 
(LTC) 
WT 
sh.scr 
7 7 7 7 7 7 7  7 7 7 7 7 7       7 7 12m 8 
CMT1A 
sh,scr 
8 8 8 8 8 8 8  8 8 8 8 8 8       8 8 12m 8 
CMT1A 
sh49 
8 8 8 8 44 75 75  8 8 8 8 75 75       75 75 12m 8 
CMT1A 
sh50 
8 8 8 8 8 76 76  8 8 8 8 76 76       76 76 12m 8 
Short 
term 
cohort 
(STC) 
WT 
sh.scr 
8 8 8      8 8             2.5m 8 
CMT1A 
sh,scr 
8 8 8      8 8             2.5m 8 
CMT1A 
sh49 
8 77 77      77 77             2.5m 8 
CMT1A 
sh50 
8 8 8      8 8             2.5m 8 
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Table 11: Summary of electrophysiological measurements, molecular and biochemical analysis 
SN= Sciatic Nerve; RT qPCR= Reverse Transcriptase quantitative Polymerase Chain Reaction, it was done for PMP22 mRNA in SN and also for biomarkers 
analysis in SN and skin for all the rats of the STC; NF= Neutralizing Factors; DRG= Dorsal Rot Ganglion; qPCR= quantitative Polymerase Chain Reaction 
1:1 CMT1A rat euthanized due to paw infection and a second no signal detected; 2: 1 CMT1A rat euthanized due to paw infection; 3: 1 CMT1A rat died from a 
visceral tumor 
For NF and qPCR, littermates and age-matched non-injected controls were dissected; NOT RATS THAT WERE USED FOR MODEL CHARACTERIZATION 
 
Cohort Group 
Total 
initial 
Number 
ELECTROPHYSIOLOGY 
(month) 
RT 
qPCR 
NF qPCR Biodistribution of AAV9+ Histological analysis except for blood 
1 2 3 4 6 9 12 SN Skin Serum SN Muscle DRG 
Spinal 
cord 
Heart Liver Spleen Kidney Brainstem Blood 
Non-
injected 
WT 22       12   2   
        
CMT 1A 20       12   2 1 1 1 1 1 1 1 1 1 1 
Long 
term 
cohort 
(LTC) 
WT 
sh.scr 
7 7 7 7 7 7 7               
CMT1A 
sh,scr 
8 8 8 8 8 8 8               
CMT1A 
sh49 
8 8 8 8 61 72 72               
CMT1A 
sh50 
8 8 8 8 8 73 73               
Short 
term 
cohort 
(STC) 
WT 
sh.scr 
8 8 8      8 8 5 8 4 8 8 4 4 4 4 4 4 
CMT1A 
sh,scr 
8 8 8      8 8 5 4 2 4 4 2 2 2 2 2 2 
CMT1A 
sh49 
8 8 8      8 8  2 1 2 2 1 1 1 1 1 1 
CMT1A 
sh50 
8 8 8      8 8  2 1 2 2 1 1 1 1 1 1 
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Results  
 Our goal as described in the introduction was to reduce PMP22 expression. Our 
collaborators P. Young and B. Gess had attempted to reduce PMP22 expression in CMT1A rats 
through the intraperitoneal injection of “nude” (not cloned in a plasmid) shRNAs without success. 
Consequently, we chose a gene therapy approach based on AAV viral vectors expressing shRNA 
to downregulate PMP22 expression. My thesis project intended to correct the impaired phenotype 
of the CMT1A rat model (motor deficits, electrophysiological abnormalities, sensorial as well as 
myelination problems) using the approach previously stated. 
 
I. Therapeutic tools validation 
 
A. Efficiency to transduce myelinating Schwann cells in vivo 
1. Efficiency to transduce target cells in rodents 
 In a collaborative work between Nicolas Tricaud’s and Patrick Aubourg’s lab (INSERM 
U1169 (EX U986)) laboratories, Benoit Gautier (Aubourg’s lab), Claire Perrin-Tricaud, Jade 
Berthelot, Marie Deck and Sergio Gonzalez (Tricaud’s lab) studied the transduction efficiency of 
single stranded AAV9 and 10 carrying a GFP transgene under the control of a CAG promoter 
(CMV enhancer fused to chicken beta actin promoter) in the sciatic nerves of mice and rats. 
(Figure 14). 
 First, 2 month-old-adult mice were injected either with AAV9 (4.6x1010vg/nerve) or 
AAV10 (4.6x1010vg/nerve) in their sciatic nerve. All injections in this project, except for 
macaques, were done with a microinjector technique developed in the lab of Nicolas Tricaud 
(Figure 18). Briefly, anesthetized animals were placed on their belly; the skin on the thigh was 
shaved and cleaned before to be cut; two muscles biceps femoris and gluteus superficialis were 
then carefully disjointed and the sciatic nerve under the muscles was hold by a spatula. Then the 
viral solution stained with Fast Green dye was injected using a fine glass needle linked to a 
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microinjector controlled by a pulse generator. This system allowed for multiple pulsed injections 
of small volumes in the hundreds of nanoliters range to almost completely fill the sciatic nerve. 
 
Figure 18 : Injection procedure in the sciatic nerve of an adult rat: A: anesthesia; 
B: Surgery; C: Injection of virus diluted with Fast Green and PBS; D: Suturing 
with surgical clips. Adapted and modified from Gonzalez et al, 2014 
 
 One month later, sciatic nerves were teased in small fibers bundles to identify the different 
types of transduced cells based on their morphology: long and large cells were myelinating 
Schwann cells; fine bipolar cells were non-myelinating Schwann cells; fine never-ending 
processes were axons (Figure 19). Teasing analysis indicated that a very high proportion of 
transduced cells with both viruses were myelinating Schwann cells. AAV9 remained the most 
specific one for these cells (Figure 19). Few non-myelinating Schwann cells were also transduced. 
AAV9 did not transduce many axons while AAV10 did infect only a few of them. Thus, AAV9 
was selected to carry on testing in 1-month-old adult rats (1.8x1011vg/nerve) with very similar 
results as in the adult mouse (Figure 19). We also tested the transduction of pre-myelinating 
Schwann cells in the sciatic nerves of mouse and rat pups at postnatal day 3-4 (P3-4) for the mouse 
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(1.15x1010vg/nerve) and P6-P7 for the rat (1x1011vg/nerve), the ages when myelination starts. 
Similar results as in adult animals were obtained with AAV9 (Figure 19), showing that this virus 
very specifically targets myelinating Schwann cells when injected directly in the nerve.  
 
Figure 19 : Teasing results of rats and mice injected with AAV9 or 10: 3 animals per viral vector 
were injected in the sciatic nerve unilaterally (n=3).  A: Microscopic image of adult mouse AAV10-
injected nerve showing transduced myelinating Schwann cells (white arrows), non-myelinating 
Schwann cells (white arrowheads) and axons (white star). Scale bar=20 µm. B: Table representing 
the type of cells transduced in percentage (%): mSC (myelinating Schwann cells), non-mSC= non- 
myelinating Schwann cells and axons. AAV9 targets almost exclusively mSCs. 
2. Transduction rate of myelinating Schwann cells in rodents 
 We next immunostained cryosections of rat and mouse sciatic nerves injected with AAV9 
or 10 to measure the percentage of transduced myelinating Schwann cells. Myelinated fibers were 
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detected using MBP for the myelin sheath and Tuj1 for myelinated axons. The number of GFP 
labelled myelinating Schwann cells per myelinated fiber was counted. We found that both viruses 
transduced a high number of myelinating Schwann cells (Figure 20).  In adult mice AAV9 
transduced more myelinated Schwann cells than AAV10 at the injection site (93% compared to 
51 %). In addition, AAV9 diffused more than AAV10 along almost the entire nerve of adult mice 
(Figure 20). In general, for both mice and rats, in adults or pups, a large majority of myelinating 
Schwann cells were transduced (80-90%) by AAV9 (Figure 20).  
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Figure 20 : Transduction of myelinating Schwann cells in the sciatic nerve of rats and mice 
3 animals per viral vector (n=3). A: Cryosection of an adult mouse sciatic nerve injected with 
PBS, AAV9 or 10. Scale bar=10 µm; B: Cryosection of a rat pup sciatic nerve injected with AAV9. 
Scale bar=100 µm; C: Example of an infected cell expressing GFP (green). Myelinating Schwann 
cells are labelled by Myelin Basic Protein (MBP, purple) and axons by Tubulin β 3 (TUJ1, red). 
Scale bar=2.5 µm; D: Table representing the percentage of transduced myelinating Schwann cells 
at the injection site and at different distance of this site (proximal: 1 cm above the injection site, 
distal: 1 cm below the injection site). AAV9 has a high transduction rate and a good diffusion. 
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3. Efficiency of transduction in macaca fascicularis  
 Injection of AAV into the sciatic nerve of 2 year-old-macaques (macaca fascicularis) was 
done at the MIRCEN facility of the CEA Fontenay aux roses by the neurosurgeon Dr Michel 
Zerah, with the help of Benoit Gautier and Claire-Maëlle Fovet. These injections were done using 
a capillary fiber linked to a Hamilton syringe right above the split of the sciatic nerve into common 
fibular and tibial nerves. 40µL were injected for AAV9 and 400µL for AAV10 over 10 minutes 
for AAV9 (5x1011 vg/nerve) and 30 minutes for AAV10 (5x1012 vg/nerve). The characteristics of 
the injected animals are shown in Table 7. These animals were sacrificed 30 days after injection 
and their nerves analyzed by cryosections and immunostaining.  
 In these animals, we could not detect any transduced cells with AAV10 while AAV9 
transduced mostly myelinating Schwann cells. The transduction rate of myelinating SCs was high 
(70%) at the injection site and the virus showed a relatively good diffusion rate along the nerve as 
nerve sections located up to 3 cm from the injection site in the proximal direction were infected at 
a significant rate (Figure 21). Overall the diffusion reached up to 5.5 cm. 
 Taken together these data indicated that AAV9 injected directly in the sciatic nerve was 
the most specific and the most efficient virus to transduce myelinating Schwann cells in vivo. 
These proves of concept for the use of AAV9 to transduce myelinating Schwann cells in vivo was 
patented by the two labs and INSERM Transfer in 2017 (Patent WO2017005806A1). 
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Figure 21 : Transduction of myelinating Schwann cells in the sciatic nerve of macaques:  
mSC= myelinating Schwann cells; SN= Sciatic Nerve; CFN= Common Fibular Nerve; TN= Tibial 
Nerve. Good transduction rate of AAV9. Scale bar=50 µm.. 
 
B. Design, cloning and validation of shRNAs targeting mouse PMP22 
mRNA  
 Next, we designed shRNAs targeting mouse PMP22 mRNA, which is overexpressed in 
CMT1A rats. Our collaborators Burkhard Gess and Peter Young (University Hospital Münster, 
Department of Sleep Medicine and Neuromuscular Diseases, Germany) had already designed and 
characterized two shRNAs, shRNA PMP22-49 (sh49) and shRNA PMP22-50 (sh50), to silence 
mouse PMP22 in CMT1A rats (Figure 22.A). These shRNAs target the coding sequence of the 
mouse PMP22 mRNA (Figure 22.B and C). These sequences were homologous of rat but not 
human or macaque sequences (Figure 22.B and C). We chose a control shRNA as a shRNA 
without any target in mammals. We cloned these shRNA sequences into a recombinant AAV 
plasmid (pAAV2/9, CPV, UMR1089, Nantes) under the control of a U6 promoter next to the GFP 
under the control of a CMV promoter. These plasmids were validated by sequencing.  
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After that, we examined the impact of shRNA therapeutic tool on PMP22 mRNA and 
protein levels in vitro.  Mouse Schwann cell line (MSC80) expressing PMP22 and CMT1A rat 
Schwann cells were transfected with shRNA constructs: scramble shRNA (scr.sh or control sh), 
shRNA PMP22-49 (sh49) or shRNA PMP22-50 (sh50). PMP22 mRNA expression was then 
quantified by real-time PCR. We found that MSC80 cells transfected with sh49 and sh50 plasmids 
showed a significantly decreased expression of PMP22 (Figure 22.D). In Schwann cells of the 
CMT1A rat, PMP22 mRNA expression was also significantly reduced compared to control 
shRNA (Figure 22.E). In addition, PMP22 protein levels were also downregulated by sh49 and 
sh50 in MSC80 (Figure 22.F and G) and in CMT1A rat Schwann cells (Figure 22.H and I), 
showing that these shRNAs against mouse PMP22 mRNA are effective in reducing mouse PMP22 
expression.  
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Figure 22: Downregulation of 
PMP22 by shRNA in vitro: 
scr.sh= scramble shRNA, sh49 = 
shRNA PMP22-49, sh50= shRNA 
PMP22-50.  A: AAV shRNA 
cassette diagram. Alignment of 
sh49 (B) and sh50 (C) sequences 
with PMP22 mRNA of rat (rattus 
(R)Norvegicus), mouse (Mus (M) 
musculus, human (homo (H.) 
Sapiens) and macaque (macaca 
(M.)  fascicularis); D: Real-time 
PCR of PMP22 mRNA extracted 
from MSC80 cells after 
transfection with shRNA 
constructs; scr. sh normalised as 
100%; mean +/- standard 
deviation shown, 4 independent 
experiments per condition; *** 
p<0.001 (performed by Gess, B 
and Young, P). E: Real-time PCR 
of PMP22 mRNA extracted from 
CMT1A rat Schwann cells after 
transfection with shRNA 
constructs; scr.sh not shown but 
considered 0; mean +/- standard 
deviation shown; ** p<0.01 
(performed by Gess, B and Young, 
P).  F, G: Western blots and 
quantifications in percentage of 
MSC80 cell lysates after 
transfection with shRNA plasmids; 
3 independent experiments per 
condition; * p<0.05, **p<0.01 
(performed by Benoit Gautier). H, 
I: Western blots and 
quantifications in percentage of 
CMT1A rat Schwann cell lysates 
after transfection with shRNA 
plasmids; * p<0.05, **p<0.01 
(performed by Gess, B and Young, 
P). 
Statistical analysis  was  done using  
Graphpad  Prism 7,  Ordinary-
One-Way ANOVA  followed  by 
Tukey’s test.  Mean  ±  standard  
deviation shown. 
 
CMV 
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 We were then confident for the use of AAV9 viral vector expressing shRNAs 49 and 
50 to reduce mouse PMP22 overexpression in myelinating Schwann cells of CMT1A rats.  
 
II. CMT1A rat model characterization 
 Next, I functionally characterized the CMT1A rat model using different behavioral tests 
cited in the literature: Rotarod and grip test to study motor impairments seen in CMT1A rats, 
catwalk to assess the unsteady gait of CMT1A rats and electrophysiological measurements of 
nerve conduction velocity known to be decreased in CMT1A. I did the behavioral analysis on a 
regular basis, every 1-2 months until 6 months of age of rats then at 12 months right before 
sacrifice except for NCV measurements which I only did at 12 months. I used CMT1A rats (20 
animals) heterozygous for mouse pmp22 transgene and control WT animals (22 rats) from the 
same litter (Table 10, Table 11). The animals utilized to develop our colony were kindly provided 
by Michael Sereda laboratory in Germany.  
 
A. Motor deficits 
 Motor deficits cited in the literature (Fledrich et al., 2014; M. Sereda et al., 1996) were 
confirmed by rotarod (Figure 23.A) for motor coordination and equilibrium and grip test (Figure 
23 .B) for muscle strength. CMT1A rats fall faster than WT from the rotating bar of the rotarod 
apparatus. Moreover, they have lower muscle strength as seen by grip test of the rear paws. These 
deficits start to be statistically significant at 1 month of age for rotarod and 4 months for grip test 
and are maintained over 12 months. 
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B. Clumsiness in walking  
 As far as I know, the Catwalk test was never used to study the gait of CMT1A rats. This 
test allows for analyzing rat gait while they cross a corridor. It is a modern version of the ink-
based trace analysis. Two (Figure 24.A) and four (Figure 24.B) months-old-CMT1A rats were 
analyzed for several parameters. The parameters we retained were: “Max contact”, inter-paw 
coordination parameters “regularity index”, “phase dispersions” and “couplings” as well as “left 
hind paw single stance”. CMT1A rats of both ages leave their paws on the glass plate of the 
Figure 23: Motor impairments in 
CMT1A rats:  
A: Rotarod, latency to fall in  
seconds (s).  
B: Grip strength test in Newtons 
(N). 
 
 
 
 **** p<0.0001. 
 
 Statistical analysis was done on 
Graphpad Prism 7: Two-Way-
ANOVA with repeated measures 
followed by Tukey's test. 
 
Mean ± SEM per time point.   
 
WT n=22 per time point except at 12  
months n=12.   
CMT1A n=20 per time point except at 
12 months n=12.  
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apparatus with less intensity than WT (“Max Contact”, Figure 24.A and B). Four month-old-
CMT1A-rats have less inter-paw coordination than WT as seen by the regularity index, phase 
dispersions and couplings parameters (Figure 24.C). CMT1A rats leave one of their hind paws a 
shorter time on the glass plate compared to WT as indicated by the single stance parameter (Figure 
24.D). For detailed definition of each parameter refer to the legend of figure 24 and to material 
and methods chapter. 
 
Figure 24: Locomotion problems in CMT1A 
rats: RF=right front, RH=Right hind, LF= 
Left front, LH=left hind. Max contact in 
arbitrary units (a.u) for 2- (A) and 4-month-
old rats (B): print intensity of animals when 
their whole paw is in contact with the glass 
plate of the Catwalk. C: Interpaw 
coordination parameters in percentage (%), 
4-month-old rats: Regularity index expressing 
the number of normal step sequence patterns 
relative to the total number of paw 
placements, phase dispersions describing the 
temporal relationship between placement of 
two paws, ranges from -50 to 75% and 
couplings similar to the phase dispersions 
parameter but ranges from 0 to 100%. D: LH 
single stance: the duration (in seconds) of 
ground contact for a single hind paw. It is the 
part where the contralateral hind paw does 
not touch the glass plate  
*p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. Graphpad Prism 7: Ordinary 
One-Way-ANOVA followed by Tukey's test 
except for Figure 7D: t-test. Mean ± SEM. WT 
n=22. CMT1A n=20. 
C. Reduced Nerve Conduction Velocity (NCV)  
 Briefly, after anesthetizing animals with isoflurane, electrodes are placed at both proximal 
and distal site of the rat’s sciatic nerve (refer to material and methods II.C) to stimulate the nerve 
and record a signal as compound muscle action potentials (CMAP). CMAP is defined as the sum 
of activity in muscle fibers following motor nerve stimulation. The very start of the CMAP 
apparition is used as the time measure. The distance between proximal and distal electrodes is also 
measured and NCV is then calculated based on the classical velocity formula of distance over 
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duration time. Duration time or latency is the difference between the start of the CMAP response 
at the proximal and at the distal measure sites:  
NCV (m/s) =
!"#$%&'(
)*+,"-%./0%$(&'1/2"#$%./0%$(&'1/
3 
Using this setup NCV of 12 month-old-CMT1A-rats was significantly lower compared to WT 
(Figure 25). 
 
 
                           Figure 25: Decreased NCV in CMT1A rats: A: Electrophysiological  
                          measurements method; B: NCV= Nerve conduction velocity in meter  
                     per second (m/s) **** p<0.0001 (t-test). Mean ± SEM. WT n=12. CMT1A n=12.  
 
  
Taken these data together we concluded that rotarod and grip tests were suitable to study motor 
deficits seen in diseased animals. In addition, NCV was an essential parameter to measure since 
reduced values (like I found in CMT1A rats) are a typical feature of CMT1A. We decided to add 
the measure of the CMAP amplitude to the analysis. However, I noted that Catwalk was time-
consuming for analysis with often inconclusive results. Furthermore, since there was a large 
variability between rats, the sample size had to be increased to observe statistically significant 
differences. In line with the 3Rs ethic rule (Replacement, Reduction and Refinement, Fenwick, 
Griffin, & Gauthier, 2009) of animal use in research, we decided not to use the Catwalk for 
studying the efficiency of the gene therapy approach in rats but only rotarod, grip test and 
electrophysiological measurements.  
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III. Experimental design  
 Together with Nicolas Tricaud and Benoit Gautier who joined Nicolas Tricaud’s lab in 
October 2016, we carefully designed the experimental plan. First, we chose to create two cohorts 
of rat subdivided into 4 groups each. The two cohorts were termed “long term cohort or LTC” and 
“short term cohort or STC”. LTC served to study the efficiency of the gene therapy on the long 
term (sacrifice at 12 months) while STC was used to correlate behavioral analysis and 
electrophysiological measurements with biochemical and morphological studies (sacrifice at 2.5 
months) (Figure 26). 
The 4 groups were: 
· WT injected with AAV9 scramble shRNA (WT scr.sh) (8 animals) 
· CMT1A injected with AAV9 scramble shRNA (CMT1A scr.sh) (8 animals) 
· CMT1A injected with AAV9 shRNAPMP22-49 (CMT1A sh49) (8 animals) 
· CMT1A injected with AAV9 shRNAPMP22-50 (CMT1A sh50) (8 animals) 
 In this experimental plan all animals, even WT, are injected in order to detect whether the 
injection itself affects the animal phenotype, comparing their performance to the previously 
described non-injected cohort. Then, defects of CMT1A animals in injected conditions only (AAV 
with control shRNA) can be observed when compared to WT injected animals. Finally, the 
beneficial effect of shRNA 49 and 50 can be analyzed comparing CMT1A rats injected with AAV 
control shRNA with mutant animals injected with AAV shRNA 49 and 50.   
 We chose for assessing motor performance rotarod and grip strength test since I obtained 
good results with these tests in the preliminary characterization of the animal model. We also 
decided to add a sensory test, the Randall-Selitto pain test, because a large number of sensory 
fibers are myelinated and therefore affected in CMT1A. This test had never been used before on 
CMT1A rats.  
 At the moment, among all the behavioral and biochemical tests we planned in this 
experimental plan (Figure 26), only the morphological analyses of LTC are still ongoing. 
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          Figure 26: Summary of experimental design. 
   
IV. Efficiency of AAV9 shRNA PMP22 in vivo  
 We first measured the efficiency of AAV9 expressing shRNAs 49 and 50 to decrease 
mouse PMP22 in myelinating Schwann cells in vivo. 
  Total mRNA of STC sciatic nerves were collected for each animal. Mouse PMP22 mRNA 
was quantified by RT qPCR using rat Hprt as the reference gene. This work was done in 
collaboration with Dr. Caroline Le Guiner and Virginie François (Translational gene therapy for 
genetic diseases-UMR1089, Nantes, France). Results were normalized to values obtained in 
CMT1A animals expressing control shRNA. Given that WT rats do not possess the mouse PMP22 
gene, the PMP22/HPRT mRNA relative expression is null. Nevertheless, this was not statistically 
significant (Figure 27.A). We plan to reproduce the experiment because the reference gene was 
weakly expressed in rat sciatic nerve. We will use Rps9 and Actb as reference gene instead.  
 We also measured the protein expression level of mouse and rat PMP22 in treated or 
control sciatic nerves. These levels were normalized on rat MPZ protein level because myelin 
amount is highly heterogeneous in CMT1A rats (Grandis et al., 2004). PMP22 expression 
increased in CMT1A rats versus WT animals and treatment with PMP22 shRNA 49 and 50 
138 
 
significantly reduced it (Figure 27.B).  Interestingly, PMP22 expression mouse and rat reached 
control level in nerve treated with PMP22 shRNAs, suggesting that the downregulation was not 
sufficient enough to induce deleterious effects such as in animals and patients with PMP22 loss of 
function.  
 Thus, taken together these data show that our gene therapy approach is able to restore the 
correct amount of PMP22 expressed in myelinating Schwann cells of CMT1A rats.  
 
                Figure 27: Downregulation of PMP22 by AAV9 shRNA in sciatic nerves of rats: scr.-shRNA=  
                Scramble shRNA, shRNA49 = shRNA PMP22-49, shRNA50= shRNA PMP22-50 Sciatic nerve          
                extracts from 2.5 months-old-rat, n=8 per group.   
                 A: Real-time PCR of MOUSE PMP22 mRNA (performed at the UMR1089, Nantes). Results (still   
                 preliminary) are presented as relative expression (% of CMT1A scr.sh).  
B: Western blots quantifications of TOTAL PMP22. a.u= arbitrary units. 
                *p<0.05, **p<0.01. Statistical analysis was done on Graphpad Prism 7: Ordinary One-Way- 
                ANOVA followed by Tukey's test. Mean ± SEM.   
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V. Functional recovery of treated rats  
 To assess whether a functional recovery was achieved following gene therapy, LTC rats 
were tested 1, 2, 3, 4, 6, 9 and 12 months post injections. Tests included rotarod for motor 
coordination and equilibrium, grip test for muscle strength and Randall Selitto (6 and 11 months 
post injections) for pain sensitivity assessment.  
A. Gene therapy improved motor deficits in CMT1A-treated rats  
 All injected animals of LTC were tested on the rotarod and for the grip test 1, 2, 3, 4, 6, 9 
and 12 months post injections. I found that, at the same age, WT and CMT1A rats treated with 
control shRNA virus had a phenotype like non-injected WT and CMT1A animals respectively 
(Figure 28. B and D). This showed that injection of the virus, infection of myelinating Schwann 
cells and control shRNA expression had no effect on the phenotypes.  
 Starting as early as 2 months of age, the latency to fall and the rear limb strength of CMT1A 
rats treated with both AAV9 shRNA PMP22-49 and 50 were significantly higher than CMT1A 
rats treated with AAV9 control shRNA (Figure 28. A and C). 1-month post-injection, the rotarod 
and grip test performance of PMP22 shRNA treated CMT1A rats were maintained close to control 
shRNA treated WT regardless of the time post injection, showing that the treatment with PMP22 
shRNA prevent the disease to develop in CMT1A rats. With a single injection at 6-7 days after 
birth, motor and strength performances could be maintained close to the WT performances for up 
to 12 months. Performance of CMT1A treated rats reach WT levels in rotarod 4 and 12 months 
post injections of both sh49 and sh50 while for grip test, 6 and 9 months with both shRNAs 
injections and 12 months with sh49 only. 
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Figure 28: Improvement of motor phenotype in treated rats:  Latency to fall in rotarod is expressed in 
seconds (s) for injected rats (A) and non-injected rats (B). Grip strength of the hind paws is expressed in 
Newtons (N) for the injected rats (C) and non-injected rats (D). Gene therapy corrected the motor 
coordination and equilibrium problems as well as increased muscular strength of CMT1A rats. ** p<0.01, 
*** p<0.001, **** p<0.0001. Statistical analysis was done on Graphpad Prism 7: Two-way ANOVA with 
repeated measures followed by Tukey's test. Mean ± SEM and n=8 per group and per time point. 
 
B. Hypoalgesia of CMT1A rats alleviated by gene therapy 
 Randall Selitto measures the nociceptive threshold of rats by applying an increasing 
pressure on their hind paws using a calibrated weight. This test was done by Antoine Jouvenel 
(PhD student, INM) on LTC rats 6 and 11 months post injections (Figure 29).  
 We observed hypoalgesia in CMT1A rats treated with control shRNA virus as they can 
bear a higher pressure applied on their hind paws compared to WT. CMT1A rats treated with 
PMP22 shRNA viruses had a higher sensibility to pain reaching WT levels even 11 months after 
the treatment. Consequently, treatment is efficient to maintain the normal response to pain in 
CMT1A rats (Figure 29).  
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Figure 29: No more hypoalgesia in treated rats: Pressure applied on the hindpaw 
is represented in grams (g) Gene therapy effectively reduced hypoalgesia**** 
p<0.0001. Statistical analysis was done on Graphpad Prism 7: Two-way ANOVA 
with repeated measures followed by Tukey's test. . Mean ± SEM and n=8 per group 
and per time point. 
 
VI. Reduced Nerve Conduction Velocity (NCV) in CMT1A rats 
corrected by gene therapy  
 As a quick reminder of the technique (for further details refer to material and methods II.C 
or to this chapter section II.C), stimulation electrodes are placed at both proximal and distal site 
of the rat’s sciatic nerve and the recording of the compound of muscle action potentials (CMAP) 
is done in the hindpaw muscle. Nerve conduction velocity (NCV) is then calculated based on the 
following formula: 
NCV (m/s) =
!"#$%&'(
)*+,"-%./0%$(&'1/2"#$%./0%$(&'1/
3 
 NCV was measured on LTC rats 1, 2, 3, 4, 6, 9 and 12 months post injections. NCV of 
CMT1A rats treated with control shRNA virus was reduced compared to WT, such as in non-
injected CMT1A rats. However, the NCV of CMT1A rats treated with PMP22 shRNA viruses 
was significantly higher than their genetic CMT1A siblings treated with control shRNA virus. 
Starting 1 month after treatment with PMP22 shRNA viruses maintained the NCV close to WT 
animals’ values for up to 12 months. However, this therapy had no effect on the amplitude of the 
compound muscle action potential (CMAP) (Figure 30).  
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Figure 30: Increased of NCV in treated rats: A. NCV (Nerve Conduction Velocity) 
is denoted in meter per second (m/s) and B. CMAP (Compound Muscle Action 
Potentials) in millivolt (mV). Gene therapy is efficient for NCV but not CMAP.   
*** p<0.001, **** p<0.0001. Statistical analysis was done on Graphpad Prism 7: 
Two-way ANOVA with repeated measures followed by Tukey's test. . Mean ± SEM 
and n=8 per group and per time point. 
 
VII.  Appropriate age of correlation between behavioral analysis, 
electrophysiological measurements and molecular, 
biochemical and morphological studies  
In order to test the homogeneity of experiments I performed, rotarod latency to fall, grip test 
muscle strength and NCV of injected rats were also measured in the second cohort, STC, at 2 
months of age. Similar results were obtained in the STC compared to LTC. A statistically 
significant difference was only seen in NCV between AAV9 sh49 and sh50 injected groups 
(Figure 31).  
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Figure 31: Comparison between 2 cohorts: STC= short term cohort; LTC= long term cohort. No 
difference was found between LTC and STC except for shRNA 49 and 50 in NCV.A: Latency to fall in 
rotarod expressed in seconds (s). B: Grip strength of hind paws expressed in Newtons (N). C: NCV 
expressed in meter per second (m/s). *p<0.05. Statistical analysis was done on Graphpad Prism 7: 
One-way ANOVA followed by Tukey's test. Mean ± SEM and n=8 per group.  
  
 Gene therapy is certainly one of the future treatments proposed to CMT patients. However, 
several parameters outside the disease symptoms must be assessed in animals before to propose it 
as a safe clinical treatment. One of these parameters is the immune responses generated against 
the virus and/or against the transgene in treated animals. We therefore performed a neutralization 
assay, which measure the immune response against the viral vector. Briefly, cells in culture were 
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transduced with an AAV9 expressing the reporter gene Lac Z in presence of serial dilutions of the 
serum of our injected rats. Then a chemiluminescent method was used to detect gene expression. 
When sera contain anti-AAV9 factors fewer cells are transduced. In this assay more than 50% 
inhibition of transduction was considered as a positive test for anti-AAV9 factors. This assay was 
done at the Gene Therapy Immunology core GTI- UMR 1089-Nantes by Célia Couzinié under the 
supervision of Dr. Oumeya Adjali.  
 We tested 10 sera of animals injected with different AAVs used in the STC (Table 12). 
Only two of them were positive. In addition, these sera were positive but only at the second lowest 
dilution tested 1/500, suggesting that anti-AAV9 factors were not abundant. All non-injected 
control animals’ sera were found negative indicating that the test was efficient and that most 
probably there is no pre-existing immunity against AAV9 in those rats.  
Table 12 : Neutralising factors against AAV9 
Group 
Number of rats 
tested 
AAV9 neutralising factors 
Conclusion Titer 
WT 
scr.sh 
4 Negative - 
1 Positive 1/500 
CMT1A 
scr.sh 
4 Negative - 
1 Positive 1/500 
Non-injected controls 
2 WT Negative - 
2 CMT1A Negative - 
scr.sh= scramble shRNA,WT= Wild-type, CMT1A=Charcot-Marie-Tooth 1A rat model. Positive test means >50% of 
transduction inhibited in the presence of AAV9 neutralising factors in serum. Assay done at the Gene Therapy 
Immunology core GTI- UMR 1089-Nantes. Total: n=14 rats.   
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VIII. Viral biodistribution  
 Another important parameter to be tested before proposing a clinical trial for gene therapy 
is biodistribution of viral vectors that were injected in the body. Indeed, viral vectors may well 
infect the target cells of the therapy, but they may also infect non-target cells in the same organ as 
target cells but also in other organs when the virus enters the vascular system. This off-target 
infection depends on the viral tool but also on the delivery route. Viral biodistribution test is based 
on the detection of the viral DNA in multiple tissues and organs using q-PCR. This test was done 
in collaboration with Dr. Caroline Le Guiner and Virginie François (Preclinical Analytics core 
PAC- UMR 1089-Nantes). Results are expressed as vector genome per diploid genome (vg/dg) of 
cells. 
 Therefore, we collected and snap froze several organs (sciatic nerve, muscle close to the 
sciatic nerve, lumbar dorsal root ganglions L4 and L5, lumbar spinal cord, liver, spleen, kidney, 
brainstem and blood cells) in the sacrificed animals of the STC cohorts at 2.5 months post-injection 
(Table 11). DNA was extracted and the GFP marker of AAV9 gene expression was detected using 
qPCR together with a linearized DNA plasmid as PCR internal control and Hprt1 as reference 
gene. We found viral genome in the sciatic nerve of almost all injected rats. The ratio viral genome 
on diploid cell genome was 0.56, suggesting that almost half of the cells present in the nerve were 
infected with at least one virus. As myelinating Schwann cells represent 30% of the Schwann cells 
present in the rat sciatic nerve (Schmalbruch, 1986), other cells being non-myelinating Schwann 
cells, fibroblasts, immune cells, this suggests that almost 100% of the myelinating Schwann cells 
are infected with at least one virus.  
 The viral genome was also detected in muscles that surround the sciatic nerve because 
some leak occurs during the injection of the virus into the nerve and AAV9 readily infects 
muscular cells. 3 out of 16 animals showed AAV9 infection of dorsal root ganglions (DRG), which 
are in the continuum of the sciatic nerve just before the spinal cord. This indicated that in some 
animals the injection went so well that the viral solutions reached the DRGs, which are more than 
1 cm away from the injection site in rat pups. Only 1 animal out of 8 showed heart infection and 
1 out of 8 showed blood infection. No off-target infection was found in spinal cord, liver, spleen, 
kidney and brainstem (Figure 32) 
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Figure 32: AAV9 biodistribution: scr.sh= scramble shRNA, CMT1A=Charcot-Marie-Tooth 1A rat model. CMT!A 
sh49 and 50=CMT1A rat injected with AAV9 shRNA PMP22-49 and 50; SN=Sciatic Nerve; DRG= Dorsal Root 
Ganglion.; (-) = below detection limit so <0.002; vg/dg= vector genome/diploid genome. Mean ± SEM.                            
Test done at  the Preclinical Analytics core PAC- UMR 1089-Nantes. 
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Discussion  
 Myelinating Schwann cells highly express PMP22 mRNA as well as protein (Giambonini-
Brugnoli et al., 2005; Li et al., 2013; Ohsawa et al., 2006). PMP22 downregulation gene therapy 
approach for CMT1A would be more efficient if it targets those cells. Many attempts by our 
laboratory and others, targeting myelinating Schwann cells with viruses were not efficient enough 
(Gonzalez et al., 2014; Homs et al., 2011). Adenovirus serotype 5 with a cytomegalovirus (CMV) 
promoter transduces mostly non-myelinating Schwann cells when injected in the sciatic nerve of 
mice. In addition, adenoviruses are immunogenic and can only be injected in immunodeficient 
animals (Glatzel et al., 2000; Gonzalez et al., 2014; Perrin-Tricaud et al., 2007; Tricaud, 2005). 
Lentiviral vectors do not have this problem. Some reported that lentivirus injected intrathecally in 
adult mice could migrate to peripheral nerves and infect a significant amount of myelinating 
Schwann cells even as far as the paws (Kagiava et al., 2016). However, in our lab lentivirus 
infected efficiently only pre-myelinating Schwann cells when injected in the sciatic nerve of P3-
P5 mice pups and was not efficient in adults (Gonzalez et al., 2014; Ozcelik et al., 2010). In 
addition the transduction rate of both adenoviruses and lentiviruses was low: 10% of myelinating 
Schwann cells in a nerve section (Ozcelik et al., 2010) and neurons. AAV8 transduced more 
Schwann cells than AAV2 with few infected Schwann cells away from injection site. Furthermore, 
vector copy number per cell decreased with time (Homs et al., 2011). Thus, we tested AAV9 and 
AAV10 to obtain a better transduction rate of Schwann cells and an improved diffusion of the viral 
vector along the nerve. Both AAV9 and AAV10 transduced mostly the targeted myelinating 
Schwann cells and at a very high transduction rate for AAV9, after injections in the sciatic nerve 
of adult mice (4.6x1010 vector genome/nerve). Moreover, AAV9 diffused along almost the entire 
nerve more than AAV10. AAV9 high transduction rate of myelinating Schwann cells was also 
found in rats (1.8x1011 vector genome/nerve for adults and 1x1011 for pups) and macaques (5x1011 
vector genome/nerve) after injections in the sciatic nerve. Therefore, we used AAV9 viral vector 
for PMP22 gene downregulation approach (shRNA) in rat pups’ sciatic nerves. 
 Gene downregulation is possible via RNA interference (RNAi) silencing approaches 
(Burnett et al., 2011) small interfering siRNA and the cloned form of siRNA, shRNA. Gene 
silencing by shRNA had been widely used for different purposes such as study on specific 
molecules or disease mechanism (Djelti et al., 2015) and therapy. Our laboratory used this 
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approach to define the role of many molecules in the myelination process(Cotter et al., 2010; 
Ozcelik et al., 2010; Perrin-Tricaud et al., 2007; von Boxberg et al., 2014). Gene silencing by 
shRNA was tested as a potential treatment for the autosomal dominant neurodegenerative disease 
Spinocerebellar ataxia type 1 (SCA1) in transgenic mouse models. A polyQ (poly glutamine) 
expansion in Ataxin1 (ATXN1), which encodes the ATXN1 protein, causes SCA1. Injecting 
recombinant AAV1 expressing shRNA against human ATXN1 (1 × 1012 vg)/mL) into SCA1 mice 
cerebellar cortices reduced protein levels of ATXN1, enhanced motor coordination as seen by 
better rotarod performance, cerebellar morphology and cleared the typical ATXN-1 nuclear 
inclusions seen in SCA1 mice (Ramachandran, Keiser, & Davidson, 2013; Xia et al., 2004). Those 
studies among other in the literature established that shRNA knockdown is never 100%; so, a 
significant amount of the target protein is still expressed in cells infected with a virus expressing 
shRNA. In the TrJ mice model carrying a Leu16Pro Pmp22 mutation, injecting intraperitoneally 
an allele-specific siRNA without a viral vector, significantly improved motor function as seen by 
rotarod. This approach also ameliorated muscle volume as observed in magnetic resonance 
imaging analysis, increased motor nerve conduction velocity and compound muscle action 
potentials as well as enhanced myelination as depicted by electron microscopy of the sciatic nerves 
and by higher levels of myelinating proteins like myelin basic protein and myelin protein zero. 
Therefore, siRNA is a potential treatment for inherited peripheral neuropathies caused by point 
mutations (J. S. Lee et al., 2017). Finally, several clinical trials are in course using siRNA such as 
Patisiran drug for Hereditary Transthyretin Amyloidosis (NCT01960348) and QPI-1007 drug for 
Non Arteritic Anterior Ischemic Optic Neuropathy (NCT02341560) (Refer to Introduction 
VI.D.2). Alnylam Pharmaceuticals are about to obtain the first RNAi drug approval (C. Morrison, 
2018).  
 For my thesis project, due to the laboratory strong expertise in viral vectors and shRNA, 
we opted for the AAV9 shRNA gene therapy approach for CMT1A in the rat model overexpressing 
mouse PMP22. ShRNA constructs were carefully chosen and tested to decrease PMP22 gene 
expression without completely deleting this gene and causing another disease, “Hereditary 
Neuropathy to Pressure Palsies” (HNPP). With our collaborators, we selected two shRNA 
constructs targeting the mouse and/or rat PMP22 gene (shRNA PMP22-49 and shRNA PMP22-
50) (Figure 22.B and C). Two shRNA constructs were used to confirm that the effect of the 
shRNA is due to its specific silencing of PMP22. 
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 The chosen two constructs downregulate PMP22 mRNA and protein levels in vitro and in 
vivo. Mouse PMP22 mRNA is decreased by shRNA as seen by RT-qPCR of MSC80-transfected 
cells (MSC80 cells express mouse PMP22). Since the antibody we used for PMP22 protein levels 
reacts with rat and mouse PMP22, we don’t know which of rat or mouse PMP22 is decreased; we 
only know that total PMP22 (mouse and rat) is decreased. We did not differentiate between rat and 
mouse PMP22 because one of the two shRNA constructs (sh49) we used targeted both. The second 
shRNA construct (sh50) totally recognizes mouse PMP22 and not rat PMP22. Not distinguishing 
rat PMP22 from mouse PMP22 is not necessarily important as at the end we anyway reduced the 
PMP22 protein level to control level. In addition, to translate to clinical trials, human patients 
possess the PMP22 gene from only one species, human PMP22. Patients do not have PMP22 
genes from two different species like in the CMT1A rat (endogenous rat PM22 and overexpression 
of mouse PMP22). The purpose of the therapy was to decrease the excess of PMP22 in CMT1A 
rat overexpressing mouse PMP22 no matter which species it was. We succeeded in that objective 
as shown in Figure 27.  
 In addition, it is important to note that by decreasing PMP22, we reduced CMT1A 
symptoms and we did not cause any other pathology. Indeed, treated CMT1A rats grow normally 
and did not lose weight (Figure 33). In order to rule out concerns about shRNA off-target effects, 
we had injected both WT and diseased rats with shRNA control/scramble. AAV9 shRNA PMP22 
decreased PMP22 mRNA and protein levels. In this way, the cause of the disease (PMP22 gene 
overexpression) was corrected.  
 
Figure 33: No weight loss observed following injections: AAV9 
shRNA did not cause any pathology. No difference in weight with 
non-injected rats. For each  time point:  Injected  rats:  n=8  per 
group and non-injected rats: WT n=22. CMT1A n=20.  
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We chose the CMT1A rat because it is one of the best models of the human disease. First, 
similarly to CMT1A patients, it presents a 1.5-fold increase of the PMP22 gene expression due to 
mouse PMP22 extra gene. This is not the case in other mouse models which possess several fold 
increases of this gene (Magyar et al., 1996; M. Sereda et al., 1996; Zu Hörste & Nave, 2006). 
Secondly, the CMT1A rat model mimics the human neuropathy. Based on the behavioural and 
electrophysiological analysis presented in the results chapter and in literature, CMT1A rats show 
motor and locomotion deficits and reduced nerve conduction velocity as well as compound muscle 
action potentials (CMAP) like patients. CMAP is the sum of activity in muscle fibers following 
motor nerve stimulation. The motor deficits seen in diseased rats were lack of motor coordination 
and of equilibrium as demonstrated by a poor rotarod performance in addition to muscle weakness 
as proven by decreased strength in grip test. Clumsiness in walking as deduced from Catwalk 
analysis of parameters in rats is a common feature of CMT1A rats and patients. I believe that I am 
the first one to have studied the gait of CMT1A rats using the Catwalk apparatus. In the literature, 
the footprint analysis with ink is used for this purpose. During the footprint analysis, rats usually 
overlap their hind paw with previous front paw position thus spreading the inks and impeding 
analysis (Hamers, Koopmans, & Joosten, 2006). The print intensity of CMT1A rats when their 
whole paw is in contact with the glass plate of the Catwalk is less than in wild-type (“Max Contact 
Max Intensity” parameter) (Batka et al., 2014). This intensity parameter indicates weight bearing 
of paws or paws weight load distribution that could be associated with pain (Masocha & Pavarthy, 
2009; Vrinten & Hamers, 2003) or with muscle weakness. The latter is the most plausible for 
CMT1A rats since they cannot stand their body weight due to muscle weakness (M. Sereda et al., 
1996). Moreover, CMT1A rats do not have much inter-paw coordination during walking as shown 
by the diminished values in the parameters of “ Regularity index”, “Phase dispersions” and 
“Couplings” in CMT1A rats versus WT (Batka et al., 2014; Kloos et al., 2005; Mountney et al., 
2013). This could be explained by the fact that diseased rats dragged their paws (dragging resemble 
the foot drop symptom in human patients). This is suggested by a significant increase in the 
parameter “left hind paw single stance”, a parameter of the hind paw indicating that the 
contralateral paw is not in contact with the glass plate. The contralateral paw of the left hind paw 
being the right hind paw not touching the glass plate as if dragged (Coulthard et al., 2002). As in 
human patients, there is a reduced nerve conduction velocity in CMT1A rats indicating a 
demyelinating neuropathy. In comparison, CMT1A mouse models display either a mild clinical 
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phenotype like C61 heterozygotes and C3-PMP or a very severe phenotype - closer to CMT3- such 
as C22 and My41(Magyar et al., 1996; Zu Hörste & Nave, 2006). Histological characteristics of 
peripheral nerves in CMT1A patients and rats include demyelination, onion bulbs and secondary 
axonal loss. The important disease variability found in CMT1A patients is also present in the rat 
model (Fledrich, Stassart, et al., 2012).  
 The P6-P7 age of rats was specifically chosen for multiple reasons. First, we aimed at a 
preventive rather than a curative treatment since signs and symptoms appear before 20 years of 
age, even during childhood (Harding & Thomas, 1980; Yiu et al., 2008). Second, at P6, CMT1A 
rats overexpress PMP22 (both mRNA and protein) with values higher than at a later age, at the 
adult stage (2.5-month-old- CMT1A rats) (M. W. Sereda, 1999). Third, by P30, CMT1A rats 
present the first signs of demyelination and onion bulb formation. Last, by P60 axons are lost, 
hence myelin recovery is impossible (Fledrich et al., 2014).  
 In order to target specifically myelinating Schwann cells, we injected the virus directly in 
the nerve. For that, I used the innovative microinjection technique settled by Dr. Tricaud. This 
method consists in filling the nerve as much as possible with viral solution at high pressure 
(Gonzalez et al., 2014). I injected repetitively very small volumes for a total of 8µL over a 15 min 
period time. The injection took time allowing good spreading of the virus along the nerve to obtain 
high transduction efficiency. The dose was 1x1011vg/nerve. Both sciatic nerves were injected to 
obtain a bilateral recovery. It is also important to inject the lower limbs since this is where CMT 
diseases start before affecting the higher limbs (Tooth, 1886). 
Several clinical assays are in course to treat CMT1A (Table 4). In addition an ASO 
approach has been recently proposed at a preclinical stage (Zhao et al., 2017) (refer to Introduction 
IV.B.2). All these therapeutic proposals require multiple and regular administrations to keep the 
level of PMP22 lower in the myelinating Schwann cell, which may be cumbersome for patients 
and costly for the community. With only a single injection of AAV9 shRNA PMP22 in sciatic 
nerves of rats, we succeeded in obtaining a practically total rescue of the motor and sensory 
phenotype with a considerably increased nerve conduction velocity. The therapy remained very 
efficient for a long time (more than 9 months). Precisely, AAV9 shRNA PMP22 gene therapy 
corrected motor impairments and hypoalgesia in CMT1A rats. As seen by rotarod (Figure 28.A) 
and grip test (Figure 28.B), therapy significantly ameliorated motor performance for coordination, 
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equilibrium and muscle strength. Treated CMT1A rats had an almost total motor functional 
recovery. In addition, therapy is 100% efficient for hypoalgesia given that treated CMT1A rats 
have the same behavior of WT rats in Randall Selitto pain assessment test. To my knowledge, no 
one has ever done the Randall Selitto test on the CMT1A rat model. The sensory phenotype is not 
much explored in CMT1A rats. Only Fledrich et al (2012) have found that severely affected 
CMT1A rats are less sensitive to heat pain compared to mildly affected and Wild-type rats. Not 
feeling pain (hypoalgesia) either by mechanical stimuli (Randall Selitto) or thermal stimuli (hot 
plate) could be explained by the loss of sensory fibers (Baumgärtner et al., 2002; Fledrich, 
Schlotter-Weigel, et al., 2012; Zu Horste et al., 2007). Axonal loss is an important feature of 
CMT1A rats (Fledrich, Schlotter-Weigel, et al., 2012; Fledrich, Stassart, et al., 2012; Zu Horste et 
al., 2007). 
AAV9 shRNA PMP22 gene increased the nerve conduction velocity but not compound 
muscle action potentials (CMAP) in CMT1A rats. The reason for this is not clear. In the literature, 
electrophysiological improvements were variable (Table 4). Indeed, some treatments could only 
correct the CMAP with no effect on NCV (Fledrich et al., 2014; Sereda et al., 2003; Zu Horste et 
al., 2007) or correct both NCV and CMAP (Meyer zu Horste et al., 2011; Zhao et al., 2017) or 
correct none of NCV and CMAP (Sociali et al., 2016) . With our therapeutic strategy, although we 
had a very high transduction rate and a good diffusion, the whole nerve was not entirely filled with 
viral vector carrying shRNA PMP22. Thus, we are rectifying myelination mostly around the 
injection site and not all along the nerve. This may be sufficient to restore a correct nerve 
conduction velocity but may not be enough to prevent the temporal dispersion of action potentials 
(Figure 34). Temporal dispersion is a typical feature of CMT1A rats since they present a 
dysmyelinating phenotype (abnormal myelin formation) (M. Sereda et al., 1996). In any case the 
correction of the NCV but not of CMAP was enough to restore motor and sensory phenotypes. 
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Figure 34:  Action potentials in myelinated versus demyelinated axons: A: Myelinated neuron with action potential 
initiation signal (AIS) and propagation. B In myelinated fibers, the action potentials jump from one node of Ranvier, 
to the other. Red arrows indicate high membrane currents. This leads to the generation of single peaks of CMAP as 
one example is depicted in C.  In the case of a demyelinated axon, the propagation of action potentials is slowed down 
or blocked hence temporal dispersion of action potentials occurs as depicted in D.  Adapted and modified from 
Freeman, S.A., Desmazières, A., Fricker, D. et al. Cell. Mol. Life Sci. (2016) 73: 723. 
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 In order to check for the robustness of my injection protocol in nerves, I have compared 
the results of motor and electrophysiological tests between the short term cohort and the long term 
cohort. Actually, both cohorts showed a very similar recovery, implying that the injection 
technique is reproducible in my hands.  
 The recent rapid progression of the gene therapy field results in viral vectors with greater 
titers, higher transduction efﬁciencies, and frequently with broader tissue/organ tropism. This high 
efficiency always raises concerns regarding the risk of germ line transmission (Le Guiner et al., 
2011). Subsequently, it is crucial to evaluate the safety of those new technologies by analyzing the 
immune response towards the virus (neutralization assay) and the viral infection in different tissues 
other than the targeted one(s) (AAV biodistribution).  
 The high prevalence of neutralizing antibodies against AAV in the human population 
presents a considerable obstacle to the broad use of AAV vectors in clinical gene therapy (Boutin 
et al., 2010; Rapti et al., 2012). It was long assumed that preclinical animal research models do not 
have pre-existing neutralizing factors against AAV except for nonhuman primates (Jiang et al., 
2006; L. Wang et al., 2010). Nevertheless, Rapti et al proved that wrong. All of the six animals 
species tested (mouse, rats, pigs, sheep, dogs and rabbits) had pre-existing neutralizing factors 
against one or more AAV serotypes 1, 2, 6 or 9 (Rapti et al., 2012). This is why we thought it was 
important to test for serum factors that can neutralize transduction of AAV9 in the AAV9 shRNA-
injected rats.  Two out of 10 injected rats were found positive for the neutralization assay but at a 
very low titer. Thresholds of positivity, prevalence and cut-off values can vary among the different 
laboratories that perform the analysis because there is no standardized method across laboratories 
(Vandamme et al., 2017). Depending on the method used, the cut-off is set, and animals are 
excluded from the study if they display a neutralizing factor titer higher than this value. For 
example, in certain laboratories where they use serum serial dilutions of 1/2, 1/4 etc…until 1/128 
(twofold serial dilution), the cut-off value is 1/2 (Rapti et al., 2012). At the Gene Therapy 
Immunology (GTI) core (UMR1089, Nantes, France), they do serum serial dilutions of 1/10 
starting from 1/50, 1/500 until 1/500 000. Due to high background noise in rats, the minimal 
dilution is 1/50. The titer of positivity of 1/500 is considered a very low titer based on the method 
used (personal communication with Célia Couzinié and Oumeya Adjali- GTI core - UMR1089, 
Nantes, France). Since Rapti et al (2011) observed no inhibition for AAV9 in serum of non-
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injected rats prior to injections, they suggested that neutralization factors present in the sera of 
positive rats were probably caused by injections and not by pre-existing neutralization factors 
(Rapti et al., 2012). This suggests that in our case a seroconversion occurred in 2/10 rats. AAV 
can initiate an immune response in animal models (Chirmule et al., 2000; Vandamme et al., 2017) 
and humans (Flotte et al., 2011; Vandamme et al., 2017) even if they were previously seronegative. 
Species, vector and injection route do not affect seroconversion. The problem with the 
seroconversions is that it will inhibit infection after the re-injection of the same AAV vector (Jeune 
et al., 2013; Vandamme et al., 2017). Usually in adult patients, one single AAV injection is enough 
since expression of the transgene is long-lasting (Buchlis et al., 2012; Vandamme et al., 2017). 
This is not the case in pediatric animal models where the expression maybe lost overtime 
(Vandamme et al., 2017; L. Wang et al., 2011). However, our experiments show long lasting effect 
after treatment of very young pups P6-P7. In patients we aim at a preventive rather than a curative 
treatment. Consequently, if our therapeutic approach was translated to clinical trials, children 
would be injected with AAV. If there was a need for AAV re-injection, this might therefore be 
possible since only a small minority of tested rats were found positive and at a very low titer. More 
extensive research needs to be done before passing to clinical trials.  
 AAV serotypes infect different organs and tissues depending on their administration route 
(Zincarelli et al., 2008). Focusing on AAV9, intrathecal or intravenous injection in mice led to 
several off-target effects: colon, ileum, liver and adrenal cortex and central nervous system 
(Armbruster et al., 2016; Schuster et al., 2014). Intracerebroventricular injection of AAV9 results 
in infecting the spinal cord, the liver, the heart and hindlimb skeletal muscles (Armbruster et al., 
2016; Zincarelli et al., 2008). AAV9 showed the highest viral genome distribution among AAV 
serotypes 1-9 (Zincarelli et al., 2008). After injection in the sciatic nerve we did not observe AAV9 
infection neither in the liver nor in the brainstem. We only detected important amount of AAV9 
viral genome at the site of injection (sciatic nerve) and in the muscle that surrounded this site 
_probably due to leakage of the viral solution during injection or because of the high tropism of 
AAV9 to hindlimb muscles as demonstrated by Armbruster et al (2016) and Zincarelli et al (2008) 
(Armbruster et al., 2016; Zincarelli et al., 2008). Furthermore, virus was detected in very few 
DRGs (3/16) that are in the continuity of the nerve. Two animals showing viral expression in 
DRGs showed also expression either in the heart (1/8) or in the blood (1/8), suggesting a small 
leak into the vascular system in very few animals. Three out of sixteen animals showed no viral 
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expression in the nerve (Figure 32). The explanation is that those rats were the ones with which I 
experienced some technical difficulties during injections, suggesting that not much virus was 
injected inside the sciatic nerve. One of the two positive rats in the neutralization factors assay 
showed viral off-target in the DRGs. The presence of anti-AAV9 did not affect the transduction 
capacity of the virus further supporting that the titer of those factors is very low.  To conclude, 
AAV9 transduced almost exclusively the injection site (sciatic nerves) with only a distribution 
nearby, in the muscle. There were not important off-target effects of AAV9. Thus, it appears safe. 
All those results are very promising for moving to clinical trials. 
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Conclusion and Perspectives 
 
 The aim of my thesis project was to test a gene therapy approach using AAV9 virus 
expressing shRNA PMP22 on a rat model of CMT1A. We found this therapeutic approach very 
promising since I obtained a high transduction rate, around 90%, in myelinating Schwann cells, a 
downregulation of PMP22 mRNA back to control levels and a very significant functional recovery 
with only one single bilateral injection in sciatic nerves of young pups. Furthermore, the treatment 
efficiency was maintained for at least 9 months post injections, way much longer than the daily or 
weekly pharmacological treatments proposed up to now in these rats. 
 In order to translate this gene therapy approach to clinical trials, a bit more research is 
required. First, the minimal effective dosage should be very carefully defined because if PMP22 
expression is too low, another disease is caused. Testing for the dose could be done using two 
ways: first by transfecting Schwann cells from CMT1A patients with different doses of shRNA 
targeting human PMP22 and second, by infecting myelinating Schwann cells in the sciatic nerve 
of non-human primate macaca fascicularis with different doses of the therapeutic virus AAV9 
expressing human+macaca PMP22 shRNA.  
 Second, the vector delivery should be optimized to maximize the transduction and diffusion 
rates in human nerves. In rodents it is easier to target Schwann cells by injecting in the sciatic 
nerve than in monkeys or humans. This is due to the complex anatomy of peripheral nerves. As a 
matter of fact, each nerve is made of the epineurium, a connective tissue that surrounds several 
groups of axon bundles known as fascicles. In these fascicles axons are grouped forming the 
endoneurium. Each of these fascicles is encircled by a perineurium, a single layer of connective 
tissue (Figure 35). The difficulty is to inject the virus into the endoneurium in order to infect 
myelinating Schwann cells and to restrict the diffusion. While the epineurium is almost absent in 
mice and rats, it is really thick in monkey and humans. Crossing the epi- and peri-neurium to reach 
the endoneurium is therefore a challenge in monkeys and humans. The microinjection technique 
developed by Dr Tricaud should be adapted to large animals and to humans because it allows such 
a fine injection at the right place. Preliminary experiments performed in the lab of Prof. Patrick 
Aubourg (INSERM U1169 and MIRCEN, Fontenay-aux-roses) on macaques were very 
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encouraging. Nevertheless, they need further enhancements to increase transduction and diffusion 
rates, such as injecting at different sites and use the appropriate needle size and the right angle for 
entering the nerve. This requires a large amount of organization and collaboration since usually a 
neurosurgeon does the injections and veterinarians closely follow-up macaques. 
 Furthermore, if injection in sciatic nerves is too complicated in humans, another 
administration method could be tested: intravenous injections. The safeness of this technique 
should be also assessed by immunological response against the viral capsid (neutralization assay) 
and AAV biodistribution (off-targets of the virus).   
In addition, a curative therapeutic approach might be tested (inject AAV shRNA PMP22 
at a later age in CMT1A rats) and compare with the preventive approach which I demonstrated the 
efficacy during my thesis.   
Taken together, these data along with the proposed future studies constitute a strong proof 
of principle to possibly use AAV9 shRNA PMP22 in clinical trials.  
 
 
Another perspective include studying the inflammatory response in CMT1A rats and check 
the effectiveness of the gene therapy on that response. As a matter of fact, in CMT1A mouse model 
C61, high levels of macrophages in peripheral nerves suggest that those cells might partially 
mediate myelin degeneration (Kobsar et al., 2005; Kohl et al., 2010). 
 
 
Figure 35:  Anatomy   of   a   peripheral    nerve:  
Longitudinal section showing the epi-, peri- and 
endo-neurium as well as a fascicle, myelinated 
axons and blood vessels   
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CHAPTER 2: LABEL-FREE NON-LINEAR 
MICROSCOPY PROJECT 
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Introduction 
 Clinical trials evaluating the outcome of a treatment require strong readouts: consistent, 
reliable and quantitative. In the case of demyelinating diseases such as CMT1A, there is a lack of 
such readouts to measure outcome of an anti-demyelinating or pro-myelinating therapy. The most 
straightforward readout is to look directly at peripheral nerves and in particular at the myelin sheath 
in vivo with minimal invasiveness. I have presented some myelin imaging approaches in the 
introduction among which MRI and SCoRe (Introduction III.H.5). A secondary project in my 
thesis was to evaluate the use of a novel imaging techniques, non-linear microscopy, to image 
peripheral myelin sheath in living animals. These techniques are label-free which means they allow 
imaging of myelin in vivo without any labeling at all. We first compared three different non-linear 
microscopy methods (Second Harmonic Generation: SHG, Third Harmonic Generation: THG and 
Coherent Anti-Stokes Raman Scattering: CARS) to study peripheral nerve myelin in WT mice and 
rats ex vivo and in vivo. We next tested the most promising, CARS, to image and quantify 
demyelination and dysmyelination in CMT1A rats. Results are presented in the following 
manuscript under revision at Journal of Biophotonics. This work was done in collaboration with 
Hassan Boukhaddaoui, research engineer of the Montpellier Ressource Imaging platform of the 
INM. 
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Abstract:  
Myelin sheath produced by Schwann cells covers and nurtures axons to speed up nerve conduction 
in peripheral nerves. Demyelinating peripheral neuropathies result from the loss of this myelin 
sheath and so far, no treatment exists to prevent Schwann cell demyelination. One major hurdle to 
design a therapy for demyelination is the lack of reliable measures to evaluate the outcome of the 
treatment on peripheral myelin in patients but also in living animal models. Non-linear microscopy 
techniques SHG, THG and CARS were used to image myelin ex vivo and in vivo in the sciatic 
nerve of healthy and demyelinating mice and rats. SHG did not label myelin and THG required 
too much light power to be compatible with live imaging. CARS is the most reliable of these 
techniques for in vivo imaging and it allows for the analysis and quantification of myelin defects 
in a rat model of CMT1A disease. This microscopic technique therefore constitutes a promising, 
reliable and robust readout tool in the development of new treatments for demyelinating peripheral 
neuropathies. 
 
 
 
 Introduction: 
In peripheral nerves of vertebrates, most of the axons are covered by an insulating and nurturing 
myelin sheath produced by Schwann cells [1,2]. This sheath is critical for fast nerve conduction 
and long-term survival of motor and some sensory axons of the peripheral nerve. Indeed, numerous 
human diseases result from the destruction of the myelin, termed demyelination. These 
demyelinating peripheral neuropathies include acquired diseases such as diabetic demyelinating 
neuropathy, leprosy, Guillain-Barré syndrome and chronic inflammatory demyelinating 
neuropathy, and hereditary diseases such as Charcot-Marie-Tooth (CMT) diseases [3]. Together 
these diseases represent a large spectrum of patients in Europe and worldwide, and while there is 
no specific treatment, different therapies are being investigated at clinical and preclinical stages. 
 One major hurdle in the development of these therapies is measuring the outcome of the treatment 
on peripheral nerve demyelination [2] and eventually on remyelination, the limited regenerative 
process that occurs spontaneously [4].  None of the methods currently used are really convenient 
for a longitudinal study for the fate of myelin in a therapy assay. Therefore, one critical step toward 
the success of a therapy is to design a method that allows imaging peripheral nerve myelin in a 
live animal without labelling. 
Non-linear optic microscopy relies on the absorption of at least two incident photons on molecules, 
which generates scattered photons with different energy levels [5]. The energy level of the 
scattered photons is related to both the energy of the incident photons and the structure of the 
molecules with which the photons collide. Indeed, incident photon wavelengths allows for a 
resonance effect with particular moieties located on a group of molecules. When two incident 
photons generate harmonically scattered photons, this is called Second Harmonic Generation 
(SHG). This is not specific to any molecule, but occurs more efficiently with fairly ordered, large 
non-centrosymmetric molecules such as collagen helicoid fibrils. When three incident photons 
generate harmonic scattered photons, this is called Third Generation Harmonic (THG). This also 
occurs non-specifically but more efficiently at the interface between groups of molecules with 
different light excitabilities such as between water and lipids or lipid membranes. These two 
approaches, SHG and THG, have been used to efficiently image biological tissues without any 
labelling [6].  
 More recently a novel form of non-linear microscopy has emerged that enables the targeting and 
imaging of specific molecular bonds. This scheme uses three incident photons where the frequency 
difference of two of these photons (namely the pump and the stokes photons) can be made resonant 
to drive a specific vibrational chemical bond. The interaction of the third photon with this driven 
vibrational bond generates new wavelengths that can be detected in a way that is similar to 
fluorescence microscopy. This approach is termed Coherent Anti-Stokes Raman Scattering 
(CARS) microscopy. While CARS microscopy can be used to image different kinds of molecules, 
it is particularly efficient in detecting lipids and lipid-enriched myelin has been one of the first 
biological objects to be imaged by physicists using CARS [7–9]. 
These different nonlinear optical microscopy techniques have the important advantage of being 
label-free and are therefore applicable for in vivo imaging. However, SHG, THG and CARS 
techniques are not widely used in the biological and medical communities because the 
experimental apparatus of the excitation laser and the microscope are complicated, costly and 
require spatial and temporal synchronization between two independent laser sources [7, 8]. We 
recently addressed this problem by adapting a commercial setup involving a single laser source 
duplicated through an optical parametric oscillator (OPO) and by temporally synchronizing the 
two laser lines through a delay line [10].  In the present work, beyond the described feasibility of 
using non-linear microscopy for myelin imaging in vivo, we addressed the following questions: 
which exact structures each non-linear microscopy techniques are imaging in peripheral nerves, 
and then, which technique is really compatible with live imaging, for example whether the 
peripheral myelin could indeed survive the imaging. Finally, we chose a rat model of CMT1A, the 
most common of the CMT disease, which compiles several characteristics of these diseases such 
as demyelination but also abnormal myelination (dysmyelination): heterogenous myelin thickness, 
focal hypermyelination and short internodal segment [11]. Using this model, we investigated 
whether the CARS technique, the most adapted for in vivo imaging of myelin, could allow for the 
characterization and the quantification of myelin defects in this disease. 
 
 
 
 Results 
Second, third harmonics and CARS imaging in the sciatic nerve of healthy mice 
Using 1097 nm wavelength light to generate SHG we observed a strong signal (548 nm, band-pass 
filter 500-550) coming from the perineurium, the membrane that collects nerve fibres together, 
and a weaker signal coming from the endoneurium where there are nerve fibres (Fig. 1A). At 
higher magnification the strong perineurium signal appeared as the addition of signals coming 
from many long fibrous structures (Fig. 1B). These structures were likely to be collagen fibrils as 
SHG at this wavelength is known to emerge from these fibrils [6,12] and electron microscopy 
shows a high density of these fibrils in the perineurium [13]. The weaker signal, which was better 
detected when the perineurium was mechanically removed, appeared also at high magnification as 
collagen fibrils running along myelinated fibres (Fig. 1C). These collagen fibres are easily seen in 
electron microscopy (Fig. 1D, red overlay). When SHG imaging was performed on sciatic nerve 
of transgenic mice expressing Yellow Fluorescent Protein (YFP) in axons (Thy-1 mice), SHG 
signal located distantly from the axon (Fig. 1E). This is consistent with the presence of the myelin 
sheath between axon and collagen fibrils (see Fig. 1D).  
 
 
 Using 1300 nm wavelength for THG we observed a strong signal (433 nm, band-pass filter 400-
480) coming from the endoneurium and the fat bodies located outside the perineurium (Fig. 1F). 
Fat bodies did not produce THG signal all over but actually only at their edges (Fig. 1G upper 
panel). This indicated that lipids themselves did not produce THG signal but this signal was 
emerging at the interface between lipids and the aqueous environment.  In the endoneurium at high 
magnification this signal appeared as a hatched pattern with lines of different sizes (Fig. 1H). Using 
YFP axonal labelling, we found that this hatched signal came from a domain outlining the axon 
(Fig. 1I red arrowheads) and a domain outlining the myelin sheath (Fig. 1I black arrowheads). 
Taken together these data and previous reports in the literature [14] indicated that THG signal was 
produced at interfaces of the myelin with the axon (Fig. 1H and I, red arrowheads) and of the 
myelin and the extracellular environment (Fig. 1H and I, black arrowheads). These THG signals 
appeared as very large bands when the focus reached the surface of these interfaces (Fig 1H, red 
and black lines). So, THG can be used to image lipid-enriched myelin but only at its interfaces 
with the aqueous environment and the THG signal forms therefore a complex pattern. 
Using 836nm and 1097 nm wavelengths for pump and stokes photons respectively, we were able 
to generate a CARS signal coming from lipids. Illuminating the mouse sciatic nerve in these 
conditions we observed a strong signal (670 nm, band-pass filter 660-685) coming from the 
endoneurium and fat bodies (Fig. 1J). Fat bodies produced a CARS signal all over (Fig. 1G lower 
panel) in sharp opposition to THG signal (Fig. 1G upper panel), which confirmed the lipid origin 
of this signal. At high magnification the endoneurium signal also appeared as a hatched pattern 
but less complex than with THG (Fig. 1K). When this signal was overlapped with YFP axonal 
labelling (Fig. 1L) the hatches finely surrounded the axon suggesting CARS signal was derived 
from the lipid-rich compact myelin. However, unlike the THG signal, emerging CARS signal fully 
covered the compact myelin sheath, resulting in two large lines flanking the axon (Fig. 1L). CARS 
signal was robust and discriminating since cytoplasm-filled incisures that cross the myelin could 
be nicely seen as successive exquisitely delimited “bubbles” opening up in the myelin signal (Fig. 
1M white arrowheads). Nodes of Ranvier also appeared devoid of compact myelin (asterisk Fig. 
1M, see Fig. 1D).  
 
 
 Ex vivo SHG, THG and CARS imaging of myelin during demyelination and remyelination  
As our goal was also to compare non-linear microscopy approaches in demyelinating conditions 
we next used these approaches in traumatic nerve demyelination conditions. Mouse sciatic nerve 
was crushed or ligatured and imaged at different time points. In these conditions, axons degenerate 
distally to the lesion in a few hours; Schwann cells de-differentiate and myelin degenerates distally 
in 4-5 days forming myelin ovoids that are degraded by the Schwann cells themselves or by 
macrophages. Then around day 10, Schwann cells remyelinate axons that have grown back from 
the lesion. The remyelination process is progressive and myelin sheathes are back to normal around 
two months later (day 60) [2,4].   
 
Using SHG and THG we imaged injured mouse sciatic nerves at the peak of demyelination after 
dissection and fixation (Fig. 2): at the site of the lesion a scar enriched with transversal collagen 
fibrils appeared as seen with SHG (Fig. 2C). While upstream of the lesion (Fig 2A, B) the THG 
signal was similar to the signal detected in non-injured nerves (see Fig. 1A, F), downstream of the 
lesion (Fig. 2D, E) this signal was fragmented indicating compact myelin fragmentation that 
characterizes demyelination. The fragmentation of the THG signal at 4 days post injury (Fig. 2F) 
Figure 2: SHG and THG imaging of myelin during demyelination and remyelination 
A, B, C, D, E - Successive optical sections from proximal to distal respective to the spinal cord of a 
crushed mouse sciatic nerve imaged with SHG (red) and THG (green) (scale bars=100mm). F, G, H- 
SHG (red) and THG (green) imaging of a crushed mouse sciatic nerve distal to the lesion at 4 (F), 
15 (G) and 30 (H) days post-crush (scale bars: 100mm). 
 was followed by a significant decrease of the signal 15 days post injury (Fig. 2G), illustrating the 
destruction of the compact myelin. By 30 days post injury this THG signal returned (Fig. 2H), 
illustrating the remyelination process.  
 
The CARS signal change during demyelination and remyelination was slightly different: 4 days 
post injury the CARS signal also showed a fragmentation of the compact myelin compared to non-
injured nerves (Fig. 3A), however myelin ovoids were more detailed than with THG; 8 days post 
injury the CARS signal was still very intense but it exclusively constituted myelin debris of all 
sizes (Fig. 3A). By 15 days post injury, fine myelin sheathes and some large debris could be 
detected using CARS (Fig. 3A). This was different with the THG signal, which was much lower 
(Fig. 2G) showing that THG signal results from interfaces between structured myelin and 
Figure 3: CARS imaging of myelin during demyelination and remyelination 
A- CARS imaging of sciatic nerves of mice crushed at day 0 and imaged at different days post-crush (dpc) 
(same scale bar for all pictures =10mm). B- Graph showing intact myelin area measured with CARS imaging 
at different days post-crush. C- Graph showing myelin debris area measured with CARS imaging at different 
days post-crush. D- Graph showing G-ratio measured with CARS imaging at different days post-crush. 
Statistical analysis uses one-way ANOVA followed by Tukey test. All values were compared to 0 days post 
crush or to control *, P-value <0.05; **, P-value <0.01; ***, P-value <0.001; P-value >0.05 are non-
significant and not shown. 
 
 cytoplasm, which are mostly lost in myelin debris and which are much weaker in very fine myelin. 
By 30 days, myelin segments were back to their original appearance (Fig. 3A), showing a complete 
regeneration of the myelin.  
 
CARS imaging of demyelination and remyelination in vivo 
We next investigated whether THG or CARS imaging could be used to follow quantitatively and 
longitudinally myelin maintenance, demyelination and remyelination in living mice. 
We first anesthetized adult mice and, after a small surgery, gently placed their sciatic nerve under 
the lens of the multiphoton microscope as previously described [15]. Nerve of control mice were 
not illuminated while experimental mouse nerves were illuminated for THG or CARS imaging (1 
minute at different laser power). Then nerves were placed back, the wound sutured and animals 
were left to wake up. After 7 or 14 days animals underwent the same in vivo imaging and we 
evaluated the demyelination in illuminated or control nerves using THG or CARS.  All our 
attempts to image myelin in vivo using THG induced a significant demyelination of the fibres, 
indicating that the laser power required to image myelin with THG is deleterious for myelinating 
Schwann cells. A similar outcome resulted from the illumination of the nerves for CARS imaging 
at high power (100mW, 50mW, 30mW) but no demyelination could be detected at lower power 
intensity (20mW and 10mW).  
We then used CARS imaging at a safe intensity (10mW) to analyse the myelin of mouse sciatic 
nerve in living animals after a nerve injury in a longitudinal study. Mice were first imaged before 
crush (Online supporting information live imaging video 1) and then imaged a second time at 
different time points distally to the injury (Online supporting information live imaging video 4, 8, 
15, 30 days post crush, (dpc)).  Qualitatively, demyelination and remyelination could be followed 
along the same time intervals and with similar images as observed ex vivo in Fig. 3A. These 
processes could also be quantitatively measured by quantifying the relative myelin surface, the 
relative debris surface and the g-ratio (axon diameter on myelinated fibre diameter). Myelin area 
decreased sharply 4 days after crush and recovered progressively after 15 days (Fig. 3B), whilst 
the exact opposite occurred with debris surface as this increased sharply during and after 
demyelination and decreased when cells remyelinated (Fig. 3C). G-ratio, axon diameter on full 
 fibre diameter, is a commonly used read-out of the myelin thickness. We measured this ratio using 
the inner and the outer diameter of the CARS labelled rings. While it could obviously not be 
measured when cells demyelinated, we found that by 15 days after crush it increased compared to 
control (Fig. 3D), showing that remyelinating cells had a thin myelin. This ratio remained higher 
than control even at 60 days post crush, after remyelination was complete (Fig. 3D), suggesting 
the myelin sheath remained thinner than before crush. This is consistent with previous reports 
using electron microscopy showing a hypomyelination following demyelination in injured nerves 
[16].   
Qualitative and quantitative imaging of defects in CMT1A rat sciatic nerves myelin using 
CARS 
 To go further we investigated whether CARS imaging is sensitive enough to detect myelin defects 
that occur in a rat model of the hereditary disease Charcot-Marie-Tooth type 1A. Indeed, at the 
present time, these defects can only be addressed using electron microscopy imaging, which is 
time and resource consuming. Using this imaging technique, demyelination, focal 
hypermyelination, short internodal length and onion bulbs are characteristic of the CMT1A nerve 
in a transgenic rat model of the disease, the CMT1A rat [11].  We anesthetized adult CMT1A rats, 
exposed their sciatic nerves and imaged them using CARS in vivo. Subsequently, we dissected the 
nerves and imaged them ex vivo. In vivo imaging revealed the fractioned morphology of the myelin 
sheath in transgenic rats compared to wild-type. (Fig. 4A, B). Ex vivo imaging allowed a more 
detailed analysis of the morphology. Firstly, some fibres were clearly degenerating, forming 
beaded structures in a necklace pattern known as myelin ovoids (arrowheads, Fig. 4C). Activated 
macrophages, clearly seen thanks to their round inclusions (insert Fig. 4C), were abundant.  
Macrophages participate in the clearance of degenerated myelin. At higher magnification, the main 
characteristic of transgenic rats’ nerves was the high diversity of myelinated fibres phenotypes in 
the same imaging field. This diversity was also noticed along the same fibre: some fibre parts were 
clearly hypermyelinated with myelin forming discrete masses along the axon (white arrows, Fig. 
4E, F); some fibre parts on the opposite were devoid of detectable myelin or were thinly myelinated 
(arrowheads, Fig. 4D) and sometimes these thinly myelinated or unmyelinated parts of the fibre 
were in the continuity of some hypermyelinated parts (red arrowheads, Fig. 4D). In addition, in 
CMT1A rats, nodes of Ranvier were enlarged (asterisks, Fig. 4G) and myelin sheathes were 
 completely different from one side of the node to the other (red arrowheads, Fig. 4D, E, G) while 
wild-type myelin sheath was similar along the same axon (red arrowheads, Fig. 4I). This indicates 
that on the same axon of a CMT1A rat, some myelin segments are not homogeneous, being hyper- 
or hypo-myelinated. Furthermore, we observed in many places short myelinated segments between 
two nodes of Ranvier (Fig. 4G). This shows that myelin defects are not localized in the nerve but 
occur everywhere leading to a strongly heterogeneous pattern. 
 
 
  
Figure 4: imaging of defects in CMT1A rat sciatic nerves myelin using CARS 
A, B- In vivo live imaging of wild-type (A) and CMT1A (B) rats sciatic nerves (scale bars= 50µm). C- CMT1A rat sciatic nerve 
imaged ex vivo with CARS shows a degenerating fibre displaying fragmentation and myelin ovoid (arrowheads) (scale 
bar=40µm). Insert: detail of a CARS image of CMT1A rat sciatic nerve showing a macrophage with round inclusion (scale 
bar= 5µm). D- CARS image of CMT1A sciatic nerve showing a demyelinated fibre (white arrowheads) and a node of Ranvier 
separating a hypermyelinated from a hypomyelinated fibres (red arrowheads) (scale bar=10µm). E- CARS image of CMT1A 
sciatic nerve showing focally hypermyelinated regions (white arrows) and a node of Ranvier separating a hypomyelinated from 
a hypermyelinated fibres (red arrowheads) (scale bar=10µm). F- CARS image of CMT1A sciatic nerve showing focally 
hypermyelinated regions with myelin inclusions (white arrows) (scale bar= 10µm). G, I- Z-projection of CARS images of 
CMT1A (G) and wild-type (I) rat sciatic nerves. Some fibres have been coloured for better clarity. Asterisks show the location 
of some node of Ranvier and red arrowheads the myelinated fibres flanking nodes of Ranvier (asterisks) (scale bars =10µm). 
H, J- coloured fibres in G and I were extracted and are shown isolated at the same magnification. Black arrowheads show the 
location of Schmidt-Lanterman incisures. 
 This heterogeneous pattern hindered the quantitative analysis of the myelin defects with the 
methods we previously used. Nevertheless, we measured the myelin surface to find less myelin in 
CMT1A rat nerve (Fig. 5A). G-ratio was difficult to measure because hypermyelinated segments 
were adjacent to hypomyelinated or demyelinated segments. However, overall we detected a lower 
G-ratio in CMT1A rat nerves (Fig. 5B), showing a hypermyelination. A significant characteristic 
of CMT1A rat fibres versus control animal fibres was the shortening of the inter-incisural distance 
of the remaining myelinated fibres compared to wild-type (black arrowheads, Fig. 4H, J). This 
feature was the result of the dilatation of the Schmidt-Lanterman incisures that stakes the myelin 
sheath: in normally myelinated fibre only large and regular incisures are clearly visible while in 
unstable myelin sheathes all incisures, large and small, dilate resulting in shorter inter-incisural 
distances [17]. Using this method we could reliably quantify the amount of defective myelin in 
CMT1A rat sciatic nerves (Fig. 5C). Taken together these data indicated that CARS microscopy 
allows for imaging and measuring myelin defects in the CMT1A rat model.  
 
Discussion 
We first compared SHG, THG and CARS in the imaging of mouse and rat peripheral nerves. SHG 
can be used for imaging collagen fibers both in the perineurium and the endoneurium. THG 
exposes interfaces between the compact myelin and the surrounding environment, such as axon 
and extracellular domain resulting in a complex pattern that outlines the myelin sheath without 
Figure 5: quantitative imaging of defects in CMT1A rat sciatic nerves myelin using CARS 
A, B, C- Graphs showing intact myelin area (A), G-ratio (B) and inter-incisural distance (C) measured with 
CARS imaging in wild-type (WT) and CMT1A (CMT1A) rat sciatic nerves ex vivo. Statistical analysis 
uses Student T test. *, P-value <0.05; **, P-value <0.01; ***, P-value <0.001. 
** *** *** 
 labelling it directly. Using CARS imaging, the myelin sheath is directly labelled thank to its rich 
content in lipids and it appears as a large band surrounding axons. These results are consistent with 
previous analysis by specialists in optics [18,19] and in peripheral nerve biology [7,14].  
We then compared these techniques to analyse demyelination and remyelination in an injury 
context. SHG signal was increased at the site of the injury but remained relatively weak in the 
endoneurium during demyelination and remyelination. THG signal decreased sharply after 
demyelination and resumed during remyelination. However, myelin debris remained mostly 
undetected. CARS signal changed during demyelination as the linear bands of myelin disappeared 
to give rise to bright ovoids containing myelin debris. Myelin disappearance and recovery were 
more precisely measured with CARS because this signal was directly correlated to myelin sheath 
thickness.  
One of the main hurdles to design a therapy for peripheral nerve diseases is the lack of techniques 
to reliably measure the outcome of therapy on the myelin sheath. Non-linear label-free imaging 
may therefore represent a significant advance in this domain. However, this kind of imaging 
requires light to fully penetrate the sample. As nerves are below the skin, this requires at least a 
skin incision to expose it. Imaging myelin in vivo was not trivial due to the breathing movements 
that change the focus and to the low penetration of the light, which limited the imaging to the nerve 
surface. In larger animals such as monkeys, and in humans, the epineurium being much larger, it 
is likely that CARS imaging will be limited by the light penetration through this surrounding tissue. 
Demyelinating peripheral nerve diseases are complex pathologies because they are mostly chronic 
diseases. Beyond of the cause of the disease, the complexity of chronicity also results in the 
heterogeneous appearance of diseased nerves. Indeed, while some cells are normal, some 
demyelinate and some remyelinate. In addition, extra-nerve cells are also recruited such as 
macrophages. So, as we saw with the imaging of the CMT1A rat model using CARS, the diseased 
sciatic nerve shows a complex pattern both on the same axon and between axons. We found that 
CARS imaging can be used to characterize the loss of myelin (relative myelin surface), the hypo- 
or hyper-myelination (G-ratio) and also dysmyelination (malformed myelin sheath) using the 
interincisural distance.  
Finally, the interest of CARS imaging probably also resides in the improvements that are being 
implemented by physicists in the field. Indeed spectral focusing CARS and stimulated Raman 
scattering microscopy [20] allows for the distinction between several type of lipids, notably 
 oxidized lipids that are found in lesioned tissues [21,22], but also proteins and ribonucleic acids 
[23,24]. Another interesting improvement is the use of rotating polarization CARS to detect the 
spatial orientation of CH2- moieties on lipids [25]. In “healthy” myelin moieties polarity is much 
more homogenous than in diseased or ageing myelin [7]. In conclusion, non-linear label free 
CARS microscopy and potentially endoscopy [26] represents a consistent and strong readout tool 
in the development of new treatments for demyelinating peripheral neuropathies [27,28]. 
 
 
  
 Material and methods 
 
Animals 
PMP22 transgenic CMT1A rats [11] expressing mouse PMP22 cosmid gene as well as Swiss mice 
(Janvier, France) were used for this study. Wild-type (WT) littermates of rats served as controls. 
The genotyping was done with genomic DNA from tail biopsies of rats using polymerase chain 
reaction with mouse transgene-specific primers as previously described [11]. All experiments were 
performed accordingly to French regulations for animal experimentation (Comité d’éthique pour 
l’expérimentation animale Languedoc-Roussillon, #1307). 
Sciatic nerve surgery, microscopy set-up and image acquisition 
For in vivo imaging mice were imaged between 9 and 11 weeks of age and rats between 17 and 21 
weeks of age. Animal surgery is described in the supplementary material. The nerve was gently 
lifted out and a thin and flexible plastic bridge was inserted below the nerve very carefully without 
damaging it. The nerve was moistened with sterile Phosphate-buffered saline (PBS) in order to 
prevent the nerve from drying out. Two magnetic brackets were utilized to fix the bridge. The paw 
was fixed with a scotch tape to minimize movement. A very small and round cover slip was placed 
on top of the nerve. Then the animal was positioned along with the anaesthesia mask under the 
multiphoton microscope coupled to a microscope incubator (XL S Examiner Dark, Zeiss) in which 
the temperature was kept at 37 °C. It was made sure that the coverslip was as flat as possible to 
get good resolution images. Deionized water was added to immerse a water 20 x objective lens (W 
Plan-Apochromat 20x/1.0 DIC, Zeiss). After imaging, the sciatic nerve was put back into the 
cavity, the muscles were readjusted, and the wound was closed using clips. The analgesic 
Buprenorphine (0.1 mg/kg) was administrated to mice before surgery and after surgery for 48 
hours every 12 hours.  For longitudinal studies, mice underwent the same surgery after 7 or 14 
days to again image the same sciatic nerve in vivo.  
Animals were then sacrificed and the nerve was dissected to obtain ex vivo images. To obtain fixed 
samples, sciatic nerve was dissected and the epineurium was removed. Nerves were then fixed in 
4% paraformaldehyde (PFA) for 2 h at 4°C and kept in PBS at 4°C until imaging (maximum of 
one week) and then fixed again overnight in 4% PFA and stored in PBS at 4°C.  
 
 
 Non-linear microscopy setup  
A multiphoton microscope LSM 7 MP OPO (Zeiss, France) using an upright Axio Examiner Z.1 
optical microscope associated with a femtosecond Ti:sapphire laser (680-1080 nm, 80MHz, 140 
fs, Chameleon Ultra II, Coherent, France) pumping a tunable optical parametric oscillators (1000-
1500 nm, 80MHz, 200 fs, Chameleon Compact OPO, Coherent, France) was utilised to acquire 
images. Depending on the type of studies (in vivo or ex vivo), different types of images were 
obtained: time- lapse images for in vivo studies (several images of one single plane across a specific 
time of around 10s) and z-stack for ex vivo studies (several images of multiple planes, 
approximately 40 µm depth). A 20x water immersion lens (W Plan Apochromat DIC VIS-IR) was 
used for images. The characteristics are the following: 1024 pixels frame size, scan speed of 7 
(Pixel Dwell 3.15 μsec/ Scan Time 3.87 sec) and either a zoom x1 or x3.  
 
Four non-linear microscopy techniques were used for images: the two-photon standard fluorescent 
method, the second harmonic generation (SHG), the third harmonic generation (THG) and 
Coherent Anti-Stokes Raman Scattering (CARS). The fluorescent method was used for Thy-1 
mice with an excitation wavelength of the Ti-saphire laser of 870 nm and a narrow band pass filter 
at 500-550 nm in front of one of the detectors. The SHG and THG were utilised for Swiss mice. 
SHG excitation wavelength of the OPO laser is 1097 nm, the signal detection at half of the 
excitation wavelength i.e. 548 nm and the filter at 500-550 nm. THG excitation wavelength of 
OPO laser is 1300 nm, the signal detection at one third of the excitation wavelength i.e. 433 nm 
and the filter at 400-480 nm. As described by Mytskaniuk V et al, the CARS technique is based 
on the synchronization of two laser beams: the Ti-saphire with an excitation wavelength of 836 
nm and the OPO with an excitation wavelength of 1097 nm. The signal is detected at 670 nm and 
the filter ranges from 660-685nm.  
 
Image analysis  
Images were analysed by the software Imaris 8.4 (Bitplane, Switzerland). In vivo images were 
cropped due to respiration. The image analysis processes are detailed in supplementary material. 
Statistics were done using Graphpad Prism 7 software. 
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Graphical abstract: 
Measuring the treatment outcome of chronic diseases such as the hereditary peripheral 
neuropathies is not straightforward. It requires specific analyses among which imaging of 
peripheral nerve myelin. In this article myelin of healthy, injured and diseased small rodents was 
imaged ex vivo and in vivo using several non-linear microscopy approaches. CARS microscopy 
allows for the qualitative and quantitative assessment of peripheral nerve myelin defects in living 
diseased animals.  
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Sciatic nerve surgery 
Animals were anesthetized by inhalation of isoflurane (5%) with a constant oxygen flow (1.5 
L/min) inside an induction box for around 5 min. Then anesthesia was upheld with a nose cone 
using 2% isoflurane and 0.8 L/min oxygen flow. Ocry-gel was put on the eyes of animals to avoid 
ocular dryness. The analgesic Buprenorphine (0.1 mg/kg) was administrated to mice just before 
surgery and for 48 hours after surgery every twelve hours. Incision area was shaved and cleaned 
with betadine solution then 70% ethanol and again betadine. Skin was cut at the level of the thigh 
and the muscles were separated to expose the cavity containing the sciatic nerve. The nerve was 
gently lift out and a thin and flexible plastic bridge was inserted below the nerve very carefully 
without damaging it. The nerve was moisten with sterile Phosphate-buffered saline (PBS) for the 
nerve not to dry. Two magnetic brackets were utilized to fix the bridge. The paw of rat was fixed 
with a scotch tape to minimize movement. A very small and round cover slip was placed on top of 
the nerve. Then the animal was positioned along with the anesthesia mask under the multiphoton 
microscope coupled to a microscope incubator (L S1 Dark, Zeiss) in which the temperature was 
kept at 37 °C. It was made sure that the coverslip is as flat as possible to get good resolution 
images. Deionized water was added to immerse the 63x objective lens. After imaging, the sciatic 
nerve was put back into the cavity, the muscles were readjusted, and the wound was closed using 
clips.  
  
After 7 or 14 days, mice underwent the same surgery to image again the same sciatic nerve in vivo. 
They were then sacrificed and the nerve was dissected to obtain ex vivo images.  
 
Rats were imaged between 17 and 21 weeks of age. Both in vivo and ex vivo images were acquired. 
Nerves were then fixed in 4% paraformaldehyde (PFA) for 2 h at 4°C and kept in PBS at 4°C until 
imaging (maximum for one week) and then fixed again overnight in 4% PFA and stored in PBS at 
4°C.  
 
Image analysis using Imaris 
After opening the image with Imaris, we selected in the menu toolbar at the upper left ‘View’ - 
‘3D view’ 
  
For the quantitation of myelin and debris, we selected the blue ellipsoid icon ‘Add new Surfaces’  
  
We selected the ‘Create’ submenu (magic wand icon) and clicked on the ‘Next’ button 
 
 We checked the Smooth option from the Source Channel dropdown menu since smoothing can 
facilitate object identification in noisy images. In ‘Thresholding’ we chose the ‘Background 
Subtraction’ option because objects we measure are touching. Then we clicked ‘Next’.  
 
 
 
We adjusted the threshold and clicked ‘Next’  
 
  
We selected the filter “Area above 5 µm2” for myelin quantitation  
          
 
We selected “Area between 1-20 µm2” for debris.   
          
We selected the ‘Finish’ button    
 In the ‘Statistics’ submenu, we selected ‘Detailed’ and exported data to excel (‘Disk’ icons at the 
bottom of the Statistics window) 
 
 
For interincisural distance and g-ratio analysis, we selected the icon “Measurement Points”  
 
 We selected the Settings sub-menu  of Measurement points, chose the point shape ‘Sphere’ and in 
‘Line Mode’ polygon points to be drawn for interincisural distance and pairs of points to be drawn 
for g-ratio. 
 
We changed the Mouse Pointer option from ‘Navigate’ to ‘Select’ mode 
 
We pressed the pencil icon to add points and followed instructions displayed. 
 
 
 Interincisural distance 
  
g-ratio 
 
 In the ‘Statistics’ submenu, we selected ‘Detailed’ and exported data to excel (‘Disk’ icons at the 
bottom of the Statistics window) 
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Conclusion and Perspectives 
 Imaging myelin in living animals and potentially in humans without using any label is an 
evolving research field. Many techniques exist including SHG, THG and CARS. In peripheral 
nerves of mice and rats, SHG can be used for imaging collagen fibers in the perineurium and 
endoneurium, THG the interfaces of compact myelin with the aqueous environment and CARS 
the myelin sheath as a large bright band surrounding axon. After comparing those techniques in 
healthy and injured nerves of mice (demyelination and remyelination), we found out that CARS is 
the best method of the three since its signal emerges directly from the myelin sheath as clear and 
strong. Thus, we used CARS for a myelin readout tool in the sciatic nerve of healthy and diseased 
rats. With CARS imaging, we were able to successfully characterize myelin defects (loss, 
hypo/hyper- and dysmyelination). Therefore, CARS label-free microscopy is a promising 
technique as a consistent, reliable and quantitative outcome measure for developing new therapies 
for demyelinating peripheral neuropathies. However, further research need to be done in order to 
solve some technical difficulties we encountered during in vivo imaging: invasiveness and low 
light penetration in the tissue. One solution is to use CARS imaging along with technical 
improvements such as a Bessel beam illumination. This technique allows for the extension of the 
axial depth of field, which should give a better light penetration: field depth for Bessel Beam is 
10µm versus 3.5µm for the classic Gaussian beam (Masia et al., 2018). 
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GENERAL CONCLUSION  
  
  
165 
 
 As part of the myelin team at the Institute of Neurosciences in Montpellier, my thesis 
research project covered several topics of the myelin translational research. Myelin that wraps 
axons is essential to protect and nurture them. It also increases nerve conduction velocity to levels 
that allow large animals and humans to move their bodies fast enough to run at 37 km/h such as 
Kylian MBappé in the last football world cup. I had the pleasure to work on a dramatic disease 
called Charcot Marie Tooth type 1A (CMT1A) and the honour to try to find a cure for it. It is 
caused by a duplication of the PMP22 gene on the chromosome 17 of humans resulting in an 
overexpressed PMP22 protein. There is still no cure for CMT diseases despite extensive research. 
Gene therapy seems a logical approach since the disease is chronic and inherited. In addition, it is 
considered as a very innovative treatment compared to classical pharmacological costly and 
burdensome treatments. Thus, I studied the efficiency of a gene therapy approach which targeted 
myelinating Schwann cells (highly express PMP22) aiming at reducing the excess of PMP22. The 
strategy consisted in injecting viral vectors AAV9 carrying the gene silencing therapeutic tool 
shRNA PMP22 in both sciatic nerves of a rat model of the disease, the CMT1A rat. This model 
closely mimics the human disease. AAV9 highly transduced the targeted cells, the myelinating 
Schwann cells and PMP22 mRNA as well as protein levels were downregulated. Therapy 
corrected the motor deficits seen in diseased rats to almost a full recovery as proved by rotarod 
and grip test. In addition, treatment alleviated hypoalgesia as seen in Randall Selitto test (the first 
real pain test realized on this rat CMT1A model so far) and increased nerve conduction velocity 
as calculated from electrophysiological measurements. This was all achieved with only one single 
bilateral injection in sciatic nerves. Treatment is still efficient even on the long run; after more than 
9 months. Furthermore, safety assessment by testing the immune response against AAV 
(neutralization assay) as well as off-targets infections of the virus (AAV biodistribution) came out 
almost completely “clean”. This means that successive injections of the therapeutic vector could 
safely be performed in order to reach several human nerves. All those results appear very 
promising and encourage us to translate to clinical trials.  
 However, no tool consistent enough exists for examining the peripheral nerve. Therefore, 
it is crucial to find a strong readout to evaluate the outcome of a treatment before moving to clinical 
trials. Non-linear, label free microscopy seems very appropriate. Among different techniques we 
found that CARS is the best method to image myelin in vivo as its signal comes directly from the 
myelin sheath as clear and strong. Using CARS imaging on sciatic nerves of rats, we successfully 
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characterized loss of myelin, hypo-hyper- and dys-myelination in CMT1A rats. Consequently, 
CARS label-free microscopy could be used as a consistent outcome measure for developing new 
therapies for demyelinating peripheral neuropathies.  
 Taken together I realize that the three years of my life I have spent in Montpellier were 
very useful not only for me as a researcher-student but also, I believe, for all the people suffering 
with CMT1A. Indeed, I am convinced that in the future an efficient, convenient and well-accepted 
gene therapy will be available for all these patients around the world.  
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